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Drug design and discovery is a daunting task. To date, the pharmaceutical 
industry is continuously experiencing high attrition rates in research and 
development (R&D) of drug candidates. One of the major reasons for drug 
failure is lack of efficacy.1 Apparently, the current evaluation strategies, often 
measurements based on examining a compound’s affinity and selectivity, are 
not sufficient to predict in vivo drug efficacy. A more predictive experimental 
paradigm is, therefore, highly desired. Several recent reviews, in an a posteriori 
perspective, showed that many marketed drugs—in other words successful 
examples—favor certain kinetic aspects.2-4 In particular, the residence time of 
a drug on its target may be more relevant for the in vivo efficacy of medicines 
than their typical in vitro equilibrium binding constants, e.g., Ki values. 
However, this hypothesis is merely supported from retrospective studies. 
Only a few kinetics-directed studies have been performed so far. As such, 
more insight into ligand-receptor binding kinetics, in an a priori manner, 
might be beneficial in the early phases of drug discovery.
About this thesis
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Drug discovery and development pipeline1.1 
Figure 1.1 represents a summary of the sequential steps that are essential for 
a drug to progress through the R&D pipeline. This process on average takes 
10-15 years. It usually starts from a large number of hits (e.g. 5,000-10,000) 
which are selected from high-throughput screening, a step that enables 
running more than 50,000 compounds a day with complex work-stations.5 
In a typical scenario, approximately 250 candidates (leads) are selected for 
preclinical testing. Following a program with 3-6 years’ duration, about 5 
candidate drugs will progress into clinical trials of three consecutive phases 
(I-III) to examine their efficacy and safety among an increasing number of 
volunteers and patients. Finally, only one will receive approval, if at all. The 
average cost to research and develop a successful drug is estimated to be $800 
million to $1 billion.
Lack of efficacy: the main reason of drug attrition1.2 
An investigation into the causes of drug attrition is very necessary and 
instructive in the identification of strategies and tactics to improve the 
Figure 1.1 | Figure is adapted from Drug Discovery and Development: Understanding the 
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Drug-target residence time: the ‘time’ to fix the leaky 
drug candidate pipeline?1.3 
Drug-target residence time (RT) is the duration a drug stays in a complex 
with the target, which is defined as the reciprocal of the dissociation rate 
constant of the drug-target complex (1 / koff).6 Recently, awareness of the 
importance of residence time has started to increase since accumulating 
evidence suggested that the in vivo efficacy of a ligand may be attributed 
efficiency of drug development. In a recent survey of 108 reported phase 
II failures from 2008 to 2010 (Figure 1.2),1 44 drugs had failed due to 
insufficient efficacy, which accounted for 51% of 87 cases with reported 
reasons for failure. Following this, 29% (25 out of 87) were due to strategic 
reasons and 19% (17 out 87) were due to clinical or preclinical safety concerns. 
Pharmacokinetics (PK) or bioavailability (BA) issues are seldom reported.1 
Apparently, lack of efficacy is the main reason for drug attrition. This, in 
part, results from the insufficiently predictive efficacy in animal models for 
translation into clinical efficacy. The development of more predictive animal 
models—where possible—is therefore needed. Yet, what might be more 
important is to develop experimental paradigms that are more predictive of 
clinical outcomes in much earlier phases of drug design and discovery.
Figure 1.2 | Phase II failures: 2008-2010. The 108 failures are divided according to reasons 
for failure when reported (87 drugs). Figure is adapted from Arrowsmith, 2011.1
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Supposed that marketed drugs are the most successful clinical candidates, 
many of them have been shown, in retrospect, to favor certain kinetic aspects. 
In a survey of 50 drugs on 12 different drug targets by Swinney, about 70% 
of long residence time therapeutics displayed higher efficacy than comparable 
faster dissociating drugs.10 One example is the well-known HIV-1 protease 
inhibitor, Darunavir, which is an extremely effective drug due to its RT of 
more than 14 days (over 340 h).11 Examples in the field of G protein-coupled 
receptors (GPCRs) include tiotropium,12 the muscarinic M3 receptor 
antagonist for clinical indication of Chronic Obstructive Pulmonary Disease 
(COPD),13 maraviroc, an allosteric inhibitor of the CCR5 receptor for 
HIV/AIDS,14 and ‘sartan’ antagonists for the angiotensin II receptor to treat 
hypertension.15 Notably, tiotropium is non-selective in its affinity for the five 
subtypes of muscarinic receptors. However, due to its very slow dissociation 
kinetics from the M3 receptor compared to the other subtypes it is kinetically 
selective. On the other hand, there are cases where mechanism-based or 
‘on-target’ toxicity outweighs the therapeutic advantages of long receptor 
occupancy. In this situation, a fast dissociating compound displaying short-
lived receptor intervention is preferred. This is the case for some antipsychotic 
D2 dopamine receptor antagonists, where long RT is undesirable due to 
on-target toxicity associated with strong extrapyrimidal motor effects. The 
clinical benefits of optimized RT will be further discussed in Chapter 2.
Clinical benefits of drugs with optimized residence time
to the time it resides at its receptor.2,7-9 However, this parameter has so far 
been overlooked or neglected in the traditional drug discovery process. 
Currently, mostly steady-state metrics have been used in practice, e.g. affinity 
or potency, as predictor for in vivo drug efficacy. Yet, the aforementioned high 
attrition rate and the insufficient in vivo efficacy led to the realization that 
this equilibrium-based strategy might be too simplistic. Thus, introducing 
analysis of binding kinetics in the pipeline of drug research might provide a 
better predictor for in vivo efficacy in the earlier phases of drug design and 
discovery, and should be explored better. This added knowledge might foster 
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Finding new chemical entities with optimized kinetics
The examples mentioned above are prospective drivers for design and 
development of new candidate compounds with appealing kinetic profiles 
for proof of concept. Figure 1.3 describes such a scheme of a kinetics-
directed process in combination with the affinity-based evaluation. It 
includes the kinetic profiling (on-rate and off-rate) of compounds of interest 
(SKR, structure-kinetics relationships), complementary to the traditional 
equilibrium measurements (SAR, structure-affinity relationships), such as 
IC50 or Ki, and the characterization of pharmacological responses upon the 
formation of the ligand-receptor binary complex. The information obtained 
from the latter further stimulates a second round of optimization. This quick 
synthesis and evaluation loop can lead to more candidate compounds with 
desired kinetics profile to fuel further in vivo proof-of-concept experiments.
(KIWTG  ^ 5VTWEVWTGMKPGVKEU TGNCVKQPUJKRU 
5-4 CPF UVTWEVWTGCHƂPKV[ TGNCVKQPUJKRU
(SAR)—an a priori approach for the design of chemical entities with desired kinetics.
Adenosine receptors—the prototypic targets1.4 
Adenosine receptors (ARs) are used as prototypical targets for binding kinetics 
investigations in the present thesis. These receptors belong to the superfamily 
of G protein-coupled receptors (GPCRs) and have four subtypes: A1, A2A, 
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Figure 1.4 | Schematic representation of the adenosine A2A receptor in complex with 
the antagonist ZM241385 embedded in a lipid bilayer. /iÃÌÀÕVÌÕÀiÃL>Ãi`ÌiwÀÃÌ
crystallographic structure of the adenosine A2A receptor (PDB: 3EML). The receptor contains 
heptahelical transmembrane motifs connected by three intracellular and three extracellular 
loops, with the amino terminus located at the extracellular side and the carboxyl terminus 
at the intracellular side.
A2B and A3. Figure 1.4 is a schematic representation of the adenosine A2A 
receptor in complex with the antagonist ZM241385 which is based on 
the first crystallographic structure of this receptor (PDB: 3EML). Like all 
GPCRs, it contains heptahelical transmembrane motifs connected by three 
intracellular and three extracellular loops, with the amino terminus located at 
the extracellular side and the carboxyl terminus at the intracellular side. The 
adenosine A1 and A3 receptors are mainly coupled to the enzyme adenylate 
cyclase in an inhibitory fashion via a Gi protein, whereas the A2A and A2B 
receptors stimulate this enzyme via a Gs protein.16 Adenosine receptors are 
promising therapeutic targets. They are involved in a wide range of conditions, 
including cerebral and cardiac ischemic diseases, sleep disorders, immune 
and inflammatory disorders and cancer.17 As such, decades of medicinal 
chemistry research has resulted in a plethora of AR ligands, which are good 
starting points for binding kinetics investigations. In this thesis we will focus 






General introduction | 17 
A1 receptor
The A1R is widely expressed throughout the body.18 Its activation inhibits 
adenylyl cyclase activity, activates potassium channels (including KATP 
channels in neurons and the myocardium), blocks transient calcium channels 
and increases intracellular calcium and phospholipase C (PLC).19 This 
receptor can exert many physiologically important effects in different organs 
and cells. For instance, A1R activation in the cardiovascular system reduces 
heart rate and atrial contractility, and attenuates the stimulatory actions of 
catecholamines on the heart.20 However, for long-term indications, selective 
A1R agonists are required to avoid side effects related to other AR subtypes 
such as hypotension (A2AR).17,19,20 A1R inhibition in the nervous system was 
reported to have potential therapeutic effects in divergent conditions, such 
as dementia, hyperactivity, anxiety, schizophrenia and sleep disorders.16,21,22
The A2AR is highly expressed in the brain striatum, leukocytes and blood 
platelets, and is also found in the heart, lung and blood vessels.16 Its activation 
stimulates the cyclic AMP-protein kinase A (PKA) pathway by coupling to a 
Gs protein in peripheral tissues or Golf in the brain.23-25 In the central nervous 
system, A2AR plays significant roles in regulating motor activity, psychiatric 
behaviors, the sleep-wake cycle and neuronal cell death. In peripheral tissues, 
A2AR is involved in the modulation of inflammation, myocardial oxygen 
consumption, coronary blood flow, angiogenesis and the control of cancer 
pathogenesis.19 Thus, activation of A2AR has clinical relevance in various 
pathological conditions such as respiratory disorders and inflammation,26,27 
while inhibition of this receptor may have potential therapeutic roles for 
syndromes such as insomnia, pain, depression, drug addiction and Parkinson’s 
disease (PD).28-30
A2A receptor
18 |  Drug-target residence time: A case for the A1 and A2A receptor
Status quo: translation of current knowledge towards clinical 
progress
The translation of the current knowledge of adenosine receptors to clinical 
progress has been disappointingly slow. After decades of research, only 
two adenosine receptor agonists have been approved by the US Food and 
Drug Administration (FDA). They are adenosine itself (Adenocard; Astellas 
Pharma) for restoring normal heart rhythm in patients with paroxysmal 
supraventricular tachycardia (PSVT) and an A1R agonist regadenoson 
(Lexiscan; Astellas Pharma) for myocardial perfusion imaging in patients 
with suspected coronary artery disease.17,31 Currently, several trials are in 
progress, which are summarized in Table 1.1.19 Revisiting the database with 
a kinetic perspective may provide additional knowledge for future medicinal 
chemistry projects. The proof of mechanism in pre-clinical trials—for 
instance, preladenant’s long duration-of-action (> 12 h in a rat model)32—
could still direct us to find compounds bearing chemical resemblance for 
similar or better kinetic behavior, even though the starting compound has 
been discontinued in clinical trials. Such strategy is exemplified in Chapter 4. 
On the other hand, investigating the residence time of UK432,097, an A2AR 
agonist that in Phase II clinical trials was not efficacious for COPD, may 
provide clues for its failure.
Long or short receptor residence time for AR ligands?
The question whether to aim for long or short residence time A1R and A2AR 
ligands needs careful consideration in the early phase of drug design and 
discovery. The same holds for all GPCRs and other drug targets as well. It is 
thus necessary to weigh both potential beneficial and detrimental outcomes 
upon longer or shorter AR occupancy. For example, myocardial A1Rs have 
been shown to inhibit a number of myocardial pathologies associated with 
ischemia and reperfusion injury.33,34 However, such desired A1R-mediated 
protective and regenerative cardiovascular effects might be counteracted 
by unintended side-effects like bradycardia or atrioventricular block, due 
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Compound Name of the study Status
Adenosine Salvage: postconditioning after STEMI Phase II ongoing
Prophylactic intra-coronary adenosine to prevent post coronary artery stenting 
myonecrosis
Phase III terminated
Caffeine Clinical study of caffeine for apnea of prematurity Phase III completed
Magnetic resonance imaging (MRI) and neurodevelopmental outcomes in preterm 
infants following administration of high-dose caffeine
Phase IV Recruiting 
Caffeine for motor manifestations of Parkinson’s disease Phase II Completed
Caffeine for excessive daytime somnolence in Parkinson’s disease Phase II Completed
GW493838 The study of GW493838, an adenosine A1 agonist, in peripheral neuropathic pain Phase II terminated
INO-8875 A dose-escalation study designed to evaluate the tolerability, safety, pharmacokinetics 
(PK), and efficacy of chronic topical ocular application of INO-8875 in adults with 




ADVANCE MPI 2: study of regadenoson versus Adenoscan® in patients undergoing 
myocardial perfusion imaging (MPI)
Phase III Completed
Regadenoson blood flow in type I diabetes (RABIT1D) Phase IV Completed
ALT-146e
(apadenoson)
Study of the safety and efficacy of apadenoson for detection of myocardial perfusion 
defects using SPECT MPI (ASPECT)
Phase III terminated





Phase 2b study to assess the safety and tolerability of IV tonapofylline in subjects with 




PROTECT-1: a study of the selective A1 adenosine receptor antagonist KW-3902 for 
patients hospitalized with acute HF and volume overload to assess treatment effect on 
congestion and renal function
Phase III completed
PROTECT-2: a study of the selective A1 adenosine receptor antagonist KW-3902 for 
patients hospitalized with acute HF and volume overload to assess treatment effect on 




Study of KW-6002 (istradefylline) for the treatment of Parkinson’s disease in patients 
taking Levodopa (6002-009)
Phase III completed
Long-term safety study of istradefylline in patients with Parkinson’s disease Phase III completed
Preladenant A placebo- and active-controlled study of preladenant in early Parkinson’s disease 
(P05664 AM5)
Phase III terminated
A placebo- and active-controlled study of preladenant in subjects with moderate to 
severe Parkinson’s disease (Study P04938 AM5)
Phase III terminated
SYN-115 Safety and efficacy study of SYN115 in Parkinson’s patients using L-DOPA to treat end 
of dose wearing off
Phase III completed
Table 1.1 | List of ongoing or recently completed phase IIb-III clinical trials targeting A1 
and A2A receptors. The table summarizes the status found at the ClinicalTrials.gov website, 
accessed at December 6, 2013, and was adapted from Chen et al.19
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A1R activation.20,35 Receptor desensitization is another potential issue when 
long residence time A1 receptor agonists are considered. Therefore, a short 
intervention might be preferred to overcome the restrictions mentioned 
above. There are also cases where long residence time AR ligands might be 
beneficial. One example could be the A2AR antagonists for the treatment of 
Parkinson’s disease (PD) in combination with levodopa (the gold-standard 
medicine to boost dopamine levels in the brain). However, many PD patients’ 
symptoms return in between doses, when levodopa’s effects wear off—the 
fluctuation known as ‘off’ time.36 In light of this, a slowly dissociating A2AR 
antagonist may have the advantage of decreasing the ‘off’ time compared to a 
short residence time compound. Additionally, longer receptor residence time 
on one AR subtype can provide so-called kinetic selectivity over the others. 
This feature could be of great use for further optimizing those less-selective 
AR ligands in terms of affinity (i.e. the non-selective AR agonist NECA17). 
Such an advantage is well exemplified by tiotropium, the M3R antagonist 
highly selective over other muscarinic subtypes in terms of binding kinetics 
while less so in terms of affinity. To better define the optimal range of a target’s 
residence time, it is necessary to obtain a series of candidate molecules having 
a divergent frame of residence times—for instance, the A2AR antagonists 
described in Chapter 4 – for later proof-of-concept tests.
Objectives and overview of this thesis1.5 
Investigating ligand-receptor binding kinetics, in particular the residence 
time, is a leading theme in this thesis, which will be explored by several case 
studies on adenosine A1 and A2A receptors. 
In Chapter 2, the state of the art in drug-GPCR residence time is 
reviewed. We summarized a series of ligands for four prototypic GPCRs 
that have reported kinetic data, and extensively discussed these data from a 
molecular mechanism of action to in vivo pharmacology. In this chapter we 
also reviewed and summarized the emerging (in vitro) methods for studying 
binding kinetics. Among other assays, a newly developed kinetic screening 
method is listed, the so-called dual-point competition association assay. This 
assay enables fast and high-throughput assessment of ligand-receptor binding 
kinetics and is further described in Chapter 3. 
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A case for G protein-coupled receptors
Guo D, Hillger JM, IJzerman AP, Heitman LH. 
Adapted from: Med Res Rev. 2014, DOI: 10.1002/med.21307

A vast number of marketed drugs act on G protein-coupled receptors 
(GPCRs), the most successful category of drug targets to date. These drugs 
usually possess high target affinity and selectivity, and such combined features 
have been the driving force in the early phases of drug discovery. However, 
attrition has also been high. Many investigational new drugs eventually fail in 
clinical trials due to a demonstrated lack of efficacy. A retrospective assessment 
of successfully launched drugs revealed that their beneficial effects in patients 
may be attributed to their long drug-target residence times. Likewise, for 
some other GPCR drugs short residence time could be beneficial to reduce 
the potential for on-target side effects. Hence, the compounds’ kinetics 
behavior might in fact be the guiding principle to obtain a desired and durable 
effect in vivo. We therefore propose that drug-target residence time should 
be taken into account as an additional parameter in the lead selection and 
optimization process. This should ultimately lead to an increased number of 
candidate drugs moving to the pre-clinical development phase and on to the 
market. This chapter contains examples of the kinetics behavior of GPCR 
ligands with improved in vivo efficacy and summarizes methods for assessing 
drug-target residence time.
About this chapter
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Introduction2.1 
Drug-target residence time (RT) is an emerging concept in the drug research 
community. Its definition, coined by Copeland in 2006, stands for an 
experimental measure of the lifetime of a drug-target complex, reflected by 
its dissociation rate (koff).1 This is an important pharmacological feature as 
a drug is only effective when bound to, and influencing the activity of its 
physiological target.1,2 Recently, several notable reviews including Swinney et 
al.,2-5 Copeland et al.,1,6,7, Vauquelin et al.,8-11 and Zhang and Monsma,12,13 to 
name a few, have emphasized the pivotal role of RT in the early phases of drug 
discovery. These discussions led to increasing recognition that drug-target 
residence time may even be of greater importance for a drug’s effect in the 
patient than its affinity, since the body, unlike an in vitro setting, is an open 
system where the concentration of free drug fluctuates over time.13,14 The 
dynamic flow in vivo—absorption, distribution, metabolism, and excretion 
(ADME)—often prevents the free drug from reaching equilibrium conditions 
that are otherwise readily obtained in a test tube.13,14 In this sense, optimizing 
drug candidates based on equilibrium-derived parameters alone, such as 
affinity (Ki) / potency (IC50), may not be ideal.15 Drug-target residence time 
may be a useful additional parameter as it is thought to represent a surrogate 
marker of drug clinical efficacy: the longer the drug occupies the receptor, 
the more profound the drug may exert its effect.1,12 Although this reasoning 
most certainly is too simplistic, there is substantial evidence, as witnessed in 
a survey of 50 drugs on 12 different drug targets, that about 70% of long 
residence time therapeutics displayed higher efficacy than comparable faster 
dissociating drugs.5
It needs to be pointed out that the criteria for ‘long’ or ‘short’ residence 
time may vary for different targets and for divergent clinical indications.16 
For therapies requiring prolonged target occupancy, a long RT drug offers 
advantages as it remains bound to the target and continuously exerts its 
pharmacological effect even when most of the free drug has already been 
eliminated from circulation.17 Importantly, this simultaneously implies 
that a slowly dissociating drug will only offer a noticeably increased effect 
over a faster dissociating drug, when its dissociation half-life (t1/2) outlasts 
its pharmacokinetic half-life, or when there are large fluctuations in the 
endogenous competitor (e.g., hormone or neurotransmitter) concentrations.11 
Further proof for the importance of RT comes from numerous examples 







Mathematical definitions of drug-target residence 
time2.2 
Drug-target residence time is equal to the reciprocal of the dissociation rate 
constant (RT = 1 / koff).1 Its value is interchangeable with the dissociation 
half-life (t1/2 = ln2 / koff) with a factor of ln2, i.e., RT = t1/2 / ln2. Both can 
be used to represent the duration of the drug-target binary complex. For 
the convenience of discussion, we chose to use the dissociation half-life to 
describe the drug-target residence time in the following part of this chapter, 
since most of the kinetic values in literature were reported with t1/2 values.
As mentioned above, it is necessary to determine the dissociation rate 
constant to calculate the RT or t1/2. However, the definition of koff depends 
on the specific mechanism of ligand-receptor interaction.1,14 In general, three 
situations are well known. Equation 1 represents a simple one-step association 
and dissociation process, where the receptor (R) and ligand (L) encounter 
each other to form a binary complex (RL) with association rate k1 (kon) and 
dissociation rate k2 (koff), respectively.
                                                                                                           
In contrast, Equation 2 represents a more complicated process. Upon the 
binding of the ligand to the receptor, the initial complex (RL) undergoes a 
conformation isomerization leading to a much higher-affinity final complex 
of drugs that are best-in-class due to slow dissociation from their target 
receptor. One example is the well-known muscarinic M3 receptor antagonist, 
tiotropium, which is a long-acting, 24 hour, anticholinergic bronchodilator 
used in the management of chronic obstructive pulmonary disease.29 On the 
other hand, there are cases where the mechanism-based toxicity outweighs 
the therapeutic advantages by long receptor occupancy. In this situation, a 
fast dissociating compound displaying short-lived intervention is preferred. 
This may be the case for the antipsychotic D2 dopamine receptor antagonists, 
where long RT is not desired due to on-target toxicity associated with strong 
extrapyramidal motor effects. We will discuss this in a later part of this 
chapter.
(1)
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Experimental strategies to assess drug-target residence 
time2.3 
Measurement of drug-target complex lifetime, reflected by koff or t1/2, is not 
a new phenomenon per se. To date, there are several strategies available to 
examine the binding kinetics of ligand-GPCR interactions. The advantages 
and disadvantages / limitations of these experimental strategies to access 
drug-target residence time are briefly outlined in Table 2.1. Of these 
(RL*). This is also known as the ‘induced-fit’ mechanism. In this case, koff 
entails both forward (k3) and reverse steps (k4) in receptor isomerization 
as well as the on- and off-rate constants for the free ligand bound to and 
unbound from the free receptor, such that koff = k2∙k4/(k2 + k3 + k4). This 
isomerization step enhances the interaction between the ligand and the 
target, hence resulting in an extended overall t1/2.
                                                                                                           
A third mechanism is represented in Equation 3, where the receptor is in 
equilibrium between two conformational states (R and R*) in the absence of 
ligand. Of these conformational states, the ligand specifically binds to one, 
R*, rather than the other (R), to form the R*L complex. This is also known 
as the ‘conformation-selection’ mechanism. The interconversion between 
conformational states R and R* is slow relative to the binding of the ligand 
to the R* state, thus it represents the rate-limiting step for the formation of 
the binary complex. For the dissociation rate constant, its value is equal to k4.
                                                                                                                  
Among these three mechanisms, the first situation is most commonly 
encountered in ligand-GPCR binding kinetics, while the second mechanism 
can be the case for high-affinity ligand-receptor interactions, especially for 
enzyme inhibitors and receptor antagonists;1,6,14 the third situation is rarely 
observed in ligand-receptor interactions.14
(2)
(3)







approaches, the most common and straightforward method is to radiolabel a 
compound of interest with high affinity and directly measure its on- and off-
rate in a kinetic set-up of a radioligand binding experiment. Two examples, 
in the context of drug-target residence time, are radiolabeled aprepitant 
at the Neurokinin 1 (NK1) receptor and tiotropium at the muscarinic M3 
receptor (M3R). Both compounds have been well characterized by using this 
method.19,20 Alternatively, a ligand can be fluorescently labeled to calculate 
its drug-target residence time. For instance, Keppler and coworkers have 
developed a so-called Tag-lite® platform, a combination of a Homogeneous 
Time-Resolved Fluorescence (HTRF®) detection method with a covalent 
labeling technology called SNAP-tag®.21 One application note from Cisbio 
describes fluorescently labeled spiperone binding at the Tag-lite dopamine D2 
receptor.22 Nevertheless, the process of radio- or fluorescent labeling is costly 
and labor intensive, which, as a consequence, confines kinetics determinations 
to a limited scope. Therefore, alternative approaches are highly desired (See 
Figure 2.1-2.4 for experimental schemes and representative results).
Table 2.1 | The advantages and disadvantages / limitations of experimental strategies 
to access drug-target residence time.







Ligand of interest needs to be 
radiolabeled;





Only one labeled ligand necessary; 
Quantitative measurement; 
Adjustable for high throughput 
screening 






Only one labeled ligand necessary; 
Quantitative measurement
Need for suitable radiolabeled ligand; 





Only one labeled ligand necessary; 
High throughput assay format; 
Easy readout for longer or shorter 
residence time compounds










Only one labeled ligand necessary; 
Adjustable for high throughput 
screening
Need for suitable radiolabeled ligand; 





No need for labeled ligands; 
Adjustable for high throughput 
screening
Qualitative measurement; 









Low throughput assay format
47-55
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Figure 2.1 | Indirect kinetic radioligand binding assays: the receptor-bearing material 
is pre-incubated with a saturating concentration of unlabeled ligand, followed by an 
ÌiÀi`>ÌiwÌÀ>Ì>`ÉÀ¼Ü>ÃÕÌ½ÃÌi«ÌÌ>Ìi}>``ÃÃV>Ì°-ÕLÃiµÕiÌÞ]
>wÝi`VViÌÀ>ÌvÀ>`}>`Ã>``i`>`VÕL>Ìi`ÌiÀi>vÌiÀvÀ>«iÀ`LivÀi
>ÃÃ>Þ ÌiÀ>Ì° /Ã ÃVii Ã >`>«Ìi` vÀ6>ÕµÕiet al.35 In this assay a slowly 




B. (Dual-point) competition association assay
A. Indirect kinetic radioligand binding assays
Contrary to the abovementioned, one-step, direct measurement of 
radiolabeled ligands’ dissociation rates, indirect approaches usually contain 
two consecutive parts (Figure 2.1). Firstly, the receptor-bearing material 
is pre-incubated with a saturating concentration of unlabeled ligand (to 
occupy the majority of receptors), followed by an intermediate filtration 
and/or ‘washout’ step—methods vary in different labs23-26—to initiate ligand 
dissociation. Secondly, a fixed concentration of radioligand is added and 
incubated thereafter for a short period before assay termination. Thus, the 
unlabeled competitor’s dissociation rate could be inferred from the recovery 
of radioligand binding. Furthermore, this method can be adopted and 
modified for high-throughput screening; an example is at the dopamine D2 
receptor (D2R).26
The competition association assay has been shown to be highly accurate 
in determining the binding kinetics of unlabeled ligands at the beta-







adrenergic receptor,27,28 and more recently, at the muscarinic M3 receptor,29 
gonadotropin-releasing hormone (GnRH) receptor,30 histamine H1 
receptor,31 and adenosine receptors,32,33 to name but a few. This method 
is based on a framework developed by Motulsky and Mahan,34 where an 
unlabeled competitor is co-incubated with a radioligand during a kinetic 
association experiment (Figure 2.2). If the competitor dissociates faster 
from its target than the radioligand (k2 < k4), the specific binding of the 
radioligand will slowly and monotonically approach its equilibrium in time 
(Figure 2.2, c). However, when the competitor dissociates slower (k2 > k4), the 
association curve of the radioligand will consist of two phases starting with 
a typical ‘overshoot’ followed by a decline until a new equilibrium is reached 
(Figure 2.2, b).34 In contrast, the association rates of either the competitor 
(k3) or the radioligand (k1) are usually less influential on the pattern of the 
curves.34 Recently, the competition association assay has also been adopted 
and modified by Guo et al. for high-throughput kinetic screening studies 
at the adenosine A1 receptor.33 Briefly, in a so-called dual-point competition 
association assay, two time points are selected to measure radioligand binding: 
1) at which the radiolabeled ligand just reaches equilibrium under control 
conditions in the absence of an unlabeled ligand (Figure 2.2, a and t1), and 
2) at which the incubation time is long enough for the labeled and unlabeled 
compound to equilibrate with the target (Figure 2.2, t2). Next, the ratio of 
the binding at the first time point (Bt1) and that at the second time point 
(Bt2) is calculated, which Guo et al. defined as the ‘kinetic rate index’ (KRI). 
Figure 2.2 | (Dual-point) Competition association assay: an unlabeled competitor is co-
VÕL>Ìi`ÜÌ>À>`}>`>iÌV>ÃÃV>ÌiÝ«iÀiÌ]>`vÜi`vÀÌÜÀ
more time points. a: a radioligand association curve without co-incubation of an unlabeled 
competitor. b: a co-incubated unlabeled competitor dissociates slower than the radioligand 
used. c: a co-incubated unlabeled competitor dissociates faster than the radioligand used. 
Bt1\Ã«iVwVÀ>`}>`L`}>ÌÌiwÀÃÌÌi«Ì­Ì1®Æ	t2\Ã«iVwVÀ>`}>`L`}
at the second time point (t2®°iÌVÀ>Ìi`iÝ­,®Ã`iwi`>Ã	t1 / Bt2. This scheme is 
adapted from Guo et al.33
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C. Dual-point IC50 / Ki value determination
Another method enabling kinetic screening was reported by Heise et al. 
They used a scintillation proximity assay (SPA) to measure an antagonist’s 
affinity after 30 min or 10 h of incubation and examined their ratio (Ki30 min 
/ Ki10 h; Figure 2.3).30 The theory behind this is based on the observation that 
displacement curves will shift leftward over time until a state of equilibrium 
is reached; the time to reach that state is determined by the dissociation 
rate of the slower unbinding process.34 In other words, a slowly dissociating 
compound requires longer incubation times to reach equilibrium than a 
fast dissociating one, which is often neglected. This translates into markedly 
decreased experimental IC50 or Ki values over time. In this sense, the ratio of 
the dual-point IC50 or Ki values represents a surrogate of overall RT. However, 
Figure 2.3 | Dual-point IC50 / Ki value determination: an unlabeled competitor is co-
VÕL>Ìi`ÜÌ> À>`}>` vÀiÌiÀ>ÃÀÌ Ìi ­ ÌÃV>Ãi]i°}°]Îä®À> }
Ìi­ÌÃV>Ãi]i°}°]£ä®>`ÌiÀVÀÀiÃ«`}
50 or Ki values are calculated. In the 
Ài«ÀiÃiÌ>ÌÛiÀiÃÕÌ]>ÃÜÞ̀ ÃÃV>ÌV«Õ`­ÃµÕ>ÀiÃ®Ü>Ûi>Ài«ÀÕVi`
>vwÌÞÃvÌÌ>>v>ÃÌ`ÃÃV>ÌV«Õ`­ÌÀ>}iÃ®°
In this manner, the compounds that quickly dissociate from their target will 
have a KRI below or equal to one (Figure 2.2, c). Conversely, compounds 
that dissociate slowly from their target compared to the radioligand will have 
a KRI value larger than one, resulting from the typical ‘overshoot’ in the 
association curve (Figure 2.2, b). Notably, the dual-point assay and KRI value 
can be applied to screen for candidate compounds with either long or short 
RT. This suggests the general applicability of this assay for other drug targets 
as well.







the principle of this approach also simultaneously implies its limited 
application, i.e. in screening long RT candidate compounds only, since for 
short RT compounds the state of equilibrium is quickly established and the 
Ki ratio derived thereof is hardly changed.
D. Fucntional reversibility assay
A ligand’s binding kinetics profile could also be inferred from circumstantial 
evidence, which is commonly based on functional assays resembling the 
classical ‘organ-bath’ experiment. More specifically, it requires pre-incubating 
tissues / cells with antagonists (to allow them sufficient time to reach binding 
equilibrium conditions) before their challenge with an agonist (Figure 2.4).35 
As a result, fast dissociating antagonists can only cause a rightward shift of 
the agonist’s concentration-dependent curve, since the receptor can quickly 
be liberated from the antagonist’s blockade and thus readily respond to the 
subsequently administered agonist. These types of antagonists are categorized 
as ‘surmountable’ (Figure 2.4, pre-incubation experiment).9,36,37 In contrast, 
slowly dissociating antagonists or, at the extreme, irreversible binders can 
induce not only a rightward shift but also a concomitant decline in maximal 
response of the agonist, due to sustained receptor blockade which, on a 
macroscopic scale, reduces the total receptor population available for an 
agonist’s response.38,39 Such antagonists are denoted as insurmountable (Figure 
2.4, pre-incubation experiment).9,36,37,40 Notably, such an insurmountable 
pattern can also be caused by a number of different mechanisms, such as 
allosteric interactions, receptor internalization or postreceptor functional 
response blockade.41-44 None of these result from competitive antagonism. 
Nevertheless, these mechanisms can be distinguished in a co-incubation 
experiment, where a depressed maximal response can only be observed 
by a noncompetitive mechanism, but not for competitive antagonists, 
no matter how fast or slowly they dissociate from the target (Figure 2.4, 
co-incubation experiment). Thus, it is always necessary to perform a co-
incubation experiment along with the pre-incubation experiment to clarify 
the mechanism of the insurmountable antagonism.37,45,46 It is important to 
mention that the extent of the insurmountable effect, e.g. a decreased maximal 
response, is time dependent. During a short period of agonist exposure 
(following pre-incubation with a slowly dissociating antagonist), not all the 
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E. Label-free kinetic measurements
One of the most well-established label-free measurements for kinetics is surface 
plasmon resonance measurement (SPR). In SPR, the protein is immobilized 
receptor sites are liberated before the response is measured, a state of so-called 
‘hemi-equilibrium’.38,39,44 However, if the agonist exposure lasts longer, the 
occupancy of the receptors will readjust with time until, ultimately, both the 
agonist-receptor and the antagonist-receptor interactions reach equilibrium.44 
Evidently, the insurmountability of such slowly dissociating compounds will 
change if the response is measured at different time points.
Figure 2.4 | Functional reversibility experiment: in the upper panel, tissues/cells are 
pre-incubated with an antagonist before challenge with an agonist. A slowly dissociating 
>Ì>}ÃÌ ­ÃµÕ>ÀiÃ®ÜV>ÕÃi> À}ÌÜ>À`ÃvÌv ÌiVViÌÀ>ÌÀiÃ«ÃiVÕÀÛi>`
>VVÌ>Ì`iVi >Ý> ÀiÃ«Ãiv Ìi>}ÃÌÆ> v>ÃÌ`ÃÃV>Ì}>Ì>}ÃÌ
­ÌÀ>}iÃ®ÜV>ÕÃi>À}ÌÜ>À`ÃvÌvÌiVViÌÀ>ÌÀiÃ«ÃiVÕÀÛiÜÌÕÌ>vviVÌ}
Ìi>Ý>ÀiÃ«ÃivÌi>}ÃÌ°v>ÃÌiÜiÀ>ÞiÀ>>Ì>}ÃÌÃVVÕL>Ìi`
with an agonist; both slowly and fast dissociating competitive antagonists will cause a 
À}ÌÜ>À`ÃvÌvÌiVViÌÀ>ÌÀiÃ«ÃiVÕÀÛiÜÌÕÌ>vviVÌ}Ìi>Ý>ÀiÃ«Ãi
of the agonist. Otherwise they are non-competitive to the agonist; Control: agonist only 
­Ã«iÀiÃ®°/ÃÃViiÃ>`>«Ìi`vÀ6>ÕµÕiet al.35







on a coated gold chip, which is then exposed to the compound of interest 
under continuous flow. Ligand binding to the receptor immobilized on the 
chip’s surface induces a real time change in the refractive index on the sensor 
surface. As such a change is linear to the number of molecules bound, it 
allows quantitative characterization of binding kinetics (for review, see16,47,48). 
Another emerging label-free technology enabling kinetics measurement 
is by surface acoustic wave biosensor (SAW).49 This methodology captures 
real-time mass changes on the surface, which result in a shifted phase and / or 
changed amplitude of the sound wave signal.50 Besides these two biophysical 
assays, other equally valid technologies have also been reported elsewhere.51
However, these biophysical techniques have not been thoroughly tested 
on GPCRs. The difficulty is that these receptors are integral membrane 
proteins, and rapidly deteriorate when taken out of their natural environment, 
which is often a prerequisite for these newer biophysical approaches. Several 
strategies were developed to overcome this inherent difficulty. One of the 
successful examples is the application of a protein engineering method 
to generate a stabilized receptor (StaR), e.g. the adenosine A2A receptor, 
minimally modified for thermostability.52-54 The stabilized receptors can be 
purified in large quantities, whilst retaining correct folding, thus generating 
materials suitable for a broad range of structural and biophysical studies.53 
Another technique is to solubilize a given GPCR from whole cell pellets and 
capture it on antibody surfaces for analysis, exemplified by an SPR study on 
the CCR5 and CXCR4 chemokine receptors.55 These solubilized receptor 
preparations could be useful materials for binding kinetics studies.
Revisit kinetics data on GPCRs
To date, nearly 800 genes encoding GPCRs have been identified, representing a 
substantial share of the human genome.56 In general, all these receptors possess 
structurally conserved heptahelical transmembrane motifs (7TM) connected 
by alternating intracellular and extracellular loops, with the amino terminus 
located at the extracellular side and the carboxyl terminus at the intracellular 
side.57 Despite these common features in their molecular structure, GPCRs 
are characterized by a relatively low overall sequence identity (less than 20%). 
According to phylogenetic classification, these receptors can be divided into 
five main families—Rhodopsin (Class A), Secretin (Class B), Glutamate (Class 
2.4 
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Cmpd Targeta t1/2b Clinical indications Statusc Ref.
Ritanserin 5-HT2 receptor £Èä­ÎÇc
® Cocaine-related disorders Phase II 160
Risperidone 5-HT7 receptor ÀÀiÛiÀÃLi­ÎÇc
® Schizophrenia; Alcohol abuse Marketed 161
Clonidine Į2A-autoreceptor ÓÇ°ÈÃ­ÎÇc
® ADHD Marketed 99
Bopindolol ȕ1-adrenoceptor {­À>Ì® Hypertension Marketed 162
Olodaterol ȕ2-adrenoceptor 17.8 h COPD Marketed 163
Lofentanil ùÀiVi«ÌÀ ÓÈä­ÎÇc
® Analgesia Marketed 164
Candesartan AT1 receptor £Óä­ÎÇc
® Hypertension Marketed 43
UK432,097 A2A receptor £ÇÎ­xc
® COPD Terminated
d 32




® HIV Marketed 165
SCH527123 CXCR2 22 h Asthma; Psoriasis Phase II 166
PF-4850890 CRF1 receptor È°Ç­À>Ì® i«ÀiÃÃÆƂÝiÌÞ Preclinical 153
Clozapine D2 receptor £{°xÃ­ÎÇc
® Schizophrenia Marketed 135
AM432 DP2 receptor ä­ÎÇc
® COPD Preclinical 167
Uracil 3 GnRH receptor > 43 h ,i«À`ÕVÌÛii`VÀi>ÝÃ
disorders
Preclinical 168
Desloratidine H1 receptor > 6 h Allergy Marketed 169
JNJ7777120 H4 receptor 62 min y>>Ì Preclinical 170
Tiotropium M3 receptor 27 h COPD Marketed 80
Aprepitant NK1 receptor 154 min Chemotherapy-induced 
emesis
Marketed 19
Ibodutant NK2 receptor 28 min Irritable Bowel Syndrome Phase II 171
Osanetant NK3 receptor 10 min Schizophrenia Phase II 172
ƂÀiÝ>Ì OX2 receptor 139 min Chronic primary insomnia Phase III 173
Clopidogrel P2Y12 receptor ÀÀiÛiÀÃLi­ÎÇc
® Stroke; Heart attack; Severe 
chest pain
Marketed 62
Apafant PAF receptor xä­}Õi>«}® Arrhythmias; Breast cancer; 
y>>Ì
Preclinical 174
GSK1562590 UT receptor £­À>Ì® Hypertension Preclinical 175
SCH500946 Y5 receptor 71 min Obesity Preclinical 176
Table 2.2 | Overview of GPCR ligand kinetics.
a "vwV>1*Ƃ,ÀiVi«ÌÀ>i°b Dissociation half-life at room temperature and on human 
receptors unless mentioned otherwise. c Clinical status obtained from ClinicalTrials.gov.179 
dÃVÌÕi``ÕiÌ>VvivwV>VÞ°e Discontinued due to high level of central nervous 
system side effects.177,178







C), Adhesion and Frizzled/Taste2.56,58 Receptors from Class A to C have been 
most addressed in drug discovery efforts. The natural ligands of GPCRs are 
highly variable ranging from small ions and photons to large glycoproteins, 
which indicates the important and versatile roles these proteins play in a 
vast number of biological processes. These are also the reasons why GPCRs 
have developed into a very ‘druggable’ class of targets for more than 30% of 
currently available drugs.59 However, in the introduction we also mentioned 
the tremendous attrition along R&D pipelines, and suggested that detailed 
mechanism-based studies of drug-target interaction should be introduced in 
the early phases of drug discovery to prevent ‘fail late, fail expensive’ scenarios. 
For this we examined the gigantic ‘pool’ of GPCR ligands and retrospectively 
analyzed the ‘kinotype’ (kinetics features) of some cases. Without claiming to 
be exhaustive we have summarized a series of prototypic GPCR ligands that 
have known kinetics information (Table 2.2). We listed one representative 
(candidate) drug per target (26 targets in total) including their clinical 
indications. Several conclusions can be drawn from this table. Firstly, the 
existing kinetics data for GPCR ligands is nowhere near the number of 
affinity-based evaluations in the early phases of drug discovery. The sum of 
targets presented here is far behind the total population of ‘druggable’ GPCRs, 
estimated to be 300.60,61 Clearly, ligand-receptor binding kinetics has been 
overlooked and less investigated in the past. Secondly, the range of drug-target 
residence times, reflected by t1/2 in the table, varies from seconds to hours. 
Most of these are in line with the clinical applications of the related drug. 
For instance, patients with allergy can benefit from the long-lasting effect by 
desloratidine (t1/2 > 6 h) in relieving nasal congestion, or patients with COPD 
from taking tiotropium (t1/2 = 27 h) for a durable bronchodilatory effect. In 
both cases, their clinical indications favor sustained target occupancy. On 
the contrary, for some marketed drugs, serious adverse effects could go along 
with the desired effects due to unwanted kinetic rates. This is exemplified 
by clopidogrel, which is an antiplatelet agent used to inhibit the formation 
of blood clots. However, its irreversible inhibitory effect may prolong or 
exacerbate bleeding.62 Another case is represented by lofentanil for analgesia. 
Although its longer duration of action has an advantage for certain types 
of analgesia,63 it is still unsuitable for most practical applications.64 Instead, 
short-acting derivatives such as sufentanil or remifentanil are preferred for 
medical use in human surgical procedures.65,66 One can speculate that such 
clinical limitations could be avoided or at least foreseen if kinetics were to be 
incorporated in the early phase of candidate selection.
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Structure-kinetics and structure-affinity relationships
Thus far the abovementioned analyses in retrospect are still largely based on 
‘hindsight’ information; hardly any structure-kinetics relationship studies 
(SKR), in prospect, have been reported previously. Therefore, we should like 
to propose a strategy for compound optimization that combines an extensive 
structure-kinetics relationship study (SKR) with a classical structure-affinity 
relationship study (SAR). It is envisioned that this added metric, i.e., binding 
kinetics or the ‘kinotype’ of a given compound, offers several advantages over 
the traditional and simple SAR paradigm:
1) A better understanding of the molecular mechanism of action. 
This includes detailed characterization of not only the bound states under 
equilibrium conditions (SAR) but also the entire drug-target interaction that 
comprises metastable intermediate states and transition states (SKR).14,67 
Such gained knowledge offers rationales for efficient drug design.
2) A more steered drug design and development. Different targets may 
have distinct kinetics preferences. Aiming for long or short RT compounds is 
a crucial consideration in early phase discovery to triage and advance the best 
leads towards clinical applications.16 
3) An efficient translation from in vitro to in vivo settings. This may 
decrease the prevalence of the ‘fail late, fail expensive’ scenario, especially 
considering that lack of efficacy is one of the major reasons for drug 
attrition.68,69 
In addition, a detailed SKR study also describes the association rate 
of the ligand-receptor interaction, which has been less investigated and is 
often thought to be diffusion-limited.14 As a consequence, this could lead 
to the assumption that optimizing for a long residence time is tantamount 
to optimizing the binding affinity, since KD = koff / kon and kon reaches an 
(identical) limit. However, Vilums et al. have recently reported a thorough 
SKR study on the CCR2 receptor, in which it was shown that this general 
assumption is not necessarily valid.18 They documented that the compounds’ 
on-rates varied significantly from 0.01 nM-1∙min-1 to 0.0003 nM-1∙min-1 
—more than three orders-of-magnitude from the diffusion-limited value 
(approximately 1010 M-1∙min-1)1. It is also notable that the affinity difference 
of two diastereomers in that paper with Ki values of 3.6 nM and 289 nM, was 
predominantly caused by their 18-fold difference in the on-rate, rather than 









only be obtained by a detailed SKR study, which has not been reported for 
many GPCRs so far.
Evidently, a detailed SKR offers added value to the traditional metric of 
affinity. This new strategy of combining SAR and SKR can be expected to 
further enhance the success of drug discovery and development. To further 
illustrate the importance of incorporating SKR into the pipeline of early 
phases of drug research, in the following part of this chapter we will primarily 
address small molecules targeting class A and B GPCRs, which have been 
reported to have optimized binding kinetics, more specifically dissociation 
kinetics. Specific evidence will be given for three ‘long RT’ targets and one 
‘short RT’ target; muscarinic M3, tachykinin NK1 and CRF1 receptor, and 
dopamine D2 receptors, respectively, since these targets have been (most) 
extensively studied in this area. 
Drug-target residence time for class A GPCRs2.6 
Muscarinic receptors
Muscarinic receptors, or muscarinic acetylcholine receptors (mAchRs), 
are a group of class A GPCRs, which are endogenously activated by 
acetylcholine.70 To date, five subtypes of muscarinic receptors are identified, 
namely M1-M5.71,72 These receptors can be further categorized into two broad 
groups based on their primary coupling efficiency to G proteins; M2 and 
M4 muscarinic receptors couple to the pertussis toxin-sensitive Gi/o proteins, 
while M1, M3 and M5 muscarinic receptors to Gq/11 proteins.70,73 Of all five 
muscarinic subtypes, M3 receptor is located in the smooth muscles of blood 
vessels throughout the body as well as in the lung. Hyperactivation of the 
lung M3 receptor can cause over constriction of smooth muscle, such as that 
observed during bronchoconstriction. Thus, antagonizing M3 receptor can 
lead to relaxation of airway smooth muscles and result in symptom relief 
of chronic obstructive pulmonary disease (COPD).74,75 Additionally, for the 
treatment of chronic illness, long duration of action (preferably 24 h) is an 
important feature of drugs that enables both prolonged efficacy and patient 
compliance.76 Therefore, the treatment of COPD can benefit from a long-
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Tiotropium is a long-acting anticholinergic bronchodilator, which is 
currently marketed under the trade name SpirivaTM (Figure 2.5, Compound 
1).77-79 Given its long in vivo duration of action, several groups, in retrospect, 
performed in vitro time-dependent IC50 value analysis to obtain the accurate 
affinity and binding kinetics of tiotropium.29,80 It was found that equilibrium 
is reached only after 18-20 h in a radioligand binding assay. This phenomenon 
is consistent with the theory by Motulsky and Mahan that a long incubation 
time is needed for a radioligand to reach equilibrium in the presence of a 
slowly dissociating competitor.34 Thus, it also explains that different affinities 
were published by different groups; after a period of 20 h incubation, the Ki 
value of tiotropium was 8 pM,29,80 while after only 4 h incubation, its KD value 
was 0.33 nM.78 The t1/2 of [3H]-tiotropium was 34.6 h at room temperature, 
which was much longer than ipratropium (Figure 2.5, Compound 2; t1/2 = 
0.26 h, Table 2.3), a relatively short-acting agent requiring up to four doses per 
day.74,78 Similarly, a kinetics study performed by Dowling and Charlton using 
a competition association assay has also demonstrated that tiotropium has a 
very long t1/2 (7.7 h) at room temperature,29 which, however, is shorter than 
the value (34.6 h) reported by Disse et al.78 This may be due to the difference 
in their buffer for membrane preparation and / or the binding buffer for 
kinetic measurements, for instance, the presence of sodium ions. Likewise, 
tiotropium has an even shorter dissociation half-life (46.2 min) under mock 
physiological conditions at 37 °C, where the ionic strength (including 
Na+, Ca2+, K+, Mg2+ and Cl- ions) of the assay buffer was increased.81 This 
example furthermore highlights the importance of careful choices in assay 
development for kinetic measurements. Another important pharmacological 
feature of tiotropium is its ‘kinetic receptor subtype selectivity’, namely a 
longer dissociation half-life at the M3 receptor, 34.7 h, than at the M1 and M2 
receptors (14.6 h and 3.6 h, respectively).78 In contrast, tiotropium’s affinities 
at these receptors were similar and in the subnanomolar concentration 
acting muscarinic antagonist (LAMA), as evidenced by tiotropium and other 
M3 antagonists summarized below.
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range.78 Taken together, these features make tiotropium the most widely used 
LAMA worldwide so far.81,82
To understand the molecular basis of the exceedingly long RT of 
tiotropium, Tautermann et al. performed a ‘kinetic mapping’ of its binding 
sites and the ‘exit’ channel from the M3 receptor by testing the kinetics of 
tiotropium at mutant M3 receptors.83 They found that the slowly dissociating 
profile of tiotropium was attributed to interactions in the binding site 
particularly with N5086.52 (N5076.52 on the rat M3 receptor, see Figure 2.6). 
Importantly, this residue appeared to ‘anchor’ tiotropium at the receptor 
via directly interacting with its hydroxyl-group and ester-group so as to 
restrict the movement of the ligand towards the exit channel. Consequently, 
tiotropium’s RT was 45-fold longer on the wild type M3 receptor than that of 
its analogue lacking the hydroxyl-group, while little difference was observed 
at the N5086.52A mutant. 
Furthermore, a recent structural biology study of the M3 receptor (from 
rat) co-crystallized with tiotropium (PDB code: 4DAJ) provided a clear image 
for the molecular mechanism behind its long RT profile.84 As presented in 




1. Tiotropium 8 pM 34.6 h 29,78
2. Ipratropium 0.69 nM 0.26 h 78
3. Aclidinium 18 pM 10.7 h 80
4. PF-335659 132 pM > 24 h 96
5. Glycopyrronium 10.04 6.3 h 80
6. Acetylcholine 4.87 7.8 s 98
7. Carbachol 4.09 6.3 s 98
8. Methacholine 4.52 6.0 s 98
9. "ÝÌÀiÀi 4.61 7.2 s 98
10. "ÝÌÀiÀi 5.61 2.6 s 98
11. Bethanechol 3.71 3.7 s 98
12. Pilocarpine 4.78 3.0 s 98
a Compound names and synonyms used in original references. bƂvwÌÞ]iÝ«ÀiÃÃi`>Ãi 
values or pKi as reported in original references; result on human receptor unless mentioned 








Figure 2.6, tiotropium binds deeply in the receptor core and is covered by an 
aromatic ‘lid’ comprised of three conserved tyrosines—Y1483.33, Y5066.51 and 
Y5297.39. This aromatic ‘lid’ nearly occludes the ligand from the solvent thus 
preventing it from being ‘wetted’ by water molecules and then ‘washed’ off 
the binding pocket. In addition, the abovementioned N5076.52 interacts with 
the carbonyl and hydroxyl groups of tiotropium through H-bonds, while the 
ligand’s typical quaternary amine interacts with D1473.32.
The elucidation of the co-crystal structure of tiotropium in the rat M3 
receptor also facilitated molecular dynamic simulations to characterize the 
pathway by which tiotropium binds to and dissociates from the rat M3 
receptor.84 In contrast to a simple one-step dissociation process, the ligand 
appeared to firstly leave the orthosteric ligand binding pocket and then ‘pause’ 
at an extracellular ‘vestibule’, forming a loosely connected intermediate state, 
before tiotropium finally dissociated from the receptor. During this process, 
Figure 2.6 | The co-crystal structure of tiotropium in the rat M3 receptor.84/Ãw}ÕÀi
Ü>Ã}iiÀ>Ìi`ÜÌ
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Ƃ°/ÌÀ«Õ­L>V®
binds within the pocket. Three tyrosine residues, Y1483.33, Y5066.51 and Y5297.39, together 
prevent the ligand from moving out of the receptor. N5076.52 interacts with the carbonyl and 
Þ`ÀÝÞ}ÀÕ«ÃÌÀÕ}L`Ã]ÜiÌ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interacts with D1473.32.
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the first step formed a large energy barrier that involved the aromatic ‘lid’ 
(Y1483.33, Y5066.51 and Y5297.39) around the charged ligand head group 
opening up, while the second step posed a smaller energetic barrier. In this 
sense, the RT of tiotropium is greatly determined by the first step, which is 
rate-limiting for the ligand dissociation process.
As expected from the kinetic binding profile of tiotropium, an 
insurmountable antagonist behavior was observed in a functional reversibility 
experiment. This was detailed by Casarosa et al. during the preclinical 
evaluation of several long- and short-acting muscarinic antagonists, where 
tiotropium was pre-incubated for 15 min before the addition of the agonist 
muscarine in the inositol phosphate accumulation assay.80 Fitting the dose 
ratios over a large range of tiotropium concentrations (10-10-10-5 M) generated 
a Schild plot with a slope of 1.29, higher than unity. Such a value indicated 
the insurmountable M3R antagonism of tiotropium, which was a result of a 
hemi-equilibrium due to its long M3R residence time profile.37
Taken together, the in vitro results mentioned above combined with 
further evidence unveil the molecular basis of the long RT profile of 
tiotropium. These results correlate with this compound’s long in vivo duration 
of bronchoprotection (> 24 h) as determined in a model of acetylcholine-
induced bronchoconstriction in anesthetized dogs.80 Moreover, despite 
the possible influence of drug metabolism and pharmacokinetic factors,85 
the clinical profile of tiotropium in COPD highlights an inextricable link 
between long receptor RT and long duration of action that enables a simple, 
once-daily dosage regime.77,86,87
2. Aclidinium
Aclidinium (Figure 2.5, Compound 3) is a long-acting, inhaled muscarinic 
antagonist recently approved by the FDA as a maintenance treatment for 
COPD.88 The synthesis and biological evaluation of aclidinium and its 
analogues were elaborately reported by Prat et al. and Gavalda et al.20,89 This 
antagonist was specifically designed for a maintained bronchodilatory efficacy 
with fewer unwanted systematic anticholinergic effects, such as dry mouth 








of patients treated with placebo), glaucoma, constipation, increased heart 
rate, and urinary retention.90 According to Prat et al., aclidinium had a rapid 
hydrolysis in human plasma, hence minimizing the class-related systematic 
side effect. However, such a fast pharmacokinetics profile of aclidinium did 
not influence its long duration of action (over 24 h), as evaluated in an animal 
model.20 This phenomenon was attributed to aclidinium’s slowly dissociating 
profile from the M3 receptor. 
Compared to tiotropium, aclidinium had a similar affinity for the M3 
receptor (Ki = 18 pM), while its t1/2 (10.7 h) was approximately two-fold 
shorter (Table 2.3).80 In another study, Gavalda et al. used radiolabeled 
aclidinium and found a KD value of 0.32 nM; combined with t1/2 of 29.24 h, 
which was shorter than [3H]-tiotropium (62.19 h).20 
In vitro functional activity and in vivo duration of bronchoprotection of 
aclidinium was also examined by Gavalda et al.20 More specifically, they used 
the isolated guinea pig trachea and treated it with carbachol to generate dose-
dependent contraction. A 60 min pretreatment with aclidinium or tiotropium 
shifted the concentration-response curves of carbachol to the right. Along 
with the potency shift, tiotropium also suppressed the maximal agonist effect 
while aclidinium did not. Such a result is indicative of the relatively shorter 
RT of aclidinium than that of tiotropium at the M3 receptor. 
In addition to the characterization of aclidinium’s functional activity, the 
onset of action of this compound was also studied in the carbachol-induced 
contraction assay. Notably, aclidinium displayed a faster onset of action (t1/2 = 
6.8 min, tmax = 35.9 min) than tiotropium (t1/2 = 13.6 min, tmax = 61.2 min). 
For the in vivo duration of bronchoprotection, the effect half-life of aclidinium 
(defined as the time taken to reduce the maximal bronchoconstriction 
by 50%) was 29 h. This duration of action was considerably longer than 
that of ipratropium (8 h) yet shorter than tiotropium (64 h). Likewise, 
Casarosa et al. reported that aclidinium and tiotropium displayed different 
levels of bronchoprotection at 24 h after equi-effective dose administration 
(tiotropium = 35%, aclidinium = 21%).80 Clearly, these in vivo results are in 
line with the in vitro binding kinetics. 
Furthermore, compared to tiotropium’s once-daily dose regime, 
aclidinium required a twice-daily dose regime for a 24 h bronchodilation 
effect in clinical trials.91-95 Such a difference appears to be derived from their 
divergent RTs at the M3 receptor. In addition, aclidinium’s faster onset of 
action, mostly due to its fast association rate, can provide quicker symptom 
relief as compared to tiotropium.
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4. Glycopyrronium
Glycopyrronium (Figure 2.5, compound 5) is the cation and active moiety 
of glycopyrronium bromide, of which the dry-powder formulation is also 
known as NVA237.81 In vitro binding kinetics profiling of this compound 
3. PF-3635659
The synthesis and biological evaluation of PF-3635659 (Figure 2.5, 
Compound 4) and its analogues was reported by Glossop et al.96 This study 
nicely exemplifies a systematic combination of both a structure-affinity 
and structure-kinetics relationship study for early-phase drug design and 
development. More specifically in this study, Glossop et al. demonstrated 
that a gem-dimethyl substitution adjacent to the basic amine moiety of PF-
3635659 exerted a profound effect on the dissociation rate. As evidence, the 
t1/2 of the initial gem-dimethyl-free compound (38 min) was extended to 
over 1440 min, indicating the importance of the gem-dimethyl substitution 
for attaining ligand receptor RT. Further chemical modifications on the 
heterocyclic ring and the right side of the phenyl ring induced corresponding 
changes in ligand affinity and kinetics, which eventually led to the discovery 
of the candidate compound, i.e., PF-3635659 (Compound 47 in the original 
paper). Following-up binding kinetics characterization of this compound 
in a competition association assay revealed that it had an on-rate of 1.05 
× 107 M-1·min-1, slower than tiotropium and ipratropium (kon = 2.12 × 108 
M-1·min-1 and 1.00 × 109 M-1·min-1) and an off-rate of 1.39 × 10-4 min-1, 
translating into a t1/2 of more than 24 h (Table 2.3). 
Importantly, the in vivo onset and duration of action data for PF-3635659 
were in line with its in vitro binding kinetics. The profiling of PF-3635659 
in a conscious dog model of bronchoconstriction illustrated a slower onset of 
action compared to ipratropium and tiotropium, with yet a longer duration 
of action (> 24 h) than ipratropium.96 This compound has now progressed 
into a phase II clinical trial. Data from healthy volunteers demonstrated that 
PF-3635659 provided efficacious bronchodilation over 24 h from a single 
inhaled dose, thus confirming the suitability of PF-3635659 as a novel once-








in a radioligand competition association assay revealed a dissociation rate 
of 0.11 ± 0.02 h-1 from the M3 receptor, equal to a dissociation t1/2 of 6.3 h 
(Table 2.3). This value was much longer than the short-acting M3 antagonist 
ipratropium (0.22 h) but shorter than tiotropium (27 h).80 However, 
glycopyrronium had a more rapid rate of onset of action (3- to 4.8-fold) than 
tiotropium, as determined in an in vitro calcium assay and rat tracheal strip 
assay.81 This profile was similar to that obtained with ipratropium bromide in 
preparations of guinea-pig and human airways.97 
Notably, glycopyrronium also displayed higher equilibrium binding and 
kinetic selectivity for M3 versus M2 receptors as compared to both tiotropium 
and ipratropium.80,81,97 Its kinetic selectivity resulted from a 16.5-fold longer 
receptor RT at the M3 receptor than at the M2 receptor, which was higher 
than tiotropium (10.4-fold) and ipratropium (7.3-fold). Such a property may 
provide a better therapeutic window. 
5. M3 receptor agonists
The RTs of seven M3 agonists (Figure 2.5, Compound 6-12) were recently 
reported by Sykes et al.98 These agonists are acetylcholine, carbachol, 
methacholine, oxotremorine-M, oxotremorine, bethanechol and pilocarpine, 
and are not very selective. The data, however, were only collected on the 
M3 receptor subtype. Among the seven agonists, oxotremorine displayed the 
shortest t1/2 at the M3 receptor (2.6 s), while acetylcholine had the longest 
receptor RT (t1/2 = 7.8 s). In general, these agonists’ off-rates were much 
faster than that of the abovementioned M3 antagonists (Table 2.3). Further 
in vitro functional characterization of the M3 agonists demonstrated that they 
had different relative agonist efficacies. Notably, Sykes et al. found that there 
was no relationship between agonist efficacy and the equilibrium binding 
affinity of each agonist. Interestingly, when efficacy was compared with the 
dissociation rate constant, the two were highly correlated. This result suggests 
a relationship between the duration of agonist binding at the receptor and 
the intrinsic efficacy, a finding also reported by Guo et al. and Hoeren et al. 
at the adenosine A2A receptor and at the α2A-adrenoceptor.32,99 Importantly, 
such a finding again emphasizes that equilibrium models and assays alone are 
not sufficient to describe a dynamic signaling system; instead, a combination 
of kinetic models alongside the traditional affinity determination might be 
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Tachykinin receptors
Tachykinin receptors comprise three different subtypes, namely the NK1R, 
NK2R and NK3R, which can be activated by tachykinin peptides, including 
Substance P (SP), neurokinin A (NKA) and neurokinin B (NKB).100-102 The 
three members of the neurokinin receptor class are differentiated by their 
varying affinities for these three tachykinins, which are SP > NKA > NKB 
for the NK1R, NKA > NKB > SP for NK2R and NKB > NKA > SP for 
NK3R (for reviews, see100-102). All three subtypes are functionally coupled to 
Gq/11, which leads to the activation of phospholipase C-IP3/DAG signaling 
and results in elevation of intracellular Ca2+ levels.102 The localization of the 
tachykinin receptors varies between subtypes in the human body: the NK1R 
and NK3R are prominent both in the central nervous system (CNS) and in 
peripheral tissues, while the NK2R is widely expressed in the smooth muscle 
of the gastrointestinal, respiratory, and urinary tracts and to a much lesser 
extent in the CNS.102-104 A large body of preclinical evidence has suggested 
that pharmacological or gene manipulation of the NK1R has potential clinical 
utility in the treatment of chronic pain, migraine, neurogenic inflammation 
and emesis.105-107 These diseases could benefit from therapeutics with a long 
duration of NK1R antagonism.
In summary, several case studies of long acting M3 receptor antagonists 
suggest their sustained pharmacological effect lies in these compounds’ long 
receptor occupancy time. The design and development of long residence time 
antagonists may provide further candidate drugs with once-daily application 
for COPD. We also included the kinetics data of several M3 agonists, since 
they provide important information that agonist efficacy may be correlated to 
its drug-target residence time rather than the commonly tested equilibrium 
affinity. This further indicates the importance of combining both binding 
and kinetics information in the early phase of drug design and development.









Figure 2.7 | Structures of small molecule NK1 receptor antagonists.
1. Aprepitant
Aprepitant, also known as L-754,030, MK0869 or Emend (Figure 2.7, 
Compound 1),19,108-110 is the only tachykinin receptor antagonist on the 
market to date. It is a selective, slowly dissociating NK1 antagonist with a t1/2 
of 154 min at 22 °C (Table 2.4).19 In comparison, it was found by Cascieri 
et al. that the dissociation rate of the radiolabeled NK1’s natural ligand SP 
(i.e., 125I-[Tyr8]-SP) was too rapid to be measured accurately at a comparable 
temperature.111 At 15 °C, this peptide dissociates with t1/2 = 46 min and 0.2 
min for the G protein-coupled and -uncoupled receptor states, respectively.112 
Evidently, aprepitant had a much longer residence time on the NK1 receptor 
than the natural ligand which has been speculated to be the reason for its 
high potency and in vivo efficacy.
As expected from a slowly dissociating ligand, aprepitant’s activity was 
found to be insurmountable in functional assays compared to other, fast 
dissociating NK1R antagonists. This functional effect was associated with 
its long-lasting in vivo efficacy, a finding shared by many authors.19,108,110 
One of the most elaborate studies reported on aprepitant was conducted by 
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1 Aprepitant 0.019 £x{­ÓÓc
® 19
2 L-742,694 0.037 ÓÇ­ÓÓc
® 111
5 Vestipitant 0.027 x°Ç­ÎÇc
® 119
a Compound names and synonyms used in original references. bƂvwÌÞ]iÝ«ÀiÃÃi`>Ãi 
values that were reported in original references; results on human receptor unless mentioned 
otherwise. c Dissociation half-life at different temperatures indicated in brackets.
Aprepitant was originally developed from L-742,694 (Figure 2.7, Compound 
2),109,111,112 which was shown to be a pseudo-irreversible yet competitive 
antagonist by Cascieri et al. in 1997.111 The t1/2 of [3H]-L-742,694 (27 min, 
Table 2.4) at 22 °C is considerably shorter than the half-life of aprepitant 
but longer than the natural ligand SP.19,111,112 Its functional interaction was 
2. L-742,694
Lindström et al.108 Several functional experiments (i.e., pre-incubation, co-
incubation and washout experiments) were used to reaffirm that aprepitant 
was a competitive yet pseudo-irreversible antagonist with slow functional 
reversibility. Next to the measurement of its functional interactions in 
vitro, the authors also examined the pharmacokinetic/pharmacodynamics 
relationship of aprepitant in vivo by using the gerbil foot tap (GFT) assay, a 
model reflecting central NK1R activation.113 It was found that the duration of 
GFT inhibition by aprepitant outlasted the time course of its plasma or brain 
concentrations, indicating that its long duration of action was indeed more 
likely due to a sustained receptor blockade rather than a slow pharmacokinetic 
half-life. In contrast, two other structurally unrelated NK1 antagonists, CP-
99994 and ZD6021, demonstrated rapid functional reversibility that was 
in line with their pharmacokinetic profile.108 Furthermore, these authors 
also examined ex vivo receptor occupancy by autoradiography, reaffirming 
that time-dependent inhibition of GFT by aprepitant correlated well with 
NK1 occupancy in the gerbil brain, a finding that was shared by Duffy et 
al. in 2002.109 Taken together, all in vitro and in vivo results provide strong 








further characterized by Cascieri et al. by using both human and rat NK1 
receptor.111 Interestingly, its nature of NK1 receptor antagonism was species 
related as L-742,694 was insurmountable on the hNK1 receptor but not on 
the rNK1 receptor. A follow-up mutational analysis revealed that mutating 
H1975.39 in TM5 into Serine reduced L-742,694 affinity and simultaneously 
abolished its functional insurmountability at the hNK1 receptor, making it a 
key amino acid for L-742,694 interaction and function. When testing several 
structural analogues of L-742,694, the authors found that the addition of 
the triazoline moiety (as in L-742,694) converted a surmountable antagonist 
into an insurmountable one, possibly by slowing the dissociation rate.111
3. Compound 22
Aprepitant has formed the basis for the discovery of more potentially long 
acting NK1R antagonists. Young et al. developed a series of pyrrolidine-
carboxamides and oxadiazoles based on aprepitant, aiming for feasible clinical 
candidates for a once-daily dosing regimen.114 Their screening strategy was to 
find compounds with enduring functional activity in vitro and long duration 
of action in vivo at lower drug levels as to obtain an improved safety profile. 
Overall, Compound 22 (Figure 2.7, Compound 3) was found to be the best 
compound with efficacious functional activity in an IP-1 functional assay and 
long duration of action (over 24 h) in the GFT model. During the course of 
compound optimization, the authors were also able to establish a kinetically 
informed structure-activity relationship. They concluded that both receptor 
binding affinity and functional insurmountability are highly sensitive to both 
absolute and relative stereochemistry,114 which was reaffirmed for another 
compound series by Morriello et al.115
4. Compound 20
Morriello et al. employed virtually the same screening technique as described 
by Young et al.114,115 to develop both a series of long acting 5,5-fused 
pyrrolidines115-117 and later a series of 5,5,5-fused tricyclic antagonists with 
even slower dissociation rates, with cyclopentane compound 20 (Figure 2.7, 
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5. Vestipitant and its analogues
Vestipitant (Figure 2.7, Compound 5) has a t1/2 of 59.7 min (Table 2.4, 
37 °C) from the human NK1R.119 It is an insurmountable yet competitive 
antagonist with long duration of action (over 8 h) in the in vivo GFT 
model.119 Compared to other structural analogues of vestipitant, it appeared 
that certain features such as the benzylic substitution patterns and its 
stereochemistry were important for vestipitant’s mode of antagonism,119 
which was reaffirmed in another publication by Di Fabio et al.120 Surprisingly, 
even a small, hydrophobic substituent, for instance a methyl substituent, 
played an important role in determining the magnitude of an antagonist’s 
insurmountability and duration of action.120
6. MEN1149
This peptidomimetic compound (Figure 2.7, Compound 6) set the example 
that long acting small molecule antagonists can be developed from short 
acting peptide antagonists, in this case from FK888, by simple structural 
modifications. The main modification introduced, originally to increase 
metabolic stability, was the β-aminocycloalkyl carboxylic acid residue replacing 
FK888´s prolyl group.121 Interestingly, these modifications turned the purely 
surmountable FK888 into the insurmountable MEN1149 with much slower 
reversibility during organ bath washout assays and a longer duration of 
action in vivo of over 3 h.121 The authors speculated that introduction of the 
β-amino cycloalkyl carboxylic acid caused a slower rate of dissociation which 
was likely to be responsible for the change in type antagonism, but only 
provided circumstantial evidence and no direct kinetics measurements.121
Compound 4) being the most active.118 The authors found that increasing the 
overall compound rigidity as well as modifying some other specific molecular 
components, such as by the addition of a substituent on the pyrrolidine 








Overall, the examples summarized above provide a strong indication that 
NK1R are amongst the targets for which slowly dissociating antagonists could 
offer therapeutic advantages.
Dopamine receptors
Dopamine receptors are a group of class A GPCRs, which are named after 
their endogenous ligand dopamine.122 To date, five subtypes of dopamine 
receptors have been identified, namely D1 to D5.123 These receptors can be 
further categorized into D1-like (D1 and D5) and D2-like (D2, D3 and D4) 
subfamilies, based on their similarities in sequence, pharmacology and ability 
to stimulate or inhibit adenylyl cyclase activity: the D1-like subfamily couples 
to Gs and mediates excitatory neurotransmission, while the D2-like (D2, D3 and 
D4) subfamily couples to Gi/o and mediates inhibitory neurotransmission.124 
Dopamine receptors, particularly D1 and D2 receptors, are prominent in the 
vertebrate CNS,123,125 indicating their functional importance in neuronal 
signaling (for reviews, see126-131). To date, numerous drugs targeting the D2 
receptor are available on the market. Antagonizing the dopamine D2 receptor 
has been reported as the molecular foundation of schizophrenia treatment.132 
Currently, all known marketed anti-schizophrenia drugs bind to the D2 
receptor and are supposed to modulate dopamine hyperfunction.26,133 In 
general, these drugs can be categorized into two groups. The first generation 
or the so-called typical antipsychotics (e.g., haloperidol) can effectively treat 
positive schizophrenia symptoms (i.e., hallucination and delusions), yet 
they invoke concomitant on-target adverse effects, such as extrapyrimidal 
symptoms (EPS) and hyperprolactinaemia, through excessive blockade of the 
D2 receptor. The second generation, also known as ‘atypical’ antipsychotics, 
are defined according to their ‘clozapine-like’ properties, i.e., low incidence 
of the on-target/mechanism-based side effects, which are mostly attributed to 
their short residence times at the D2 receptor.134 Other theories have also been 
proposed to explain ‘atypicality’. One of these is the multi-receptor hypothesis 
or polypharmacology.180 Many atypical antipsychotics were found to have 
high affinity at other neurotransmitter receptors in addition to D2 receptors, 
in particular at serotonin 5-HT2A receptors, while typical antipsychotics, 
like haloperidol, bind more specifically to D2 receptors.135 However, fully 
occupying serotonin 5-HT2A receptors with different antipsychotics at 
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clinically relevant doses did not induce EPS to the same level.134 Hence, the 
atypicality is more likely connected to the compounds’ short residence times 
at the D2 receptor than their antagonism at the 5-HT2A receptors. 
Additionally, it is worth mentioning that interaction of atypical 
antipsychotics with additional receptors may cause undesired off-
target side-effects—distinct from its on-target side-effect (e.g., EPS and 
hyperprolactinaemia), such as 5HT2C receptors (weight gain), α1-adrenoceptors 
(orthostatic hypotension, reflex tachycardia, and hypnosedation), α2-
adrenoceptors (tachycardia), histamine H1 receptors (sedation and weight 
gain), and muscarinic receptors (blurred vision, dry mouth, constipation, 
and cognitive impairment).135 These side-effects can logically be minimized 
by decreasing the compound’s affinity or residence time on the off-targets. 
Contrary to aforementioned cases of other GPCRs, where long RT 
ligands are desired for optimal clinical outcomes, short residence time D2 
receptor antagonists are preferred, since they will supposedly induce less on-
target ‘mechanism-based toxicology’.25,35 In the following part of this section 
we will focus on published binding kinetics data of dopamine D2 antagonists 
and the related benefit from short RT in clinical applications. 
1. Haloperidol and other slowly dissociating D2 receptor 
antagonists
Haloperidol (Figure 2.8, Compound 1) was approved by the U.S. Food and 
Drug Administration (FDA) in 1967 and marketed as Haldol in U.S. and 
other countries. Haloperidol exhibited high-affinity antagonism for human 
dopamine D2 receptor (1.8 nM) with a koff of 0.01 s-1, equal to a t1/2 of 
72.4 s (Table 2.5).135 Notably, its t1/2 was substantially changed when the 
kinetics were tested at rat striatal membranes (i.e., t1/2 = 42 min), indicating 
significant species differences.134 One might argue that the absolute value 
of haloperidol’s t1/2 is much smaller than other classical slowly dissociating 
GPCR antagonists, such as aforementioned NK1R antagonist aprepitant 
(t1/2 = 154 min). It should be realized that the time scale for endogenous 
dopamine concentration burst can be within a millisecond to second range, 
which is much shorter than the t1/2 of haloperidol.136 In this sense, the receptor 
blockade by haloperidol is already too lengthy to allow normal physiological 
responses to fast and small changes in the neurotransmitter concentration. 




1 Haloperidol 1.8 72.4 s 135
2 Nemonapride ä°äÓx­À>Ì® Îxx­À>Ì® 134
3 Spiperone ä°£­À>Ì® Óää­À>Ì® 134
4 Sertindole £°Ó­À>Ì® {Ç­À>Ì® 134
5 Chlorpromazine £°Î­À>Ì® Îx­À>Ì® 134
6 Raclopride £°È­À>Ì® Ón­À>Ì® 134
7 Olanzapine È°{­À>Ì® £n­À>Ì® 134
8 Clozapine 137 14.5 s 135
9 Quetiapine ÈÇ°È­À>Ì® ÓÎÃ­À>Ì® 139
10 JNJ-37822681 158 6.5 s 135
Table 2.5 | Binding kinetics of D2 receptor antagonists.
a Compound names and synonyms used in original references. bƂvwÌÞ]iÝ«ÀiÃÃi`>Ãi 
values that reported in original references; result on human receptor unless mentioned 
otherwise. c Dissociation half-life at room temperatures and on human receptors unless 
mentioned otherwise.
Next to the result from the direct kinetic binding assay at both human and 
rat D2 receptor preparations, haloperidol was found to have long-lasting D2 
blockade by using an indirect kinetic measurement. Only 48% (lower than 
that of clozapine) of the total receptor population was recovered and able to 
bind to subsequently added [3H]-spiperone after pre-incubating haloperidol 
for one hour with the receptor.135
The binding kinetics of other slowly dissociating D2 receptor antagonists 
were elaborately studied by Kapur and Seeman.134 The authors investigated 
the affinity and the kinetics of nine typical and atypical antipsychotics (main 
results are included in Table 2.5; compound structures in Figure 2.8). Among 
these compounds, nemonapride and spiperone had a t1/2 of 355 min and 
200 min, respectively, indicative of D2 receptor blockade for more than 3 
h; these two compounds were followed by sertindole (47 min), haloperidol 
(40 min), chlorpromazine (35 min), raclopride (28 min) and olanzapine (18 
min) in terms of their t1/2 values. In contrast, the two atypical antipsychotics 
clozapine and quetiapine displayed faster dissociation half-lives, i.e., less than 
1 min. Furthermore, it is important to note that the koff values varied a 1000-
fold from 0.002 min-1 to 3.013 min-1, yet less variation was found in kon. 









Clozapine was the first atypical antipsychotic drug on the market (Figure 
2.8, Compound 8). Compared to haloperidol, clozapine had a relatively 
low affinity for the D2 receptor (Ki = 137 nM) and a 5-fold shorter t1/2 of 
approximately 14.5 s (Table 2.5).135 This (partially) explained the observation 
by Kapus and Seeman, that clozapine reached equilibrium 100 times 
faster than haloperidol in the displacement assay.134 Such a fast molecular 
interaction enabled clozapine to have a fast-on and then fast-off blockade 
of the D2 receptor. Therefore, the receptor was readily responsive to the 
endogenous dopamine burst upon physical stimulation, hence lowering the 
risk of EPS or hyperprolactinaemia. This mechanism was further supported 
by the in vivo observation that clozapine caused a surmountable blockade of 
striatal dopamine receptors in contrast to cataleptogenic neuroleptics (the 
insurmountable control).137 Moreover, clinical positron emission tomography 
(PET) analysis of a subject receiving clozapine (400 mg) revealed transiently 
high D2 receptor occupancy (i.e., 80%) that rapidly declined to low levels 
(i.e., 15%) within 48 h. In comparison, D2 receptor occupancy by haloperidol 
(5 mg) peaked at approximately 80%, but it declined more slowly over time, 
showing D2 occupancy of over 10% even 3–5 days later.138 This reaffirmed 
that fast kinetics may be favorable for a low incidence of mechanism-based, 
on-target, toxicology.
3. Quetiapine
Quetiapine (Figure 2.8, Compound 9), also known as Seroquel, Xeroquel 
or Ketipinor, is another marketed atypical antipsychotic approved for 
causes the variation in their affinity for the D2 receptor, while differences in 
kon do not account for that. Moreover, since atypical antipsychotics display 
relatively faster dissociation than typical ones, it can be inferred that the 
atypical antipsychotic effects are mostly attributed to their high koff values for 
the D2 receptor.
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JNJ-37822681 (Figure 2.8, Compound 10) was developed by Janssen 
Pharmaceuticals. One of the most elaborate studies on JNJ-37822681 has 
been reported by Langois et al..135 The compound was initially selected 
from an indirect kinetic screening assay (for method, see23,135), where JNJ-
37822681 was estimated to have a koff similar to clozapine. Subsequently, a 
kinetic [3H]-JNJ-37822681 binding experiment revealed that this compound 
had an extremely short t1/2 (6.5 s, Figure 2.5) at the D2 receptor, which was 
approximately 2-fold and 11-fold shorter than clozapine and haloperidol, 
respectively. In the follow-up in vivo profiling, JNJ-37822681 displayed a 
larger specific margin (compared with haloperidol) between the inhibition 
and blockade of apomorphine-induced behaviors, which represents a model 
for psychosis. This result was further reaffirmed in phase IIb clinical trials, 
where JNJ-37822681 displayed an efficacious antipsychotic effect but low 
propensity of EPS and prolactin liability.141,142
schizophrenia treatment. Similar to the molecular properties of clozapine, 
Caboni et al. found that quetiapine displayed low D2 receptor affinity (Ki = 
67.6 nM) and a fast dissociation rate (1.8 min-1), equal to a t1/2 of 23 s, at a 
rat striatum homogenate (Table 2.5).139 In the subsequent in vivo profiling, 
Caboni et al. performed time-dependent analysis of plasma prolactin 
levels, a surrogate of peripheral D2 receptor blockade, after orally treating 
rats with vehicle or different dose of quetiapine or haloperidol. They found 
that compared to haloperidol treatment quetiapine displayed a short-lived 
increase of prolactin level, which was in line with its short RT profile at the D2 
receptor. Moreover, serial PET scans evaluating the D2 receptor occupancy of 
quetiapine demonstrated that this compound dissociated very rapidly from 
the D2 receptor.140 Taken together, all in vitro and in vivo results provided 









5. Overall structural determinants for binding kinetics at the 
dopamine D2 receptor
Compared to the residence times of M3R or NK1R antagonists, D2 receptor 
antagonists are preferred to have a short RT to circumvent on-target side 
effects. It is therefore highly desired to analyze the structural determinants 
that increase ligand dissociation from the receptor for future rational drug 
design. For this reason, Tresadern et al. performed a comprehensive statistical 
analysis of the binding kinetics of over 1800 D2 receptor antagonists and 
examined their physicochemical properties that potentially discriminate fast 
dissociating compounds from slowly dissociating ones.26 They discovered 
that faster dissociating antagonists were in general less lipophilic and had 
lower molecular weight. This seems to hold true for other fast dissociating 
GPCR ligands as well, a finding shared by Miller et al.143 However, it is also 
important to note that other descriptors, for instance polar surface area, 
partial positive charge or the amount of hydrogen bond donor and acceptor 
groups, caused different effects on the ligand’s dissociation, depending on 
the particular cluster of chemicals that was analyzed. This suggested that 
local effects of a specific chemical scaffold on the binding kinetics could be 
dominant over other physiochemical descriptors. Thus, instead of intuitively 
modifying a compound’ lipophilicity, molecular weight or other molecular 
properties, a more specific structure-kinetics relationship study is needed to 
direct future drug design and discovery.
In summary, examples presented here demonstrate the benefit of fast 
dissociating D2 receptor antagonists for lowering the risk of mechanism-
based toxicology. Such an advantage over long RT antagonists is supported 
by evidence from preclinical and clinical aspects of the typical and atypical 
antipsychotics. This case study on the D2 receptor further emphasizes the 
necessity of characterizing a ligand’s binding kinetics profile in the early 
phases of candidate drug selection. 
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1. The binding kinetics of CRF1R antagonists and their in 
vivo pharmacodynamics
One of the most elaborate binding kinetics studies at the CRF1 receptor was 
performed by Fleck et al.151 In this article, the authors investigated a series 
of CRF1 receptor antagonists regarding their in vitro binding kinetics and in 
vivo pharmacodynamics. They found that the koff and kon values of 12 CRF1 
Drug-target residence time for class B GPCRs2.7 
Corticotrophin releasing factor type-1 receptor
Corticotrophin releasing factor (CRF) is a 41 amino-acid peptide that 
exerts its effects through activation of CRF receptors, which are members 
of the family B GPCRs.144 The CRF receptor subfamily has two subtypes, 
namely CRF1 and CRF2. Both receptors are primarily coupled to Gs protein, 
resulting in the activation of adenylate cylase and increased cAMP levels.145,146 
Since CRF acts on the pituitary gland to regulate the hypothalamic-pituitary-
adrenal axis and the CNS to modulate behavior responses to stress, it has 
caught considerable attention in drug discovery for psychiatric diseases.144-147 
In particular, antagonism of the CRF1 receptor has been proposed for 
rebalancing a dysfunctional stress axis.147-149 Although highly potent in vitro 
and efficacious in animal models, early reported compounds such as CP-
154,526 and NBI-27914 are highly lipophilic, which leads to compound 
accumulation in tissues or long elimination half-life, and thus high risks of 
toxicity.150 For this reason, efforts have been specifically directed towards 
discovering less lipophilic, fast clearance CRF1 receptor antagonists to 
decrease the incidence of toxicity but with maintained drug efficacy. A long 
residence time CRF1 receptor antagonist is therefore highly desired, which 
could provide the benefit of a long duration of action and at the same time less 
accumulation on the unwanted targets. Such compounds would exemplify 
new mechanisms for depression treatment beyond classical monoamine 
modulators.148,151







Figure 2.9 | Structures of small molecule CRF1 receptor antagonists.
receptor compounds varied 170-fold and 13-fold, respectively, which resulted 
in a maximal change of around 510-fold in the kinetically derived affinity 
(KD = koff / kon) at 37 ˚C. Notably, this finding was in stark contrast with 
the previous reported Ki values measured in radioligand displacement assays, 
where little difference was observed between compounds. This discrepancy 
was mostly attributed to insufficient incubation time to reach equilibrium 
for compounds with long residence time profile. For instance, less than 
40% of NBI 30775 dissociated from the CRF1 receptor after 2 h, far from 
equilibrium, hence the Ki values were underestimated. Furthermore, several 
lead compounds displayed divergent dissociation half-lives; NBI 35965 with 
16 min, NBI 34041 with 53 min and NBI 30775 with 130 min (Figure 
2.9, Compound 1-3; Table 2.6). This ranking of their binding kinetics, in 
fact, was consistent with the ranking of their in vivo pharmacodynamic 
profiles, at least in adrenalectomized rats, where NBI 34041 and NBI 30775 
produced sustained suppression of adrenocorticotropin for 4 h and 6 h, 
respectively, while NBI 35965 induced a more transient effect (less than 2 h). 
In addition, all three compounds (NBI 35965, NBI 34041 and NBI 30775) 
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had similar pharmacokinetics. This confirmed that the unique sustained 
adrenocorticotropin suppression evoked by NBI 30775 was derived from its 
prolonged CRF1 receptor occupancy rather than its pharmacokinetics. 
Functional reversibility assays were also performed to kinetically profile 
CRF1 receptor antagonists.152,153 Briefly, cells expressing recombinant CRF1 
receptor were incubated with CRF in either the presence or absence of an 
antagonist to measure the suppression of the maximal cell response to CRF by 
the tested antagonist. Although CRF binds to a different site on the receptor 
than the non-peptide small molecule antagonists, the insurmountability 
of the non-competitive antagonists still correlated to their off-rates. In 
particular, Miller et al. plotted the antagonists’ dissociation half-lives against 
their suppression of the maximal CRF1 receptor response to its endogenous 
ligand. They found a good correlation between the two parameters, although 
the exact molecular mechanism of this link is yet to be discovered.152 By using 
this assay, at least in a qualitative manner, Miller et al. investigated several 
other long RT compounds reported in literature. They found that DMP-
904 and R121919 almost completely suppressed the maximal CRF response 
(Figure 2.9, Compound 4 and 5). Both compounds were found to have 
slow dissociation half-lives, i.e., 5.5 h and 12.8 h, respectively, which were 
calculated from koff values determined in a competition association assay.152 




1. NBI 35965 2.3 £È­ÎÇÂ
® 151
2. NBI 34041 1.7 xÎ­ÎÇÂ
® 151
3. NBI 30775 0.36 £Îä­ÎÇÂ
® 151
4. DMP-904 1.5 5.5 h 152
5. R121919 12 12.8 h 152
6. 
«`Óx­*wâiÀ® 11 10.7 h 152
7. SN003 Î°È{­À>Ì® ä°Îx­À>Ì® 153
8. PF-4325743 n°ÓÓ­À>Ì® ä°ÎÇ­À>Ì® 153
Table 2.6 | Binding kinetics of CRF1 receptor antagonists.
a Compound names and synonyms used in original references. bƂvwÌÞ]iÝ«ÀiÃÃi`>Ãi 
values that were reported in original references; result on human receptor unless mentioned 
otherwise. c Dissociation half-life at room temperature and on human receptor unless 
mentioned otherwise.







2. Overall structural determinants for binding kinetics at the 
CRF1 receptor
A detailed structure-kinetics relationship (SKR) study was performed by 
Fleck et al., in which the authors performed a retrospective binding kinetics 
investigation on a set of CRF1 receptor ligands including the initial, low-
affinity chemical starting points up to the lead compounds. Key features of 
the high affinity or long residence time CRF1 receptor ligand are represented 
in Figure 2.10A (adapted from the models developed by Gilligan et al., Kehne 
and De Lombaert, and Fleck et al.151,154,155) and the SKRs are summarized as 
follows: 1) ortho-position substitution (R1) on the low ring was necessary 
to enforce a twisted bioactive conformation to enhance ligand-receptor 
interactions. This can be illustrated by the conformation of CP-376395 in the 
recently elucidated CRF1R crystal structure (PDB code: 4K5Y, Figure 2.10B). 
Apparently, the pose of the compound’s trimethylphenoxy moiety is rotated 
to fit in a hydrophobic pocket formed by F2845.51, L2875.54, T3166.42, L3196.45 
and L3206.46 with the pyridine nitrogen at the core to form a hydrogen bond 
with N2835.50.156 In contrast, the association rate of an ortho-substitutent 
free analogue decreased 33-fold compared to its chloro-substituted analogue, 
suggesting a substantial barrier for the free rotating ligand to fit into the 
binding pocket. 2) Adding a methyl moiety at R2 resulted in an increased 
kon and decreased koff, indicating a raised probability of successful collision 
between this group and a rigid binding pocket on the receptor, combined 
with a stabilized ligand-receptor conformation. This finding was in agreement 
with other published results which suggested that the methyl-group 
interacted with a hydrophobic pocket in the receptor.154,155,157,158 3) Chemical 
modifications on the upper aliphatic groups at R3 demonstrated varying 
effects on the binding kinetics depending on their size, branching pattern 
and the stereochemical configuration, which may affect the compound’s 
interaction with F2033.44 and Y3276.53, two aromatic residues gating the small 
access channel from the extracellular part (Figure 2.10B).156 
In another SKR study, Miller et al. started from a bicyclic purine core and 
Compound 7 and 8) such as SN003 (t1/2 = 0.35 h, Table 2.6) or PF-4325743 
(t1/2 = 0.37 h, Table 2.6) did not significantly decrease the maximal CRF 
response.153
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performed a series of chemical modifications on the substitution patterns at the 
low ring and the upper branched groups. Follow-up functional investigations 
in vitro led to the identification of compound 25 (Figure 2.9, Compound 6) 
which displayed 79% suppression of the maximal CRF response. Binding 
kinetics characterization of this compound revealed that it had a slow t1/2 of 
10.7 h, correlating well with its insurmountable antagonist behavior.152
Figure 2.10N­Ƃ®>}À>vÌi«ÕÌ>ÌÛivÕVÌ>}ÀÕ«Ã«V>Ìi`ÃÌÀÕVÌÕÀiiÌVÃ
relationships of non-peptide antagonists. This diagram was adapted from literature,160,162,163 
L>Ãi`  Ìi V«ÀiiÃÛi >>ÞÃÃ v }>` -Ƃ,° ­	® /i VVÀÞÃÌ> ÃÌÀÕVÌÕÀi v 
*
376395 in the human CRF1 ÀiVi«ÌÀ° /Ã w}ÕÀi Ü>Ã }iiÀ>Ìi`ÜÌ 
 	ÀÜÃiÀ ÛÎ°Ç
­ÃvÌ® vÀ*	V`i\ {x9°
*ÎÇÈÎx ­L>V®L`Ã`ii«ÞÜÌ Ìi«ViÌ° /Ü
aromatic residues, F2033.44 and Y3276.53, together prevent the ligand from moving out of 
Ìi ÀiVi«ÌÀ°/i«Ãiv ÌiV«Õ`½Ã ÌÀiÌÞ«iÝÞiÌÞ Ã ÀÌ>Ìi` ÌwÌ >
hydrophobic pocket formed by F2845.51, L2875.54, T3166.42, L3196.45 and L3206.46 with its 
pyridine nitrogen at the core to form a hydrogen bond with N2835.50.156
Concluding remarks2.8 
We reviewed the existing kinetics data for a number of GPCRs. The examples 
presented make a strong case for the value of measuring drug-target residence 








compound optimization in the early phases of the drug discovery process. 
Thus, a strategy is warranted that comprises both a structure-kinetics 
relationship study (SKR) and a classical structure-affinity relationship study 
(SAR). This may offer added value to the traditional metric of affinity-based 
drug evaluation. 
This chapter further summarized the factors influencing drug-target 
residence time, in particular, to find a universal molecular determinant 
or a certain ‘hot spot’ on GPCRs for designing kinetics-favorable ligands. 
Several kinetics-related statistical analyses indicated that manipulating 
physicochemical properties such as lipophilicity or molecular weight can 
lead to tuned drug-target residence times.26,143 Alternatively, this could 
be achieved by modulating the rigidity / flexibility of a drug candidate.117 
However, these ‘intuitive’, ‘one size-fits-all’ approaches are very likely too 
simple and may increase the concern of binding to collateral targets, thereby 
resulting in unwanted side effects.67,159 In this sense, fine-tuning drug-target 
residence time should probably be more specific. Despite this challenge, 
progress can still be made by gaining knowledge from both the ligand and 
target perspectives, such as by ligand modifications with subtle changes to 
probe relevant pharmacophores, mutation studies, co-crystallization and 
molecular dynamic studies to establish the corresponding ‘anchoring’ sites 
on the receptor. 
We also summarized the kinetic methodologies in this chapter. Several 
screening schemes are available and new assays are emerging, which enable 
quick identification of compounds of interest. Quantitative characterization 
of a compound’s binding kinetics can be obtained in a kinetic binding assay 
or competition association assay. Functional reversibility experiments prevail 
in drug discovery as well, which offer an alternative way to interpret a ligand’s 
kinetics profile. In addition, ex vivo receptor occupancy experiments or in 
vivo duration of action experiments can translate the in vitro binding kinetics 
into the effect in an in vivo setting, which provides further evidence for a 
compound’s drug-target residence time. Notably, it is also necessary to take 
into account the PK profile of the candidate compound, particular for one 
aiming at long drug-target residence time, since RT can only prolong the 
duration of action only when the RT outlasts the PK.2,15 
The compounds summarized in the present chapter are predominantly 
GPCR antagonists. This reflects a lack of kinetic information on agonists 
in the literature. However, more kinetics studies focused on the latter 
are emerging. For instance the case studies at the M3 and A2A receptors 
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explored the molecular basis of the compounds’ intrinsic efficacy from a 
kinetic perspective.32,98 In addition to examining an agonist’s mechanism of 
action, one can also specifically optimize an agonist’s kinetic properties for 
therapeutic benefit. This can be exemplified by the administration of long-
acting agonists at the GnRH receptor to intentionally desensitize the GnRH 
receptor and therefore antagonize gonadotropin secretion in hormone-
dependent cancers.181 Such a strategy could be a therapeutic substitute for 
targets where no antagonist is available. On the other hand, one needs to take 
into consideration that agonist-induced desensitization or internalization by 
prolonged or repeated administration can cause drug tolerance, for instance 
opiate drugs targeting µ-opioid receptors.182 In such a case, it might be 
tempting to search for shorter residence time agonists to prevent their target’s 
internalization. Thus, a study that compares agonist binding kinetics and 
GPCR desensitization / internalization kinetics would be of great interest.
Taken together, a rapid expansion of the field of GPCR binding kinetics 
may be anticipated in the near future, which hopefully will lead to the 
identification of novel and better-in-class drugs for clinical applications.
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Dual-point competition association assay
A fast and high-throughput kinetic 
screening method for assessing ligand-
receptor binding kinetics
Guo D, Van Dorp EJ, Mulder-Krieger T, Van Veldhoven JPD, Brussee J, 
IJzerman AP, Heitman LH.
Adapted from: J Biomol Screen 2013;18(3):309-320.

This chapter introduces a method that enables fast and large format kinetics 
screening—the dual-point competition association assay. It measures 
radioligand binding at two different time points in the absence or presence of 
unlabeled competitors. This assay yields the kinetic rate index (KRI), which 
is a measure for the binding kinetics of the unlabeled ligands screened. As a 
prototypical drug target the adenosine A1 receptor (A1R) was chosen for assay 
validation and optimization. A screen with 35 high affinity A1R antagonists 
yielded seven compounds with a KRI-value above 1.0, which indicated a 
relatively slow dissociation from the target. All other compounds had a KRI-
value below or equal to 1.0, predicting a relatively fast dissociation rate. 
Several compounds were selected for follow-up kinetic quantifications in 
classical kinetic assays and were shown to have kinetic rates that corresponded 
to their KRI-values. The dual-point assay and KRI-value may have general 
applicability at other GPCRs, and at drug targets from other protein families.
About this chapter
84 |  Dual-point kinetic assay
Introduction3.1 
The traditional paradigm of drug discovery places an emphasis on dose-
dependent assessments (i.e., affinity or potency) to identify lead compounds, 
which are usually performed under equilibrium conditions.1,2 With this 
approach ligand-receptor binding kinetics are usually overlooked. However, 
the importance of this latter aspect is increasingly recognized, since several lines 
of research have retrospectively suggested that the binding kinetics, especially 
the lifetime of the ligand-receptor interaction, is a critical differentiator and 
predictor for drug efficacy and safety.1-5 This emerging paradigm shift from 
a classical affinity-based approach emphasizes ligand-receptor residence time 
(RT, the reciprocal of the dissociation rate constant koff),6 which is a measure 
for the duration that a ligand stays in complex with its target.
In this chapter we introduce an assay to perform kinetic binding screens, 
namely the dual-point competition association assay. This method is based on 
the theory developed by Motulsky and Mahan, where an unlabeled competitor 
is co-incubated with a radioligand during a kinetic association experiment.11 
If the competitor dissociates faster from its target than the radioligand, the 
specific binding of the radioligand will slowly and monotonically approach 
its equilibrium in time (Figure 3.1, Curve C). However, when the competitor 
dissociates slower, the association curve of the radioligand will consist of 
two phases starting with a typical ‘overshoot’ and then a decline until a new 
equilibrium is reached (Figure 3.1, Curve B). In the dual-point competition 
association assay, we select two time points to measure radioligand binding: 
1) at which the radiolabeled ligand just reaches equilibrium under control 
conditions in the absence of an unlabeled ligand (Figure 3.1, Curve A and 
t1), and 2) at which the incubation time is long enough for the labeled and 
unlabeled compound to equilibrate with the target (Figure 3.1, Curve B and 
C, t2). Next, we calculate the ratio of the binding at the first time point (Bt1) 
and that at the second time point (Bt2), which we define as the ‘kinetic rate 
index’ (KRI) value for a certain unlabeled compound. In this manner, the 
compounds that quickly dissociate from their target will have a ratio below 
or equal to one (Figure 3.1, Curve C). Conversely, compounds that dissociate 
slowly from their target, compared to the radioligand used, will have a KRI 
value larger than one, resulting from the typical ‘overshoot’ in the association 
curve (Figure 3.1, Curve B). 
In the present chapter, we have used the adenosine A1 receptor (A1R) 






as a prototypic target to illustrate the utility of the dual-point competition 
association screening method and the resulting KRI-values. The adenosine 
A1R is one of four adenosine receptors subtypes (i.e., A1, A2A, A2B and A3 
receptors), which belong to the superfamily of G protein-coupled receptors 
(GPCRs).12,13 The A1R is a promising therapeutic target, since it has clinical 
relevance in neurological disorders, such as cognition deficits, and is involved 
in cardiovascular preconditioning.14,15 A tool compound, namely FSCPX 
(Figure 3.5), was used to set up the dual-point screening assay, since it is a 
known irreversibly binding antagonist for the A1R.16 In total 35 in-house 
synthesized A1R antagonists were screened using the dual-point competition 
association assay.17,18 Eight compounds with divergent KRI values were 
selected for extensive kinetic assessments. Moreover, we decided to radiolabel 
one of the slowly dissociating antagonists, namely LUF5962 (compound 31, 
Figure 3.5),17 tested its binding kinetics in traditional kinetic association and 
dissociation assays to validate the results from our dual-point screening assay, 
and used it subsequently to profile the same panel of 35 compounds. 
Figure 3.1 | Schematic presentation of the background for the dual-point competition 
association assay. Curve A: a radioligand association curve without a co-incubation of 
unlabeled competitor. Curve B: a co-incubated unlabeled competitor dissociates slower 
than the radioligand used (k2 > k4). Curve C: a co-incubated unlabeled competitor dissociates 
faster than the radioligand used (k2 < k4). Bt1\Ã«iVwVÀ>`}>`L`}>ÌÌiwÀÃÌÌi
point (t1); Bt2\Ã«iVwVÀ>`}>`L`}>ÌÌiÃiV`Ìi«Ì­Ì2). Kinetic rate index 
­,®Ã`iwi`>Ã	t1 / Bt2.
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Materials and methods3.2 
[3H]-1,3-dipropyl-8-cyclopentyl-xanthine ([3H]-DPCPX, specific activity 
116.7 Ci/mmol) was purchased from ARC Inc. (St. Louis, USA). Adenosine 
deaminase (ADA) was purchased from Boehringer Mannheim (Mannheim, 
Germany). CHAPS [3-((3-cholamidopropyl)-dimethylammonio)-1-
propanesulfonate)] were obtained from Carl Roth GmbH (Karlsruhe, 
Germany). DPCPX (selective A1R antagonist31), PEI (Polyethyleneimine) 
and bovine serum albumin (BSA) were from Sigma (St. Louis, MO, U.S.A). 
Bicinchoninic acid (BCA) and BCA protein assay reagent were obtained from 
Pierce Chemical Company (Rockford, IL, U.S.A.). All 35 A1R antagonists 
were synthesized in our laboratory as described previously.17,18 Chinese 
hamster ovary cells stably expressing the hA1R were obtained from Prof. Steve 
Hill (University of Nottingham, UK). All other chemicals were of analytical 
grade and obtained from standard commercial sources.
Chemicals and reagents
Preparation of [3H]-LUF5962
[3H]-8-cyclopentyl-2,6-diphenyl-9H-purine ([3H]-LUF5962, specific 
activity 51.7 Ci/mmol) was customly labeled by RC Tritec (Teufen, 
Switzerland). Unlabeled LUF5962 was provided as a dehydrogenenated 
precursor compound, namely 8-cyclopent-3-en-1-yl-2,6-diphenyl-9H-
purine. This compound was dissolved in ethanol, 10% Pd/C was added to 
the solution, and the reaction mixture was tritiated with tritium gas. After 
removal of labile tritium and purification by HPLC, the one-stage synthesis 
yielded [3H]-LUF5962 with a specific activity of 54.0 Ci/mmol (2.0 TBq/
mmol). The radiochemical purity was > 97%, as determined by HPLC.
[3H]-LUF5962 binding assay optimization






The assay conditions for [3H]-LUF5962 binding to CHOhA1R membranes 
were optimized according to a general radioligand binding protocol in our 
laboratory.21 Initial experiments were performed with 1.0 nM (approximately 
12,000 DPM) [3H]-LUF5962 and 5 µg of CHOhA1R membranes in a simple 
buffer of low ionic strength (25 mM Tris-HCl, pH 7.4) to which 5 mM 
MgCl2 was added. Next, we studied further buffer components, filters, filter 
pretreatment and different radioligand and membrane concentrations to 
improve the window of specific binding. Firstly, a relatively low concentration 
(1.0 nM) of [3H]-LUF5962 was enough for an appreciable window of 
specific binding, which was improved by the addition of 0.1% CHAPS due 
to a decrease in non-specific binding, while the addition of 0.1% BSA had 
no effect. Secondly, coating GF/B or GF/C glass fiber filters with PEI to 
separate free from membrane-bound radioligand did not significantly reduce 
the non-specific binding (data not shown). Taken together, it was decided to 
add 0.1% CHAPS in the assay buffer, use uncoated GF/B filters and 5 µg of 
membranes to yield a desired window of approximately 2000 DPM. Total 
binding of the radioligand was around 35% of the amount added and thus 
resulted in radioligand depletion that was unavoidable due to relatively high 
non-specific binding of [3H]-LUF5962 even under optimized conditions. 
Finally, initial kinetic association experiments taught us that the optimal 
incubation time to reach equilibrium was 30 min at 25 °C.
Cell culture and membrane preparation
Chinese hamster ovary cells stably expressing the human adenosine A1 
receptor (CHOhA1R) were grown in Ham’s F12 medium containing 10% 
(v/v) normal adult bovine serum, streptomycin (100 µg/mL), penicillin 
(100 IU/mL), and G418 (0.4 mg/mL) at 37 ˚C in 5% CO2. Cells were 
subcultured twice weekly at a ratio of 1:20 on 10 cm ø culture plates. For 
membrane preparation, cells were subcultured 1:10 and then transferred 
to 15 cm ø plates. Cells grew to 80%-90% confluency were detached from 
plates by scraping them into 5 mL PBS, collected and centrifuged at 700 × 
g (3000 r.p.m.) for 5 min. Cell pellets derived from 30 plates were pooled 
and resuspended in 20 mL of ice-cold 25 mM Tris-HCl buffer, pH 7.4. An 
UltraThurrax (Heidolph Instruments, Schwabach, Germany) was used to 
homogenize the cell suspension. Membranes and the cytosolic fraction were 
88 |  Dual-point kinetic assay
separated by centrifugation at 100,000 × g (31,000 r.p.m.) in a Beckman 
Optima LE-80K ultracentrifuge (Beckman Coulter, Fullerton, CA) at 4 ˚C 
for 20 min. The pellet was resuspended in 15 mL of the Tris-HCl buffer and 
the homogenization and centrifugation step was repeated. Tris-HCl buffer 
(10 mL) was used to resuspend the pellet and ADA was added (0.8 IU/mL) 
to break down endogenous adenosine. Membranes were stored in 250 µL 
aliquots at -80 ˚C. Concentrations of the membrane protein were measured 
using the BCA method.19
Radioligand saturation and displacement assays
Membrane aliquots containing 5 µg of protein were incubated in a total volume 
of 100 µL of assay buffer [25 mM Tris-HCl, pH 7.4, supplemented with 5 
mM MgCl2 and 0.1% (w/v) CHAPS] at 25 ˚C for one hour ([3H]-DPCPX) 
or three hours  ([3H]-LUF5962). Notably, optimal incubation times were 
determined with Equation 5 under Data analysis, which ensured that binding 
of the radioligand at the lowest concentration also reached equilibrium. For 
saturation experiments, a range of concentrations of [3H]-DPCPX (~0.2-20 
nM) or [3H]-LUF5962 (~0.1-13 nM) was used, respectively. In an initial 
experiment, nonspecific binding was determined at twelve concentrations 
of radioligand (i.e., [3H]-DPCPX ~0.2-20 nM and [3H]-LUF5962 ~0.1-13 
nM) in the presence of 100 µM N6-cyclopentyladenosine (CPA, selective 
A1R agonist32). Since the nonspecific binding of both radioligands proved to 
be linear for these concentrations (r2 > 0.95, P < 0.0001, data not shown), it 
was decided to use only three, evenly spaced, concentrations of radioligand 
to determine nonspecific binding in following saturation experiments. 
Displacement experiments were performed using eleven concentrations 
of competing ligands in the presence of 2.5 nM [3H]-DPCPX. At this 
concentration, total radioligand binding did not exceed 10% of that added to 
prevent ligand depletion. Nonspecific binding was determined in the presence 
of 100 µM CPA. Incubations were terminated by rapid vacuum filtration 
to separate the bound and free radioligand through 96-well GF/B filter 
plates using a Perkin Elmer Filtermate-harvester (Perkin Elmer, Groningen, 
Netherlands) or through Whatman GF/B filters (Whatman International, 
Maidstone, UK) using a Millipore manifold (Millipore, Billerica, MA, USA). 
Filters were subsequently washed three times with ice-cold wash buffer (25 






mM Tris-HCl, pH 7.4, supplemented with 5 mM MgCl2). The filter-bound 
radioactivity was determined by scintillation spectrometry using the P-E 1450 
Microbeta Wallac Trilux scintillation counter (Perkin Elmer, Groningen, 
Netherlands) for 96-well GF/B filter plates or by a liquid scintillation counter 
(Tri-Carb 2900 TR, Perkin-Elmer) for Whatman GF/B filters.
Radioligand association and dissociation assays
Association experiments were performed by incubating membrane aliquots 
containing 5 µg of protein in a total volume of 100 µL of assay buffer at 25 
˚C with 2.5 nM [3H]-DPCPX or 1.0 nM [3H]-LUF5962. The amount of 
radioligand bound to the receptor was measured at different time intervals 
during a total incubation of 20 min for [3H]-DPCPX or one hour for [3H]-
LUF5962. Dissociation experiments were performed by pre-incubating 
membrane aliquots containing 5 µg of protein in a total volume of 100 µL 
of assay buffer either for 20 min for [3H]-DPCPX or for one hour for [3H]-
LUF5962. After the pre-incubation, radioligand dissociation was initiated by 
the addition of 10 µM unlabeled CPA. The amount of radioligand still bound 
to the receptor was measured at various time intervals for a total of one hour 
for [3H]-DPCPX or two hours for [3H]-LUF5962 to ensure that they were 
fully dissociated from hA1R. Incubations were terminated and samples were 
obtained as described under Radioligand saturation and displacement assays.
Competition association assay
The binding kinetics of unlabeled ligands was quantified using the 
competition association assay based on the theoretical framework by 
Motulsky and Mahan.11 In the standard assay, three different concentrations 
of unlabeled DPCPX were tested, namely at 0.3-, 1- and 3-fold its Ki. For 
unlabeled LUF5962, 1-, 3- and 10-fold its Ki were used, while for FSCPX, 
3-, 10- and 30-fold its Ki were used. In the simplified one-concentration 
competition association assay, only a concentration of 10-fold of the Ki 
value was used to determine the binding kinetics of unlabeled ligands. The 
competition association assay was initiated by adding membrane aliquots (5 
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µg/well) at different time points for a total of 90 min to a total volume of 
100 µL of assay buffer at 25 ˚C with 2.5 nM [3H]-DPCPX in the absence or 
presence of competing ligand (10-fold Ki). Only for FSCPX the assay time 
was increased to 180 min. Incubations were terminated and samples were 
obtained as described under Radioligand saturation and displacement assays.
Dual-point competition association assay
The dual-point competition association experiments were performed by 
incubating membrane aliquots containing 5 µg of protein for 15 min or 120 
min in a total volume of 100 µL of assay buffer with 2.5 nM [3H]-DPCPX 
and for 30 min or 120 min with 1.0 nM [3H]-LUF5962 in the absence 
or presence of unlabeled ligands. The amount of radioligand bound to the 
receptor was measured after co-incubation of the unlabeled A1R antagonists 
at 10-fold their respective Ki values. Incubations were terminated after either 
15 min or 120 min for [3H]-DPCPX and 30 min or 120 min incubation for 
[3H]-LUF5962 and samples were obtained as described under Radioligand 
saturation and displacement assays. Kinetic rate index (KRI) values of unlabeled 
ligands were calculated by using Equation 6 as mentioned below in Data 
analysis.
Data analysis
All experimental data was analyzed by using GraphPad Prism 5.0 (GraphPad 
Software Inc., San Diego, CA). All values obtained are means of at least 
three independent experiments performed in duplicate. KD and Bmax values 
of [3H]-DPCPX or [3H]-LUF5962 at hA1R membranes were obtained 
by computational analysis of saturation curves. IC50 values obtained from 
competition displacement binding data were converted into Ki values using 
the Cheng-Prusoff equation.20 Association data was fitted using one phase 
exponential association as follows:
Y Y e(1 )k tmax obs= ⋅ − − ⋅ (1)






Where t is a given time, Y is the amount of specific radioligand binding, 
Ymax the specific radioligand binding at equilibrium, kobs the observed rate 
constant to approach equilibrium. The time for a radioligand to reach half of 






Values for kon were obtained by converting kobs values as follows:
k k kradioligand[ ]on
obs off=
−
where koff was determined in independent dissociation experiments. 
Dissociation data was fitted using one phase exponential decay. 
In the dual-point competition association assay, t1 was set at the time that 
radioligand binding just reached equilibrium. Specifically, we have defined 
the time to reach equilibrium, when 99.5% of total binding was reached, i.e., 
at 8-fold the association half-life. Thus,
t t8 association1 1/2,= ⋅
Taken together, t1 was determined by combining Equations 2, 3 and 4 as 
follows:
t k radioligand k
ln2
[ ]association on off1/2,
=
⋅ +
The second time point (t2) was arbitrarily set at a time long enough for the 
binding of the unlabeled ligand to reach a plateau. KRI (kinetic rate index) 
values were calculated by dividing the specific radioligand binding measured 








Association and dissociation rates for unlabeled ligands were calculated 
by fitting the data in the competition association model using ‘kinetics of 
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where X is the time (min), Y is the specific binding (DPM), k1 the kon 
(M-1∙min-1) of [3H]-DPCPX predetermined in association experiments, k2 
the koff (min-1) of [3H]-DPCPX predetermined in dissociation experiments, L 
the concentration of [3H]-DPCPX used (nM), Bmax the total binding (DPM) 
and I the concentration of unlabeled ligand (nM). Fixing these parameters 
into Equation 7 allows the following parameters to be calculated: k3 is the kon 
(M-1∙min-1) of the unlabeled ligand and k4 is the koff (min-1) of the unlabeled 
ligand. The association and dissociation rates were used to calculate the 





Results and discussion3.3 
Quantification of the KD and Bmax of [3H]-DPCPX and [3H]-
LUF5962 in saturation binding experiments
Saturation binding experiments were performed with [3H]-DPCPX and [3H]-
LUF5962 at 25˚C. Both [3H]-DPCPX and [3H]-LUF5962 bound saturably 
and specifically to a single class of binding sites at CHOhA1R membranes. 
The KD value of [3H]-DPCPX obtained from the saturation experiments was 
(8)






2.5 ± 0.1 nM and the Bmax value was 14.0 ± 1.0 pmol/mg protein, while the 
KD value of [3H]-LUF5962 was 0.83 ± 0.08 nM and the Bmax was 17.1 ± 0.9 
pmol/mg protein (Table 3.1). It should be kept in mind that ligand depletion 
was an issue when using [3H]-LUF5962, and thus it represents a less than 
ideal radioligand. However, in the paragraphs below we discuss that it can 
still be effectively used in the kinetic characterization of unlabeled ligands. 
The KD value for [3H]-DPCPX obtained in this experiment was in line with 
the KD value reported previously.21 This KD was used to derive Ki values from 
IC50 values for unlabeled ligands (see below).
Quantification of the association [kon(k1)] and dissociation 
rates [koff (k2)] of [3H]-DPCPX and [3H]-LUF5962 at 
CHOhA1R membranes
Receptor association [kon (k1)] and dissociation rates [koff (k2)] of [3H]-DPCPX 
and [3H]-LUF5962 were determined in standard radioligand association and 
dissociation experiments. Association and dissociation assays were conducted 
at 25 ˚C for both radioligands. The observed association rates (kobs) were 
converted to kon values by using Equation 3 described in Methods. The 
binding of [3H]-DPCPX and [3H]-LUF5962 approached equilibrium after 
approximately 15 and 30 min, respectively (Figure 3.2). Both [3H]-DPCPX 
and [3H]-LUF5962 had relatively fast association rates of 0.20 ± 0.01 nM-
1·min-1 and 0.13 ± 0.01 nM-1·min-1, respectively. Binding of both radioligands 
was reversible after the addition of 10 µM CPA and complete dissociation was 
reached after approximately 25 min for [3H]-DPCPX and 120 min for [3H]-
LUF5962 (Figure 3.2). The dissociation rate of [3H]-LUF5962 was eight-
fold lower than that of [3H]-DPCPX from the hA1R (Figure 3.2 and Table 
3.1). The dissociation binding constants (kinetic KD) of the radioligands were 
derived from the dissociation and association rates. [3H]-LUF5962 had an 
approximately five-fold higher affinity than [3H]-DPCPX, 0.20 ± 0.02 nM 
compared to 1.1 ± 0.1 nM, respectively.
Quantification of the affinity (Ki) of A1R ligands in 
displacement experiments
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Figure 3.2 | Association and dissociation kinetics of [3H]-DPCPX (Panel A) and [3H]-
.7(
2CPGN$CVř%VQCPFHTQOJWOCPCFGPQUKPG#1 receptors stably expressed 
on CHO membranes. ƂÃÃV>Ì`>Ì>Ü>ÃwÌÌi`*ÀÃx°äÕÃ}one-phase exponential 
association. Values for konÜiÀiLÌ>i`LÞÕÃ}µÕ>ÌÎ°ÃÃV>Ì`>Ì>Ü>ÃwÌÌi`
using one-phase exponential decay. Representative graphs from one experiment performed 
in duplicate.
Displacement experiments with several A1R ligands were performed at 25 ˚C 
to determine their affinities for the hA1R. The tested hA1R antagonists showed 
concentration-dependent inhibition of specific [3H]-DPCPX binding and 
the data was best fitted to a one-site competition model. Unlabeled DPCPX 
and LUF5962 had affinities of 2.3 ± 0.3 nM and 0.24 ± 0.03 nM, respectively 
(Table 3.1). Affinities of other antagonists shown in Table 3.2 were taken 
from previously published in-house experiments.17,18
Validation and optimization of the competition association 
assay at the hA1R
With the pre-characterized kon (k1) and koff (k2) values of [3H]-DPCPX 
binding from direct association and dissociation experiments, kon (k3) and koff 
(k4) values of unlabeled DPCPX and LUF5962 were determined by fitting the 
values into Equation 7 described in Methods. Three different concentrations 
of the unlabeled reference compounds (DPCPX and LUF5962) were tested 







in different radioligand binding assays.
Cmpd KD (nM)a Ki (nM)b kon (nM-1ŪOKP-1)c koff (min-1)d Kinetic KD (nM)e
DPCPX Ó°x´ä°£ Ó°Î´ä°Î ä°Óä´ä°ä£ ä°Ó£´ä°ä£ £°£´ä°£
1xÈÓ ä°nÎ´ä°än ä°Ó{´ä°äÎ ä°£Î´ä°ä£ ä°äÓx´ä°ääÓ ä°Óä´ä°äÓ
6>ÕiÃ>Àii>Ã́ Ã°i°v>Ìi>ÃÌÌÀii`i«i`iÌiÝ«iÀiÌÃ«iÀvÀi`̀ Õ«V>Ìi°
a [3H]-DPCPX (~0.2-20 nM) or [3R1xÈÓ ­Hä°££Î ® Ã>ÌÕÀ>ÌL`} Ì
"Ƃ1 
iLÀ>iÃ>ÌÓx Â
° b vÀ`Ã«>ViiÌv Ã«iVwV Q3R*
*8L`} vÀ
"Ƃ1 
iLÀ>iÃ >Ì Óx Â
° c Association [kon (k1)] of [
3H]-DPCPX or [3R1xÈÓ Ì
"Ƃ1R 
iLÀ>i>ÌÓxÂ




°e Kinetic KD = koff / kon. kon (k1) values were generated from [
3H]-DPCPX 




(Figure 3.3). Their kon (k3) and koff (k4) values determined by the competition 
association method were 0.14 ± 0.02 nM-1·min-1 and 0.25 ± 0.01 min-1 for 
unlabeled DPCPX (Figure 3.3A, Table 3.2), and 0.060 ± 0.010 nM-1·min-1 
and 0.021 ± 0.005 min-1 for LUF5962 (Figure 3.3B, Table 3.2), which were 
in accordance with the k1 and k2 values determined in ‘traditional’ association 
and dissociation experiments (Figure 3.2 and Table 3.1). Comparison of the 
dissociation constants and affinities obtained from the different equilibrium 
and kinetic experiments (Table 3.1) further verified that the competition 
association assay could be accurately used to determine the binding kinetics 
of unlabeled A1R ligands.
Optimization of the dual-point competition association 
assay at the hA1R
For the dual-point competition association assay it was necessary to decide 
on the optimal compound concentration and the two time points (t1 and t2) 
to obtain a robust kinetic screening assay. Therefore, we decided to optimize 
the assay using the reference antagonist FSCPX as a positive control, which is 
known to bind irreversibly to the hA1R.16 
Firstly, we used concentrations that represented 3-, 10- and 30-fold Ki 
values of unlabeled FSCPX to study the influence of different concentrations 
on the kinetic assay. It follows from Figure 3.4A that a long incubation time 
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Figure 3.3 | Validation and optimization of the competition association assay at the 





fold and three-fold Ki value of unlabeled DPCPX (Panel A) or one-fold, three-fold and ten-
fold KiÛ>Õiv1xÈÓ­*>i	®°ƂÃÃV>Ì>``ÃÃV>ÌÀ>ÌiÃvÀÕ>Lii`}>`Ã
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µÕ>ÌÇ°11 
Representative graph from one experiment performed in duplicate.
(i.e., 180 min) is needed for FSCPX to abrogate all [3H]-DPCPX binding at 
a low concentration, i.e., 3-fold its Ki value. The co-application of 30-fold 
its Ki value resulted in a faster knockdown of [3H]-DPCPX binding sites, 
i.e., after approximately 60 min. Such a significant decrease of [3H]-DPCPX 
binding reduced the KRI window. Incubation of the membranes with an 
FSCPX concentration equaling 10 times its Ki value led to an intermediate 
situation (Figure 3.4A). Notably, the set of three FSCPX concentrations 
are higher than the concentrations used in experiments with LUF5962 and 
DPCPX (Figure 3.3). In order to achieve radioligand equilibrium binding as 
much as possible with slowly dissociating competitors (or irreversibly binding 
competitors like FSCPX) in the same experimental incubation time, higher 
concentrations need to be used than for competitors with relatively faster or 
equal dissociation rates. The latter has also been described for the muscarinic 
M3 and histamine H3 receptor.9,28 In the present chapter, we observed that 
10-fold Ki of the competitor gave reasonably large assay windows for all three 
ligands displaying divergent off-rates (i.e., DPCPX, LUF5962 and FSCPX). 
Hence, for screening purposes it was decided to use concentrations equal 
to 10-fold the Ki values of the respective unlabeled ligands. It is important 
to note that 10-fold Ki is optimal for A1R in the current protocol, yet this 






concentration may not be suitable on other drug targets, especially when 
divergent concentrations of radioligand are used in the competition association 
assay. For instance, Dowling and Charlton used approximately 25-fold KD 
of the radioligand in their competition association assay on the muscarinic 
M3 receptor. This requires higher concentrations of unlabeled ligands (from 
10-fold to 1000-fold their respective Ki values) to achieve full resolution 
of radioligand equilibrium binding within the frame of incubation time.9 
Similarly, Slack et al. used higher concentrations of unlabeled ligands (from 
less than 15-fold to over 200-fold Ki) in their competition association assays 
on histamine H1 and H3 receptors.28 Therefore, for a general optimization 
of the dual-point assay on other drug targets, it is suggested that one should 
take into account the radioligand’s concentration, assay incubation time 
and expected kinetic profiles of the competitors for optimization of the 
competitors concentration, since all these parameters influence the resolution 
of the assay.
Secondly, we optimized the two time points (t1 and t2). As for t2 the 
incubation time was set at 120 min, which was based on the observation in 
Figure 3.4A that in the presence of an FSCPX concentration of 10-fold its 
Figure 3.4 | Optimization of the dual-point competition association assay at hA1R. 
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Ki value [3H]-DPCPX binding was negligible after 120 min incubation. As 
mentioned above, we assumed that within this time frame most compounds 
would equilibrate with the target, even if they were kinetically different, as 
further corroborated by Figure 3.3. As for t1 the incubation time was set at 15 
min, since under control conditions (i.e., absence of unlabeled ligand) [3H]-
DPCPX binding reached equilibrium after 15 minutes at 25˚C according 
to Equation 5 and Figure 3.2A. It was also tried to set t1 at a much longer 
(i.e., 30 min) or shorter incubation time (i.e., 3 min). From Figure 3.4B it 
follows that the selection of t1 and t2 clearly affects the KRI values obtained. 
In other words, a shorter or longer incubation time than 15 min for t1 
reduced its margin over the control (KRI = 1.0), i.e., KRI values = 3.9 or 3.8, 
respectively, while t1 = 15 min provided a more significant KRI value of 5.4 
for FSCPX. Therefore, incubation times of 15 min (t1) and 120 min (t2) were 
used for the dual-point competition association assay with [3H]-DPCPX at 
the hA1R. Notably, it is impossible to define an absolute value or cut-criterion 
of t1 and t2, since the two time point set-up is dependent on several factors 
(i.e., radioligand concentration, temperature). For a general application on 
other targets, we suggest that one can start with setting t1 at a time when 
the radioligand just reaches equilibrium by using Equation 5, while for t2 
a later time point is chosen long enough for the binding of the unlabeled 
ligand to reach a plateau. A late t2 of course compromises the convenience 
of this screening method, as the total assay time increases. Therefore, it may 
be necessary to perform similar ‘tailored’ optimizations of time points and 
concentrations, and even the choice of the radioligand, to obtain robust 
results on other drug targets.
Kinetic screening of hA1R antagonists using dual-point 
competition association assay
In the present chapter, 35 hA1R antagonists synthesized in-house17,18 were 
screened in the newly developed dual-point competition association assay 
(Figure 3.5). The specific binding of [3H]-DPCPX was measured after 15 min 
and 120 min and for [3H]-LUF5962 after 30 min and 120 min in the absence 
and presence of a single concentration of unlabeled competitive ligand (10-
fold Ki, in both [3H]-DPCPX and [3H]-LUF5962 assays). This allowed us 
to calculate the kinetic rate index (KRI) values for each compound by using 






Figure 3.5 | Kinetic rate indexes (KRI) of 35 in-house hA1R antagonists, DPCPX and 
FSCPX.£È£n The KRI values of the same panel of unlabeled ligands against [3R1xÈÓ
(gray bars) are integrated with the results obtained with [3H]-DPCPX (white bars). Values 
ÜiÀiLÌ>i`vÀÌi`Õ>«Ì>ÃÃ>ÞÃ>`V>VÕ>Ìi`LÞÕÃ}µÕ>ÌÈ°/i,v
ÌiÀiviÀiViV«Õ`Ã]Õ>Lii`*
*8À1xÈÓ­V«Õ`31), were determined 
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iÀiÃ«iVÌÛiÃVÀii°-
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i¼ÌV«Õ`½>`ÜÌ
bind irreversibly to hA1,°-iÛiV«Õ`ÃÜÌ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three separate experiments each performed in duplicate. Chemical structures of DPCPX, 
FSCPX, compound 7>`1xÈÓ­V«Õ`31) are also presented.
Equation 6. The KRI cut-off value for kinetically interesting compounds was 
arbitrarily set at 1.2 (Figure 3.5, the stippled line) rather than 1.0 to avoid 
false positives. It is worth mentioning that the cut-off value for the KRI can 
be flexible based on a different screening purpose. In other words, one can 
specifically set it higher to select only longer residence time compounds or 
lower to obtain more hits for future chemical modifications. In the present 
chapter, most compounds were found to have KRI values equal to or less 
than one (Figure 3.5) with both radioligands, which were thus considered to 
have similar or faster off-rates from the hA1R compared to the radioligands 
used, i.e., [3H]-DPCPX or [3H]-LUF5962. Seven compounds, excluding 
FSCPX, had KRI values ≥ 1.2 with [3H]-DPCPX as the radioligand, which 
indicated that these compounds dissociated more slowly from the receptor 
than [3H]-DPCPX (Figure 3.5, white bars). KRI values for the same panel 
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of unlabeled ligands against [3H]-LUF5962 were also determined (Figure 
3.5, gray bars). In the latter situation all compounds displayed a KRI < 1.2, 
except FSCPX, since the radioligand used ([3H]-LUF5962) has a relatively 
slow off-rate (0.021 min-1). Interestingly, most of the compounds adopted a 
concerted trend with a decreased KRI value compared to that obtained with 
[3H]-DPCPX. This is in accordance with the observation that indeed most 
compounds have faster dissociation rates than LUF5962 as determined by 
full kinetic experiments with [3H]-DPCPX (Table 3.2). For validation of the 
dual-point assay, four compounds with lower or similar KRI values (compared 
to DPCPX, KRI ≤ 1) and four compounds with higher KRI values (≥1.2) 
were further characterized in follow-up kinetic assays (Table 3.2).
Subsequently, competition association assays in the presence of [3H]-
DPCPX were performed to determine the binding kinetics of the eight 
compounds that had divergent KRI values (Table 3.2). In the present chapter, 
we used FSCPX as a tool compound, which had a KRI value of 5.4 ± 1.2 at 
the hA1R, indicative of negligible dissociation (Table 3.2 and Figure 3.4A). 
Similarly to FSCPX, the specific binding of [3H]-DPCPX in the presence of 
unlabeled LUF5962 (compound 31) became biphasic, which was represented 
by a decline towards equilibrium after a typical ‘overshoot’ (Figure 3.6A). 
Its dissociation rate was 0.021 ± 0.005 min-1, which was approximately ten 
times slower than DPCPX’s dissociation rate (Table 3.2). Next to that, we 
also decided to radiolabel this slow off-rate compound, which enabled us to 
directly determine its off-rate in a classic kinetic dissociation experiment. This 
assay yielded a dissociation rate of 0.025 ± 0.002 min-1, which was in good 
agreement with the off-rate determined from the competition association 
assay (Table 3.1). In addition, this matched with its KRI value of 1.6 ± 
0.4 determined in the dual-point screening method against [3H]-DPCPX. 
Subsequent KRI screening with [3H]-LUF5962 of the same set of compounds 
also supported our hypothesis that a KRI-value above 1.2 indicates a relatively 
slow dissociation from the target, while a lower KRI-value predicts a relatively 
fast dissociation rate. Moreover, additional kinetic experiments of other A1R 
antagonists proved that the obtained KRI values were a good predictor for 
their off-rates (Table 3.2). The three other selected compounds with KRI 
values bigger than 1.2 (32: 2.0 ± 0.4, 33: 1.6 ± 0.4 and 35: 1.2 ± 0.3) had 
dissociation rates of 0.027 ± 0.004 min-1, 0.038 ± 0.010 min-1 and 0.088 ± 
0.003 min-1, respectively. Next, four compounds (7, 13, 19 and 22) with KRI 
values ranging from 0.57 to 1.0 were selected for further characterization of 
the methodology. As expected, all four compounds had faster or similar off-






rates compared to DPCPX (Table 3.2). Typically, [3H]-DPCPX association 
in the presence of a ‘fast’ compound such as 7 (Figure 3.5, for its structure) 
resulted in a slow monophasic ascent of radioligand binding, indicative of 
a faster dissociation from the receptor than [3H]-DPCPX (Figure 3.6A). Its 
dissociation rate was determined as 3.0 ± 0.9 min-1, which was more than 
ten times faster than that of the radioligand. Notably, a good correlation 
(Figure 3.6B, r2 = 0.8511, P < 0.0005) was observed between the negative 
logarithm of the ligands’ dissociation rates (pkoff), excluding that of FSCPX 
(considering its unique irreversible binding character), and their KRI values 
derived from our new kinetic screening method. No significant correlation 
was observed between the negative logarithm of the ligands’ association rates 
(pkon) and their KRI values (r2 = 0.2551, P = 0.1655). This further proved 
that the KRI value is a good predictor for a ligand’s dissociation rate in the 
dual-point assay.  
Table 3.2 | Kinetics rate indexes (KRI) and binding kinetics obtained from the dual-point 
or standard competition association assay of DPCPX, FSCPX and representative hA1R 
antagonists.
Cmpd KRIa kon (nM-1ŪOKP-1)b koff (min-1)b RT (min)c Kinetic KD (nM)d Ki (nM)e
DPCPX £°ä´ä°£ ä°£{´ä°äÓ ä°Óx´ä°ä£ {°ä´£°ä £°n´ä°Î Ó°Î´ä°Î
FSCPX x°{´£°Ó ä°ääÎÇ´ä°ää£ä ä°ää£ä´ä°äääÓ £äää´ÎÎ ä°ÓÇ´ä°ä x°Ç´£°ä
1xÈÓ­31) £°È´ä°£ ä°äÈä´ä°ä£ä ä°äÓ£´ä°ääx {n´£Ó ä°Îx´ä°än ä°Ó{´ä°äÎ
32 Ó°ä´ä°{ ä°ä{Ó´ä°ääÈ ä°äÓÇ´ä°ää{ ÎÇ´È ä°È{´ä°£ä ä°ÇÎ´ä°äÇ
33 £°È´ä°{ ä°ää£Ó´ä°äää{ ä°äÎn´ä°ä£ä ÓÈ´££ ÎÓ´£{ Óx´x
35 £°Ó´ä°Î ä°ää{Î´ä°äääÇ ä°änn´ä°ääÎ ££´Ó Óä´Î ÎÈ´{
7 ä°xÇ´ä°£ä ä°{n´ä°£ä Î°ä´ä° ä°ÎÎ´ä°£ä È°Î´Ó°Î °{´Î°ä
13 £°ä´ä°£ ä°£Î´ä°äÇ ä°xÇ´ä°Óä Ó°ä´ä°Ç {°{´Î°ä n°Î´ä°Ó
19 ä°n´ä°£ä ä°ÈÓ´ä°äx ä°Èn´ä°£ä £°ä´ä°Ó £°£´ä°Ó £°£´ä°Ó
22 ä°ÇÎ´ä°Óä ä°£ä´ä°ä£ ä°Ó´ä°ä£ Î°ä´ä°Ó Ó°´ä°Ó {°´Ó°ä
6>ÕiÃ>Àii>Ã́ Ã°i°v>Ìi>ÃÌÌÀii`i«i`iÌiÝ«iÀiÌÃ«iÀvÀi`̀ Õ«V>Ìi°
a Kinetic rate indexes (KRI) were determined in the dual-point competition association assay. 




° c RT (residence time) = l / koff. 
d Kinetic KD = koff / 
kon. kon (k3) and koff  (k4) values of unlabeled antagonists were generated from [
3H]-DPCPX 
­Ó°x® V«iÌÌ>ÃÃV>Ì>ÃÃ>Þ >ÃÃV>Ì>ÃÃ>ÞÃ >Ì ÓxÂ
° e Ki values were from 
`Ã«>ViiÌ>ÃÃ>ÞÃ>ÌÓxÂ
ÀLÌ>i`vÀ
>}et al. and Van Veldhoven et al.£Ç]£n
102 |  Dual-point kinetic assay
Currently, there are several assays available developed for kinetics screening. 
For instance, Heise et al. developed a scintillation proximity assay (SPA) to 
measure Ki values for gonadotropin-releasing hormone receptor (GnRH 
receptor) antagonists after 30 min and 10 h incubation.22 This assay is based 
on the observation that a slowly dissociating compound will display a decrease 
of apparent Ki value over time, since it requires a longer incubation time to 
reach equilibrium.11,22 Another methodology is a functional assay described 
by Morriello et al., where hNK1R overexpressing CHO cells were pretreated 
with neurokinin 1 receptor (NK1R) antagonists before a measurement of the 
remaining activity induced by subsequently added substance P (endogenous 
agonist of hNK1R). A complete reversal of the hNK1R antagonism indicated 
a short receptor residence time of the compound under evaluation, while 
Advantages of the dual-point competition association assay 
and its future application in kinetic binding screening
Figure 3.6 | Panel A: Competition association assay of [3H]-DPCPX in the absence or 
presence of two unlabeled representative hA1,>Ì>}ÃÌÃ°1xÈÓ­31) and compound 
7ÜiÀivÕ`>`Õ>«ÌÃVÀii}>ÃÃ>ÞÌ>ÛiiÌVÀ>Ìi`iÝiÃv£°È´ä°£>`
ä°xÇ ´ ä°£ä] ÀiÃ«iVÌÛiÞ° ƂÃÃV>Ì >` `ÃÃV>Ì À>ÌiÃ vÀ Õ>Lii` }>`ÃÜiÀi
V>VÕ>Ìi` LÞ wÌÌ} Ìi `>Ì>  Ìi V«iÌÌ >ÃÃV>Ì `i >Ã  µÕ>Ì Ç°11 
Representative graph from one experiment performed in duplicate. Panel B: Correlation 
between the negative logarithm of the ligands’ dissociation rates (pkoff) and their kinetic rate 










an insurmountable effect of the tested ligand suggested longer receptor 
occupancy. In such a way, the recovery of the response to substance P gave 
an indication of an antagonist’s receptor off-rate.23 Similarly, the dual-point 
assay and its resulting KRI values described in the present chapter allow for 
a fast selection of long receptor residence time compounds, e.g., compound 
31 in the present chapter. Importantly, our new methodology has advantages 
over other assays. Firstly, as it only needs two assay points for testing one 
compound, the efficiency of kinetic screening is increased. Secondly, the KRI 
value derived from this assay yields direct information of a ligand’s binding 
kinetics, thus it allows for discrimination between fast, slowly and very slowly 
dissociating compounds. Moreover, this assay also provides the ability to 
identify ligands with short receptor residence times (i.e., compounds with 
KRI values lower than 1). In terms of therapies that need enduring target 
occupancy and a long-acting biological efficiency, a slowly dissociating 
compound might be an appropriate strategy for a clinical application. An 
example of a marketed long-residence-time drug is candesartan, which is an 
angiotensin II type 1 (AT1) receptor antagonist. Its enhanced long-lasting 
blood pressure lowering effects have been attributed to a slow receptor off-
rate; they even persist after the candesartan plasma concentration has become 
undetectable.24,25 In contrast, when an endogenous ligand has ubiquitous 
physiological functions, a rapidly dissociating exogenous ligand might be 
preferred to prevent the concomitant mechanism-based, on-target toxicity. An 
example is the short-lived intervention of dopamine-2 receptor (D2 receptor) 
activity by clozapine. Its ‘atypical’, short receptor residence time is thought to 
prevent adverse effects caused by lasting occupation of striatal D2 receptors, 
which respond to fast fluctuations in the local dopamine concentration.26,27 
Importantly, the dual-point assay and the KRI value could be employed to 
select both slowly and rapidly dissociating compounds (i.e., compound 31 
and 7). This versatility underscores its usability in future early phase drug 
discovery. 
As represented in Figure 3.5, the same set of unlabeled A1 receptor 
ligands have different KRI values if tested against two kinetically different 
radioligands. Indeed, since the dual-point approach and its derived KRI are 
mainly based on whether an unlabeled competitor dissociates faster or slower 
from its target than a particular radioligand, the choice of radioligand becomes 
the key for a reliable kinetic screening. Here we propose that the choice for an 
‘ideal’ radioligand (if one has the luxury of a number of radioligands) should 
take into account the drug target and the particular screening purpose. More 
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specifically, if one searches for slowly dissociating compounds, a relatively 
long residence time radioligand would be preferred, while for short residence 
time compounds, a relatively fast dissociating radioligand may be needed. 
By following this principle the load of follow-up kinetic determinations for 
selected compounds can be reduced. However, it is also necessary to take the 
assay practicability into consideration. In the present chapter, for instance, 
LUF5962 has a slow off-rate. According to Equation 5 regarding the t1 time 
point set-up, it would require nearly two hours for [3H]-LUF5962 to reach 
equilibrium when a concentration of one-fold its Ki value (0.24 nM) is used. 
Logically, this results in an even later t2 time point. Thus, we applied 1.0 
nM [3H]-LUF5962 (approximately four time its Ki) in our additional KRI 
experiments, enabling a relatively quick t1 at approximately 30 min and the 
same t2 as for [3H]-DPCPX (120 min). The robustness of the dual-point 
competition assay is underscored by the fact that even a less than ideal 
radioligand, such as [3H]-LUF5962, can still be used for screening purposes.
In the present chapter, we have merely described the application of the 
dual-point assay for a prototypical GPCR target, namely the adenosine A1R. 
We believe that this assay can have a more general application for other drug 
targets as well. This consideration is supported by an increasing amount of 
studies that characterized receptor binding kinetics, such as for the histamine 
H1 receptor, the corticotropin-releasing factor type-1 receptor (CRF1R) and 
more recently the adenosine A2A receptor, where Motulsky and Mahan’s 
theory and their competition association assay were used.28-30 Similar patterns 
of competition association curves were observed in these studies, i.e., in the 
presence of a fast dissociating competitor the specific radioligand binding 
approached equilibrium slowly; while in the presence of a slowly dissociating 
compound, it showed firstly the typical ‘overshoot’ followed by a constant 
decline to a plateau as in Figure 3.3B. This, as a proof-of-concept, implies the 
feasibility of a dual-point kinetic screening and the use of KRI for searching 
desired leads on other drug targets as well. 
In summary, the dual-point competition association assay is a valid tool 
to perform fast and high-throughput screening for compounds having either 
long or short residence times. The KRI value, which we coined in the present 
chapter, is an effective predictor of a compound’s dissociation rate from its 
target. We believe that this approach can be of general use at other drug 
targets, e.g., other GPCRs, after assay optimization for individual receptors.
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Binding kinetics of ZM241385 derivatives 
at the human adenosine A2A receptor
Guo D, Xia L, Van Veldhoven JPD, Hazeu M, Mocking T, Brussee J, 
IJzerman AP, Heitman LH.
Adapted from: ChemMedChem, 2014; 9(4): 752-761

Classical drug design and development rely mostly on affinity- or potency-
driven structure-activity relationships (SAR). So far a compound’s binding 
kinetics has been largely ignored, which importance, however, is now 
increasingly recognized. In this chapter we performed an extensive structure-
kinetics relationship (SKR) study in addition to a traditional SAR analysis at 
the adenosine A2A receptor (A2AR). The ensemble of 24 A2AR compounds, all 
triazolotriazine derivatives resembling the prototypic antagonist ZM241385 
(4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)
amino)ethyl)phenol), displayed only minor differences in affinity, while they 
varied substantially in their dissociation rates from the receptor. We believe 
that such a combination of SKR and SAR analysis as on the A2AR will have 
general importance for the superfamily of G protein-coupled receptors, since 
it can serve as a new strategy to tailor the interaction between ligand and 
receptor.
About this chapter
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Introduction4.1 
G protein-coupled receptors (GPCRs) are among the largest and most heavily 
investigated drug targets in the drug research community. Traditional early 
phase drug design and discovery campaigns of GPCRs largely depend on 
equilibrium affinity- or potency-based structure-activity relationships (SAR). 
This approach of lead optimization allows a quick synthesis-evaluation 
feedback loop to pool abundant candidate compound assemblies for further 
drug evaluation. Nevertheless, this classical SAR approach does not seem to 
predict clinical efficacy very well, which is witnessed by the high levels of 
attrition during the translation of a lead’s in vitro activity into its in vivo 
and clinical evaluation. To address this issue, several recent reviews have 
emphasized the importance of binding kinetics, and in particular the life 
time of a drug-target binary complex, i.e., drug-target residence time (RT), 
as a critical differentiator and predictor for drug efficacy and safety.1-5 Next 
to the RT, the association rate of a ligand-receptor interaction, which reflects 
the ‘target-engagement time’ (ET), should also be taken into consideration 
in the early phases of drug research. This is especially important for designing 
drugs that require a fast on-set of action and potentially for drugs that act 
on temporarily existing targets, such as protein-protein interactions.6-11 
Therefore, an extensive structure-kinetics relationship (SKR) investigation, 
in addition to the traditional SAR analysis, can be of great use in the early 
phases of candidate drug optimization.
The human adenosine A2A receptor (A2AR) is a subtype of adenosine 
receptors (others are A1, A2B and A3), belonging to the superfamily of GPCRs.12 
Antagonists for this receptor have been reported as potential treatment for 
Parkinson’s disease.13 As such, many compounds with high A2AR affinities 
have been developed,14-16 including the reference antagonist ZM241385 
(4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)
amino)ethyl)phenol)—a triazolotriazine derivative (Figure 4.1).17,18 These 
compounds were well characterized and optimized in terms of their binding 
affinity and thus benchmarked for later medicinal chemistry attempts at the 
A2AR. For example, Vu and colleagues synthesized ZM241385 derivatives 
with increased bioavailability.19-21 However, the success rate of the developed 
A2AR antagonist in clinical trials is disappointingly low. This indicates the 
results of currently used pre-clinical animal models don’t translate well into 
clinical studies. Moreover, little is known about their binding kinetics so far. 






Figure 4.1 | Chemical structure of ZM241385.
Thus, we decided to further extend this series of compounds by progressively 
modifying them at the C2 position, which would generate an insight into 
both SKR and SAR. We believe that the present study adds knowledge to our 
current understanding of drug design and development for A2AR antagonists. 
Hopefully, this methodology of combining both SKR and SAR can be 
generally applied at other drug targets as well in the future.
Results and discussion4.2 
Chemical synthesis
Synthesis routes are depicted in Scheme 4.1 and Scheme 4.2. In total, an 
ensemble of 24 triazolotriazine derivatives (12a-x) was obtained. Notably, 
compounds 12a, 12b and 12x were previously reported by Vu et al.,21 
and resynthesized in the present chapter, although in a different synthetic 
approach. All compounds (12a-x) started from furan-2-carbohydrazide (1) 
to generate 7-amino-2-(furyl)-5-methylthio[1,2,4]triazolo[1,5-a][1,3,5]
triazine (4), following the synthetic approach reported by Dolzhenko et al. 
and Jörg et al.22-25 Subsequently, 4 was oxidized with 3-chloroperbenzoic 
acid (MCPBA) to afford the corresponding sulfoxide/sulfone mixture 5,26 
which was substituted with a variety of commercially available amines (11f-
h) to generate 12f-h or with in-house prepared amines (11a-d and 11i-x) to 
generate 12a-d and 12i-x. 12e was obtained by the N-Boc deprotection of 
12d. 
For the preparation of intermediate amines 11a-d and 11i-x, synthetic 
routes are depicted in Scheme 4.2. In brief, reactions were carried out via 
N-alkylation of the commercially available piperazine derivatives (9a-d and 
9i-u) or the in-house synthesized phenylpiperazines (9v-x), which were 
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Scheme 4.1 | General synthesis route to 24 triazolotriazine derivatives. Reagents 
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derived from 6-8, 27-30 to obtain the appropriate N-phthalimide-protected 
alkyl piperazines (10a-d and 10i-x). This was followed by deprotection of the 
phthalimide to afford the free amines (11a-d and 11i-x).
SAR and SKR of triazolotriazine derivatives
The SAR and SKR analyses were initiated by testing two compounds, 12a 
and 12b, and then chemical modifications were gradually introduced to 
these two compounds (Table 4.1). Several observations were made; (1) the 
molecule with a two-carbon spacer was superior to the compound with a 
three-carbon spacer. The former (12a, Ki = 0.30 ± 0.08 nM; RT = 164 ± 32 
min) displayed a four-fold higher affinity and 41-fold longer RT than the 
latter (12b, Ki = 1.3 ± 0.1 nM; RT = 4 ± 1 min). Such a variation of the linker 
length also resulted in different association rates (12a, kon = 0.051 ± 0.005 
nM-1·min-1; 12b, kon = 0.16 ± 0.06 nM-1·min-1). (2) Upon different degrees of 
C2-phenylpiperazine modification the ligands’ affinities were moderately to 
largely affected, while their receptor RTs were drastically shortened (12d-h), 
except for the Boc-protected intermediate 12d. This compound, in fact, had 
a 30-fold and 20-fold improved affinity and RT, respectively, in comparison 
to its truncated analogue (12e). Moreover, their ETs were also significantly 
influenced by the chemical modifications on the phenylpiperazine moiety. 
Specifically, 12g displayed the fastest association rate of 0.046 ± 0.020 
nM-1·min-1. (3) Receptor RTs of 12a or 12d highlight the preference of an 
electron-withdrawing effect at the piperazine amine moiety. The insertion 
of an additional carbon into 12a (between the piperazine and the phenyl 
group; 12g) reversed the electron-withdrawing effect into a donating effect, 
which resulted in a reduced A2AR affinity (8.1 ± 0.5 nM) and RT (4 ± 1 
min). Replacement of the nitrogen by a carbon atom on the ‘right side’ of the 
piperazine (compare 12a and 12c) resulted in strongly decreased RT values 
that further confirmed the nitrogen’s importance in maintaining A2AR affinity 
and RT (Table 4.1, Figure 4.2 for 12c). Notably, ET and RT of 12c were 
the shortest of this series of compounds (except for the nearly 20-fold lower 
affinity compound 12h) without a large compromise on its affinity. Taken 
together, these results highlight the importance of the C2-phenylpiperazine-
ethyl group, and more specifically show that the electron-deficient nitrogen 
(on the right side of the piperazine) has a role in preserving a tight and 
enduring ligand-receptor interaction.














  (min-1)b RT (min)c 
i
 (nM) or %d
ZM241385 0.40 ± 0.03 0.13 ± 0.06 0.014 ± 0.003 71 ± 21 255[23]
12a 0.30 ± 0.08 0.051 ± 0.005 0.0061 ± 0.0020 164 ± 32 8%
12b 1.3 ± 0.1 0.16 ± 0.06 0.25 ± 0.01 4 ± 1 30%
12c 3.8 ± 0.8 0.20 ± 0.1 0.35 ± 0.03 3 ± 1 22%
12d 1.5 ± 0.1 0.030 ± 0.003 0.012 ± 0.004 83 ± 17 2%
12e 45 ± 0.1 0.0063 ± 0.0030 0.24 ± 0.10 4 ± 1 10%
12f 31 ± 6 0.0057 ± 0.0020 0.25 ± 0.10 4 ± 1 11%
12g 8.1 ± 0.5 0.046 ± 0.020 0.24 ± 0.10 4 ± 1 21%
12h 64 ± 1 0.020 ± 0.002 0.62 ± 0.08 2 ± 0 32%
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SAR and SKR were further analyzed with 16 phenyl-substituted 12a 
analogues (Table 4.2, 12i-x). Upon para-substitution at the phenyl ring 
(12i-n), no significant change of the ligands’ affinity (Ki values < 1 nM) 
was observed, except for 12n which had a 4.7-fold decrease in affinity (1.4 
± 0.2 nM). The latter was probably caused by steric hindrance induced by 
the bulky phenyl substituent, which presumably also limited its RT to 29 
± 2 min and decreased the association rate to 0.018 ± 0.002 nM-1·min-1. In 
contrast, the other para-substituted compounds 12i-m displayed a similar 
duration of in vitro receptor occupancy as ZM241385 (RT = 71 ± 21 min). 
In comparison to the convergent results upon para-position modifications, 





 4Figure 4.2 N ­>®Ã«>ViiÌv Ã«iVwV Q3H]-ZM241385 binding from the hA2A receptor 
by two representative compounds, namely 12x and 12c; (b) [3H]-ZM241385 competition 
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Concentration-effect curves for 12x and 12c in a cAMP assay. Data were obtained by adding 




ortho-substituted analogues (12o-12r) displayed divergent affinities and 
binding kinetics. Specifically, an ortho-methoxy substituent (12p) decreased 
A2AR affinity and RT compared to its para-substituted analogue (12m), while 
the methyl- (12o) or halogen-substituted (12q, 12r) analogues displayed 
increased A2AR affinities and RTs. For most compounds disubstitution of 
the phenylpiperazine did not dramatically change their affinities or binding 
kinetics (12t-w). Interestingly for 12x, bearing an ortho- and para-fluoro 
substituent, an exceptionally long receptor RT of 323 ± 25 min was found 
(Table 4.2) that was much longer than the simple ‘sum RT’ of mono-
fluorinated analogues (12l, 12r and 12s) and almost five-fold longer than 
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6CDNG^$KPFKPICHƂPKVKGUCPFMKPGVKEUQHKZ
Compd R= hA2AR hA1R
i (nM) 
a kon (nM
-1·min-1) b koff   (min
-1) b RT (min) c i (nM) or % 
d
12i 4-CH3 0.79 ± 0.06 0.062 ± 0.020 0.016 ± 0.006 63 ± 18 14 %
12j 4-Cl 0.29 ± 0.10 0.090 ± 0.010 0.018 ± 0.006 56 ± 11 35 ± 13
12k 4-CF3 0.38 ± 0.10 0.072 ± 0.009 0.020 ± 0.005 50 ± 37 64 %
12l 4-F 0.54 ± 0.05 0.10 ± 0.02 0.020 ± 0.005 50 ± 8 57 %
12m 4-OCH3 0.51 ± 0.10 0.064 ± 0.005 0.0079 ± 0.0020 127 ± 19 11 %
12n 4-Ph 1.4 ± 0.2 0.018 ± 0.002 0.034 ± 0.010 29 ± 2 32 %
12o 2-CH3 0.13 ± 0.04 0.062 ± 0.002 0.0075 ± 0.0020 133 ± 21 29 %
12p 2-OCH3 3.5 ± 0.7 0.032 ± 0.003 0.070 ± 0.070 14 ± 11 19 %
12q 2-Cl 0.13 ± 0.03 0.068 ± 0.016 0.0065 ± 0.0010 154 ± 25 30 %
12r 2-F 0.12 ± 0.05 0.052 ± 0.012 0.011 ± 0.002 91 ± 15 28 %
12s 3-F 0.29 ± 0.03 0.055 ± 0.009 0.012 ± 0.003 83 ± 14 62 %
12t 2, 4-diCH3 0.16 ± 0.01 0.11 ± 0.02 0.012 ± 0.001 78 ± 9 29 %
12u 3, 4-diCl 0.31 ± 0.10 0.10 ± 0.01 0.015 ± 0.004 67 ± 11 21 ± 4
12v 2, 4-diCl 0.15 ± 0.02 0.11 ± 0.01 0.014 ± 0.001 70 ± 5 80 ± 24
12w 2-F, 4-OCH3 0.24 ± 0.05 0.054 ± 0.005 0.0083 ± 0.0010 120 ± 65 27%
12x 2, 4-diF 0.33 ± 0.04 0.034 ± 0.004 0.0031 ± 0.0002 323 ± 25 22%
aÃ«>ViiÌvÃ«iVwVQ3H]-ZM241385 binding from the hA2A,>Ì{Â
°
b kon and koff were 
`iÌiÀi`V«iÌÌ>ÃÃV>Ì>ÃÃ>Þ>Ì{Â
° c RT (Residence Time) = 1 / koff. 
d % 
`Ã«>ViiÌvÃ«iVwVQ3H]-DPCPX binding at 1 µM from the hA1,>ÌÓxÂ
°>Ì>>ÀiÃÜ
>Ãi>´Ã°i°vÌÀiiÃi«>À>ÌiiÝ«iÀiÌÃi>V«iÀvÀi``Õ«V>Ìi°






ZM241385’s RT. From Figure 4.2B it also follows that 12x had a much 
longer RT than ZM241385 (the radioligand), since a typical ‘overshoot’ in 
specific radioligand binding was observed.30 On the contrary, if a competitor 
dissociates faster from its target than the radioligand, the specific binding of 
the radioligand will slowly and monotonically approach its equilibrium over 
time, as observed for 12c (Figure 4.2B).30
Almost all prepared ZM241385 derivatives displayed high selectivity 
over the human adenosine A1 receptor (A1R), i.e., < 50 % of [3H]-DPCPX 
displacement at 1 µM (Table 4.1 and 4.2). Notably, the longest RT compound 
on the A2AR, 12x, had a very good A2AR selectivity over the A1R (Table 4.2). In 
contrast, 12j, 12u and 12v, with mono- or di-chloro substitution, lost some 
selectivity over the A1R (Ki values at the A1R ranged from 20 nM to 80 nM, 
Table 4.2). Interestingly, all these compounds contain a chloro-substituent 
in the para-position, yet the substituent in other positions (e.g., 12q, ortho-
substituent) didn’t exhibit lower selectivity for the A2AR over the A1R.
Functional characterization of 12x and 12c in a cAMP assay
Subsequently, the longest and shortest RT compounds with high affinity 
(i.e., 12x and 12c) were functionally characterized in an A2AR agonist-
induced cAMP assay, which revealed their antagonistic behavior. Firstly, it 
follows from Figure 4.2C that both 12x and 12c induced a concentration-
dependent decrease of intracellular cAMP levels with 16-fold difference in 
their IC50 values, which are 1.4 ± 0.1 nM and 21.8 ± 0.5 nM, respectively 
(Table 4.3). Secondly, pre-treatment of HEK293hA2AR cells with 
different concentrations of 12x before stimulation with an AR agonist 
(i.e., 5’-N-ethylcarboxamidoadenosine, NECA) induced insurmountable 
antagonism. In other words, the NECA concentration-effect curve was 
shifted to the right with a concomitant decrease in the maximal response 
(Figure 4.3A). Conversely, 12c displayed surmountable A2AR antagonism, 
shifting NECA’s curves to the right yet without affecting its maximal 
response (Figure 4.3B). In addition, the pA2 value for 12c generated from a 
Schild-plot was 8.62 ± 0.29, which was similar to its pKi value (8.40 ± 0.10), 
and the Schild-slope was close to unity (0.93 ± 0.11) suggesting that 12c 
competed with NECA for the same receptor binding site. To further examine 
whether 12x and 12c both bound to the same site as the agonist, we also 
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Figure 4.3 | cAMP experiments were performed on human embryonic kidney 293 cells 
stably expressing the hA2AR at ambient room temperature (22–25 °C). 12x (a) or 12c (b) 
ÜiÀiVÕL>Ìi`vÀÎä«ÀÀÌÌiV>i}ivÌi>`iÃiÀiVi«ÌÀ>}ÃÌ 
Ƃ
at a concentration ranging from 100 µM to 0.1 nM for another 30 min. 12x (c) or 12c (d) 
ÜiÀiVVÕL>Ìi`ÜÌ 
Ƃ]>Ì>VViÌÀ>ÌÀ>}}vÀ£ääÌä°£]vÀÎä
min. The agonist curves were generated in the presence of increasing concentrations of 






performed a co-incubation experiment with 12x or 12c in the presence of 
NECA. It follows from Figure 4.3C and 4.3D that in this experimental set-
up both compounds produced a rightward shift in the NECA dose-response 
curve without a suppression of the maximal response, i.e., indicative of a 
competitive interaction. Hence, these findings oppose that insurmountable 
antagonism resulted from an allosteric mode of inhibition, which would 
be proven by a suppression of the maximal response in the co-incubation 
experiment.31-33 Notably, the generated pA2 values of 12x and 12c in this 
experimental set-up were similar to their pKi values and the derived Schild 






slopes were close to unity (Table 4.3). Together, this confirmed that 12x or 
12c bound fully competitively with NECA and the insurmountable A2AR 
antagonism of 12x was a result caused by so-called hemi-equilibrium during 
the functional assay due to its long A2AR residence time profile.32
It needs to point out that the results for functional characterization and 
binding kinetics determination are not obtained at a physiologically more 
relevant temperature (37 ˚C) and thus cannot be representative for residence 
times observed in vivo. However, it is reasonable to expect that the ranking 
of these compounds’ RTs at 4 ˚C should agree with the result at the room 
temperature or at the physiologically more relevant 37 ˚C. Such a discussion 
has been documented in our previous publication at the A2AR, where 
UK432,097 has a RT five-fold the length of CGS21680.34,35 This difference 
at 4 ˚C well translates into distinct duration of action in an in vivo setting 
reported by Mantell et al., that is, 8 h for UK432,097 and less than one hour 
for CGS21680.36
Table 4.3 | Functional characterization of 12x and 12c in a cAMP assay.
Potency a Pre-incubation b Co-incubation b
Compd IC50 (nM) pA2 Schild slope pA2 Schild slope
12c 1.4 ± 0.1 8.62 ±  0.29 0.93 ±  0.11 8.57 ± 0.06 0.93 ±  0.02
£ÓÝ 21.8 ± 0.5 N.A N.A 9.69 ± 0.03 1.13 ± 0.01
a Antagonists’ potency (IC50) values were determined from concentration-response curves 
for 12x and 12cÌi«ÀiÃiViv£ää 
ƂvÀ>VVÕL>ÌvÎä°ƂÌ>}ÃÌÃ
were pre-incubated for 30 min b or co-incubated cÜÌ 
Ƃ>Ì>VViÌÀ>ÌÀ>}}
from 100 µM to 0.1 nM. N.A., not applicable. Data are shown as mean ± s.e.m of three 
Ãi«>À>ÌiiÝ«iÀiÌÃi>V«iÀvÀi``Õ«V>Ìi>ÌÀÌi«iÀ>ÌÕÀi­ÓÓqÓxc
®°
Generation of a ‘kinetics map’ and physicochemical 
correlation plots from A2AR antagonist SKR data
Next, we plotted an on-/off-rate graph or so-called ‘kinetics map’, including the 
data of all A2AR ligands obtained in this chapter (Figure 4.4).37 Evidently, this 
kinetics map depicted the ligand-receptor binding affinity (KD, represented 
by the parallel diagonal lines) into detailed kinetic rates that reflect the process 
of ‘target-engagement time’ (kon, Y axis) and the target-residence time (koff, X 
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Figure 4.4 | The kinetics map (Y axis: kon, nM·min; X axis: koff, min) of all A2AR ligands 
that were tested in this chapter./iiÌV>Þ̀ iÀÛi`>vwÌÞ­D = koff / kon) is represented 
by the parallel diagonal lines. Group A: compounds that have varied kon and koff values, 
ÜiÌiD remained within a similar range (0.1-0.3 nM). Group B: compounds that have 
the same koffÛ>ÕiÃ]LÕÌ`ÛiÀ}iÌD values. Group C: compounds that have the same kon 
Û>ÕiÃ]LÕÌ`ÛiÀ}iÌD values.
axis), respectively. We observed that the compounds can be divided into three 
groups; firstly, both kon and koff values can vary across one order of magnitude 
(Figure 4.4, Group A), while the KD remained within a narrow range (0.1-
0.3 nM), as mentioned above. This indicated that compounds with the same 
affinity may have many different combinations of on- and off-rates even 
within the same scaffold and target system. Such information, often ignored 
or unavailable in traditional SAR studies, in fact can be highly decisive in 
translating a lead’s in vitro profile into in vivo pharmacokinetics (PK) and/or 
pharmacodynamics (PD) behavior.38 Secondly, compounds sharing the same 
off-rate may bear divergent KD values, due to different on-rates (Group B). It 
has been shown in several cases that a compound’s slow dissociation rate was 
pivotal for a high in vivo efficacy.34,35 Thus, in retrospect one could imagine 
that many compounds with promising koff values were overlooked simply due 
to their ‘low scores’ in classical affinity- or potency-dominated evaluations. 






Figure 4.5 | Molecular descriptors of size (MW), lipophilicity (logP), molecular surface 
area (MSA, 3D), and charge (pKa) of the substituted C2RJGP[NRKRGTC\KPGHTCIOGPVUCPF
VJGKTEQTTGNCVKQPYKVJVJGsNQIXCNWGUQHQPCPFQHHTCVGU No obvious linear correlation 
was observed between the association-/dissociation-rates and MW (for association: r2 = 
0.0089, P = 0.7180; for dissociation: r2 = 0.1059, P = 0.2024), logP (for association: r2 = 
0.0023, P = 0.8563; for dissociation: r2 = 0.0731, P = 0.2938), MSA (for association: r2 = 
0.1629, P = 0.1082; for dissociation: r2 = 0.2107, P = 0.0638) or pa (for association: r
2 = 
0.0018, P = 0.8727; for dissociation: r2 = 0.0187, P = 0.6010).
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Thirdly, the same holds for a compound’s on-rate (Group C), i.e., merely 
focusing on a ligand’s KD can result in compounds without the desired on-
rate, as exemplified by candidate drugs aiming at acute diseases where a rapid 
on-set of action is desired (e.g., acute respiratory distress syndrome).6,11 Taken 
together, the kinetics map provides a detailed interpretation of a ligand-
receptor binding process with a full inventory of kon, koff and KD values of a 
series of compounds.
Furthermore, molecular and physicochemical properties of the 
synthesized phenylpiperazine analogues (12i-x and 12a) and their putative 
relationship with the on- and off-rates were examined in efforts to identify 
key factor(s) affecting their binding kinetics (Figure 4.5). Since the main 
scaffold of these series of compounds is the same, we specifically focused 
on the properties of C2-phenylpiperazine fragments. Several descriptors 
were selected to be further examined in correlation plots. They were the size 
(molecular weight, MW), surface of the fragment (molecular surface area, 
MSA), lipophilicity (logP), and charge (ionization constant, pKa). There 
was no obvious linear correlation between the association-/dissociation-rates 
and MW, logP, MSA or pKa. We also performed a multiple linear regression 
analysis to check whether the compound’s binding kinetics is directed by a 
combination of two or more of the physicochemical descriptors. However, 
no significant correlation was found either (significance F > 0.05 in all cases). 
Altogether, this indicated that the binding kinetics was compound specific 
and that there is no general trend in the correlation to their molecular and 
physicochemical properties.
Importance of the phenylpiperazine-fragment at the C2 
position and its location in the A2AR’s ‘vestibule’
In this chapter we observed that upon minor chemical modifications of the 
phenylpiperazine side chain on the triazolotriazine scaffold (Table 4.1 and 4.2), 
binding affinity of the derivatives underwent subtle changes only, while their 
binding kinetics were very sensitive to such structural variations. For instance, 
upon substitution of 12a, 12k (para-trifluoromethyl substituted) displayed 
a similar Ki value as 12a, while its off-rate was 3.4-fold increased. In another 
case, the on- and off-rates of 12u (meta-, para-chloro disubstituted) were 
increased and decreased, respectively, in a similar magnitude (approximately 






2-fold), hence leading to an unchanged affinity value compared to 12a. Table 
4.2 as a whole exemplifies the difficulty of selecting a ‘next-stage’ candidate 
based on SAR alone. Most compounds have subnanomolar affinity, and 
compound 12x does not stand out in any particular way.
The lack of large changes in binding affinities might be expected given 
the absence of direct interactions between the phenylhydroxyl group and 
the receptor in a recently determined high-resolution crystal structure of 
ZM241385-bound A2AR.39 In this structure, the phenylhydroxyl group 
points away from the binding pocket toward the extracellular space. 
Likewise, in another crystal structure of UK432,097-bound A2AR, the bulky 
tail of the agonist UK432,097 at the adenine C2 position extends outward 
of the ligand-binding cavity.40 Notably, it was recently published that this 
agonist also has a slow association rate and long RT at the A2AR.34 Based on 
these findings, we postulated that the C2-phenylpiperazine group protrudes 
outward without forming direct interactions with residues in the binding 
pocket of the triazolotriazine core. Instead, it may interact with residues 
that are located at the extracellular loops or the adjacent regions topping 
the binding cavity, on its trajectory of associating to or dissociating from 
the receptor. Such reasoning is supported by a recent molecular dynamics 
simulation study of the β1- and β2-adrenergic receptors by Dror et al.41 They 
found that several beta blockers and one beta agonist all traverse the same 
well-defined, dominant pathway as they bind to the β1- and β2-adrenergic 
receptors, initially making contact with a so-called ‘vestibule’ on the receptor’s 
extracellular surface. Interestingly, this holds true for the ligand binding 
dynamics of the M3 muscarinic acetylcholine receptor too. Simulation results 
indicated that as tiotropium binds to or dissociates from the receptor, it 
‘pauses’ at an alternative binding site in the extracellular ‘vestibule’.42 Taken 
together, such an extracellular ‘vestibule’ appears to play an important role 
in the on- or off-trajectory to and from the binding pocket of a GPCR.41 
These molecular dynamics calculations therefore support that an extracellular 
‘vestibule’ appears to play an important role in the on- or off trajectory to 
and from the binding pocket of a GPCR, which is in accordance with our 
observation that a change in the C2-phenylpiperazine group significantly 
affected the ligand’s association and dissociation rates at the A2AR, while their 
Ki values were minimally changed.
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Conclusion4.3 
We have exemplified an extensive structure-kinetics relationship (SKR) in 
addition to a traditional SAR analysis at the adenosine A2A receptor (A2AR). 
Compound 12x, the high-affinity A2AR ligand previously reported by Vu et 
al.,21 was revealed to have an exceptional long RT (323 min). Compared to 
the traditional SAR analysis, such a kinetic insight provided a further rationale 
to support the selection of 12x from otherwise chemically and biologically 
similar compounds for further testing. Kinetics mapping all tested A2AR 
ligands also provided a detailed interpretation of the ligand-receptor binding 
process. Next, a functional comparison between a short RT antagonist 12c and 
12x in the pre-incubation experiment further revealed 12x’s insurmountable 
antagonism at the hA2AR—a phenomenon distinct from 12c. In addition, 
investigation of the molecular properties indicated that the ligand-receptor 
binding kinetics were most likely driven by specific interactions between 
the ligand and the receptor. It could also be of great interest to subject the 
compounds having similar affinity yet different binding kinetics into (pre)
clinical tests, especially to examine how relevant the variation in RT and on/
off-rate is in terms of in vivo efficacy and duration of action. We believe that 
SKR, in combination with traditional SAR, can serve as an important tool 
for more directed medicinal chemistry efforts in the future.
Experimental section4.4 
General: All solvents and reagents were purchased from commercial sources 
and were of analytical grade. Demineralised water is simply referred to as 
H2O, as it was used in all cases unless stated otherwise (i.e., brine). 1H and 
13C NMR spectra were recorded on a Bruker AV 400 liquid spectrometer (1H 
NMR, 400 MHz; 13C NMR, 101 MHz) at ambient temperature. Chemical 
shifts are reported in parts per million (ppm), are designated by δ and are 
downfield to the internal standard tetramethylsilane (TMS). Coupling-
constants are reported in Hz and are designated as J. High resolution mass 
Chemical synthesis






spectrometry was performed by the Leiden Institute of Chemistry and 
recorded by direct injection (2 µL of a 2 µM solution in water/MeCN; 50/50; 
v/v and 0.1 % formic acid) on a mass spectrometer (Thermo Finnigan LTQ 
Orbitrap) equipped with an electrospray ion source in positive mode (source 
voltage 3.5 kV, sheath gas flow 10, capillary temperature 275 ˚C) with 
resolution R = 60000 at m/z 400 (mass range m/z = 150-2000) and calibrated 
for dioctylphthalate (m/z = 391.28428). Analytical purity of the final 
compounds was determined by high performance liquid chromatography 
(HPLC) with a Phenominex Gemini 3u C18 110A column (50 x 4.6 mm, 3 
µm), measuring UV absorbance at 254 nm. Sample preparation and HPLC 
method were as follows, unless stated otherwise: 0.3-0.8 mg of compound 
was dissolved in 1 mL of a 1:1:1 mixture of CH3CN/H2O/t-BuOH and 
eluted from the column within 15 minutes, with a three component system 
of H2O/CH3CN/1 % TFA in H2O, decreasing polarity of the solvent 
mixture in time from 80/10/10 to 90/0/10. All compounds showed a single 
peak at the designated retention time and are at least 95 % pure. Thin-layer 
chromatography (TLC) was routinely consulted to monitor the progress of 
reactions, using aluminum-coated Merck silica gel F254 plates. Purification 
by column chromatography was achieved by use of Grace Davison Davisil 
silica column material (LC60A 30-200 micron). Solutions were concentrated 
using a Heidolph laborota W8 2000 evaporation apparatus and by a high 
vacuum on a Binder APT line Vacuum Drying Oven. The procedure for a 
series of similar compounds is given as a general procedure for all within that 
series, annotated by the numbers of the compounds. 
2-(Furan-2-carboxamido) guanidine (2). The mixture of the hydrazide (1) (0.1 mol, 12.6 g) and 
S-methylisothiourea sulfate (0.05 mol, 13.9 g) in an 1% aqueous sodium hydroxide solution (400 mL) 
was stirred at room temperature for 72 hrs. The precipitated solid (2), was filtered, washed with ice water, 
and used in next step without further purification. 1H NMR (400 MHz, DMSO-d6): δ 10.77 (br s, 1H, 
NH), 7.56 (s, 1H), 6.88 and 6.76 (2 x s due to dimer formation, 2H, NH2), 6.64 (d, J = 2.8 Hz, 1H), 
6.45 (dd, J = 2.0, 0.8 Hz, 1H).
5-(Furan-2-yl)-2H-1,2,4-triazol-3-amine (3). The guanidine (2) (53.6 mmol, 9.0 g) was stirred in a 
mixture of ethyl acetate and H2O with a ratio of 1:1 (400 mL) for 3 hrs. After extraction by 150 mL 
of ethyl acetate twice, the organic layer was washed with H2O and brine (2 × 100 mL), and dried over 
anhydrous Na2SO4. After removing the solvent, 6.51 g white solid (4) was obtained (two-step yield: 54 
%). 1H NMR (400 MHz, DMSO-d6): δ 12.08 (br s, 1H, NH), 7.68 (s, 1H), 6.67 (s, 1H), 6.54 (s, 1H), 
6.08 (s, 2H).
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2-(Furan-2-yl)-5-(methylthio)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (4). A mixture of the 
amine (3) (43.4 mmol, 6.5 g) and dimethyl N-cyanodithio(imino)carbonate  (47.8 mmol, 7.0 g) was 
heated at 180 ˚C  in a stream of nitrogen for 4 hrs and cooled down to room temperature to add 30 mL 
of a solution of CH2Cl2 and CH3OH with the ratio of 1:1. The mixture was refluxed for another 1.5 hrs 
and followed by a filtration. The solids were washed by the solution and the solvent was removed under 
reduced pressure. The residue was purified by column chromatography by eluting with CH2Cl2 containing 
increasing amounts of ethyl acetate (0% - 50%). This gave compound 4 as a pale yellow solid (3.2 g, yield: 
30 %).  1H NMR (400 MHz, CD3OD): δ 7.91 (dd, J = 1.7, 0.7 Hz, 1H), 7.12 (dd, J = 3.4, 0.7 Hz, 1H), 
6.70 (dd, J = 3.4, 1.7 Hz, 1H), 2.55 (s, 3H).
2-(Furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (5). A solution 
of MCPBA (70% strength, 32.5 mmol, 8.0 g) in CH2Cl2 (20 mL) was added to a stirred, ice-cooled 
suspension of the sulfide (R = MeSO) (13.0 mmol, 3.2 g) in CH2Cl2 (50 mL). The resulting solution was 
stirred overnight at room temperature. The solvent was removed and ethanol (70 mL) was added to the 
residue. The solid was collected by filtration, washed with ethanol, and dried in the vacuum oven to give 
white solid (R = MeSO2) (3.2 g, yield 88%). 1H NMR (400 MHz, DMSO-d6): δ 9.81 and 9.48 (2 x s 
due to dimer formation, 2H, NH2), 7.98 (dd, J = 1.2, 0.8 Hz, 1H), 7.34 (dd, J = 2.4, 0.8 Hz, 1H), 6.73 
(dd, J = 2.4, 1.2 Hz, 1H), 3.35 (s, 3H). 
1-(2,4-Dichlophenyl)piperazine (9v). A mixture of 6 (16.7 mmol, 2.0 mL) and piperazine (83.6 mmol, 
7.2 g) in 10 mL of N,N-dimethylacetamide was heated in the microwave at 165 ˚C for 6.5 hrs after which 
6 was consumed, shown by TLC. Water and CH2Cl2 was added and the pH value was adjusted to 1 with 
1 mol/L HCl (aq.). The aqueous layer was washed three times with CH2Cl2 and subsequently basified to 
pH 12 with 5 mol/L NaOH(aq). After extraction of the basified aqueous layer with CH2Cl2 the combined 
organics were backwashed four times with water, dried over MgSO4 and concentrated in vacuo to yield 9v 
as yellow oil (2.4 g, yield 61%). 1H NMR (400 MHz, CDCl3): δ 7.36 (d, J = 2.4 Hz, 1H), 7.19 (dd, J = 
8.8, 2.4 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 3.06-3.02 (m, 5H, 2 × CH2 and NH), 2.99-2.96 (m, 4H).
1-(2-Fluoro-4-methoxyphenyl)piperazine hydrochloride (9w). A mixture of bis(2-chloroethyl)
amine hydrochloride  (9.59 mmol, 1.7 g) (7)  and 1-butanol (20 mL) was treated slowly with 2-fluoro-
4-methoxybenzenamine (9.14 mmol, 1.3 g) at room temperature. After the addition, the mixture was 
refluxed for 48 hrs and then cooled. The solid was filtered and rinsed with MeOH and Et2O to give a white 
solid 9w (660 mg, yield 29%). 1H NMR (400 MHz, CDCl3): δ 9.21 (br s, 2H, NH and HCl), 7.07-7.02 
(m, 1H), 6.86-6.83 (m, 1H), 6.74-6.71 (m, 1H), 3.72 (s, 3H), 3.28-3.20 (m, 4H), 3.14-3.10 (m, 4H).
1-(2,4-Difluorophenyl)piperazine (9x). A mixture of piperazine (24.9 mmol, 2.14 g) and 1-bromo-2,4-
difluorobenzene (8) (4.1 mmol, 0.8 g), t-BuONa (5.8 mmol, 0.56 g), BINAP (0.25 mmol, 0.16 g), and 
Pd2(dba)3 (0.083 mmol, 0.048 g) in dry toluene was heated at 110 ˚C under a nitrogen atmosphere for 
24 hrs. The mixture was filtered over Celite and rinsed with dichloromethane. The solution was washed 






with H2O and brine (2 × 10 mL), dried over Na2SO4 and the solvent evaporated in vacuo. The residue 
was purified by silica gel via CH2Cl2/CH3OH, 10:1 to give compound 9x as pale yellow oil (337 mg, yield 
42%). 1H NMR (400 MHz, CDCl3): δ 6.91-6.87 (m, 1H), 6.83-6.78 (m, 2H), 3.06 (t, J = 3.6 Hz, 4H), 
3.00-2.97 (m, 4H), 1.80 (s, 1H, NH)
General procedure for preparation of compounds 10a-d, 10i-x. The mixture of the appropriate 
phthalimide-protected alkyl bromide (7.5 mmol), piperazine derivative (5 mmol) and K2CO3 (10 mmol) 
in DMF (5 mL) was stirred at 70 ˚C overnight. The reaction mixture was cooled, washed with H2O (5 
mL) and then extracted with ethyl acetate (3 × 10 mL). The organic phase was then combined, dried over 
Na2SO4 and evaporated in vacuo to give the crude product, which was recrystallized from EtOH and/or 
CH3OH, or purified by chromatography (petrol ether/ EtOAc).
2-(2-(4-Phenylpiperazin-1-yl)ethyl)isoindoline-1,3-dione (10a). Pale yellow solid was obtained by 
column chromatography with petrol ether/ EtOAc, 5:1~1:1 (1.5 g, yield 43 %). 1H NMR (400 MHz, 
CDCl3): δ 7.86-7.80 (m, 4H), 7.25-7.24 (m, 2H), 6.91-6.88 (m, 2H), 6.80 (t, J = 8.1 Hz, 1H), 3.87 (t, 
J = 6.3 Hz, 2H), 3.15-3.12 (m, 4H), 2.72-2.68 (m, 6H).
2-(3-(4-Phenylpiperazin-1-yl)propyl)isoindoline-1,3-dion (10b). Pale white solid was obtained by 
recrystallization from EtOH (1.4 g, yield 79 %). 1H NMR (400 MHz, CDCl3): δ 7.89-7.85 (m, 2H), 
7.74-7.71 (m, 2H), 7.30-7.24 (m, 2H), 6.90-6.84 (m, 3H), 3.85-3.80 (m, 2H), 3.07 (br s, 4H), 2.57 (br 
s, 4H), 2.53-2.49 (m, 2H), 1.95-1.92 (m, 2H).
2-(2-(4-Phenylpiperidin-1-yl)ethyl)isoindoline-1,3-dione (10c). Pale white solid was obtained by 
recrystallization from EtOH (1.3 g, yield 37 %). 1H NMR (400 MHz, CDCl3): δ 7.88-7.85 (m, 2H), 
7.76-7.71 (m, 2H), 7.30-7.28 (m, 2H), 7.21-7.18 (m, 3H), 3.87 (t, J = 6.8 Hz, 2H), 3.13 (d, J = 9.6 Hz, 
2H), 2.71-2.65 (m, 2H), 2.51-2.44 (m, 1H), 2.19-2.13 (m, 2H), 1.83-1.66 (m, 4H).
tert-Butyl-4-(2-(1,3-dioxoisoindolin-2-yl)ethyl)piperazine-1-carboxylate (10d). White solid was 
obtained by silica gel with CH2Cl2/EtOAc (10:1~8:1) (558 mg, yield 57 %). 1H NMR (400 MHz, 
CDCl3): δ 7.79 (dd, J = 5.6, 3.2 Hz, 2H), 7.71 (dd, J = 5.6, 3.2 Hz, 2H), 3.77 (t, J = 6.4 Hz, 2H), 3.30 
(t, J = 4.8 Hz, 4H), 2.59 (t, J = 6.4 Hz, 2H), 2.41 (t, J = 4.8 Hz, 4H), 1.39 (s, 9H).
2-(2-(4-(4-Methylphenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10i). Pale white solid was 
obtained by recrystallization from EtOH (1.5 g, yield 44 %). 1H NMR (400 MHz, CDCl3): δ 7.88-7.82 
(m, 2H), 7.75-7.69 (m, 2H), 7.09-7.03 (m, 2H), 6.82 (t, J = 8.8 Hz, 2H), 3.87-3.84 (m, 2H), 3.08-3.06 
(m, 4H), 2.70-2.66 (m, 6H), 2.26 (d, J =10 Hz, 3H ).
2-(2-(4-(4-Chlorophenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10j). Pale white solid was 
obtained by recrystallization from EtOH (1.7 g, yield 58 %). 1H NMR (400 MHz, CDCl3): δ 7.84 (dd, J 
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= 5.2, 2.8 Hz, 2H), 7.7.1 (dd, J = 5.2, 2.8 Hz, 2H), 7.17 (dd, J = 6.8, 2.4 Hz, 2H), 6.79 (dd, J = 6.8, 2.4 
Hz, 2H), 3.85 (t, J = 6.4 Hz, 2H), 3.08 (t, J = 4.8 Hz, 4H), 2.69-2.66 (m, 6H).
2-(2-(4-(4-(Trifluoromethyl)phenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10k). White solid 
was obtained by recrystallization from EtOH/CH3OH, 1:1 (985 mg, yield 49 %). 1H NMR (400 MHz, 
CDCl3): δ 7.83 (dd, J = 5.2, 2.8 Hz, 2H), 7.71 (dd, J = 5.2, 2.8 Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H), 6.88 
(d, J = 8.8 Hz, 2H), 3.86 (t, J = 6.4 Hz, 2H), 3.21 (t, J = 4.8 Hz, 4H), 2.71-2.66 (m, 6H).
2-(2-(4-(4-Fluorophenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10l). White solid was obtained 
by silica gel with Petrol Ether/ EtOAc, 5:1 (1.7 g, yield 49 %). 1H NMR (400 MHz, CDCl3): δ 7.87-7.85 
(m, 2H), 7.84-7.82 (m, 2H), 6.98-6.81 (m, 4H), 3.05-3.02 (m, 2H), 3.19-3.07 (m, 4H), 2.70-2.66 (m, 
6H). 
2-(2-(4-(4-Methoxyphenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10m). Pale white solid was 
obtained by recrystallization from EtOH (813 mg, yield 45 %). 1H NMR (400 MHz, CDCl3): δ 7.84 
(dd, J = 5.2, 2.8 Hz, 2H), 7.71 (dd, J = 5.2, 2.8 Hz, 2H), 6.88-6.86 (m, 2H), 6.82-6.80 (m, 2H), 3.88 (t, 
J = 6.4 Hz, 2H), 3.75 (s, 3H), 3.04-3.02 (m, 4H),  2.70-2.69 (m, 6H).
2-(2-(4-([1,1’-Biphenyl]-4-yl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10n). Pale white solid was 
obtained by recrystallization from EtOH (1.0 g, yield 55 %). 1H NMR (400 MHz, CDCl3): δ 7.84 (dd, 
J = 5.2, 2.8 Hz, 2H), 7.72 (dd, J = 5.2, 2.8 Hz, 2H), 7.54 (d, J = 7.6 Hz, 2H), 7.49 (d, J = 8.8 Hz, 2H), 
7.39 (t, J = 7.6 Hz, 2H), 7.25 (s, 1H), 6.95 (d, J = 8.8 Hz, 2H), 3.87 (t, J = 6.8 Hz, 2H), 3.19-3.17 (m, 
4H), 2.72-2.70 (m, 6H).
2-(2-(4-(2-Methylphenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10o). Pale white solid was 
obtained by column chromatography (CH2Cl2 - 2% MeOH/CH2Cl2) (1.9 g, yield 57 %). 1H NMR (400 
MHz, CDCl3): δ 7.86-7.83 (m, 2H), 7.75-7.68 (m, 2H), 7.17-7.11 (m, 2H), 6.99-6.92 (m, 2H), 3.87 
(d, J = 6.4 Hz, 2H), 2.90-2.84 (m, 4H), 2.76-2.68 (m, 6H), 2.29 (s, 3H).
2-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10p). Pale white solid was 
obtained by column chromatography (CH2Cl2 - 2% MeOH/CH2Cl2) (2.49 g, yield 60 %). 1H NMR 
(400 MHz, CDCl3): δ 7.86-7.83 (m, 2H), 7.73-7.70 (m, 2H), 7.00-6.96 (m, 1H), 6.92- 6.87 (m, 2H), 
6.84 (d, J = 7.6 Hz, 1H), 3.87-3.84 (m, 5H), 3.10-2.93 (m, 4H), 2.74-2.67 (m, 6H).
2-(2-(4-(2-Chlorophenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10q). Pale white solid was 
obtained by column chromatography (CH2Cl2 – 2% MeOH/CH2Cl2) (2.11 g, yield 64%). 1H NMR 
(400 MHz, CDCl3): δ 7.88-7.83 (m, 2H), 7.74-7.70 (m, 2H), 7.33 (dd, J = 8.0, 1.6 Hz, 1H), 7.19 (td, 
J = 8.0, 1.6 Hz, 1H), 7.01 (dd, J = 8.0, 1.2 Hz, 1H), 6.94 (td, J = 7.6, 1.2 Hz, 1H), 3.87 (d, J = 6.8 Hz, 
2H), 3.10-2.94 (m, 4H), 2.81-2.63 (m, 6H).






2-(2-(4-(2-Fluorophenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10r). Pale white solid was 
obtained by recrystallization from EtOH (1.97 g, yield 74%). 1H NMR (400 MHz, CDCl3): δ 7.87-7.83 
(m, 2H), 7.74-7.70 (m, 2H), 7.21-7.17 (m, 2H), 6.97-6.93 (m, 2H), 3.90-3.84 (m, 2H), 3.10-3.00 (m, 
4H), 2.65-2.52 (m, 6H).
2-(2-(4-(3-Fluorophenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10s). Pale white solid was 
obtained by recrystallization from EtOH (1.97 g, yield 74%). 1H NMR (400 MHz, CDCl3): δ 7.83-7.82 
(m, 2H), 7.71-7.67 (m, 2H), 7.18-7.12 (m, 1H), 6.64-6.63 (m, 1H), 6.55-6.47 (m, 2H), 3.86-3.83 (m, 
2H), 3.15-3.10 (m, 4H), 2.75-2.60 (m, 6H).
2-(2-(4-(2,4-Dimethylphenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10t). Pale white solid 
(852 mg, yield 45%)  was obtained by column purification (2% MeOH/CH2Cl2). 1H NMR (400 MHz, 
CDCl3): δ 7.88-7.83 (m, 2H), 7.75-7.69 (m, 2H), 6.98 (s, 1H),  6.94 (d, J = 8.0 Hz, 1H), 6.89 (d, J = 
8.4 Hz, 1H), 3.86 (t, J = 6.8 Hz, 2H), 2.90-2.81 (m, 4H), 2.73-2.68 (m, 6H).
2-(2-(4-(3,4-Dichlorophenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10u). Pale white solid  was 
obtained by recrystallization from EtOH.(1.78 g, yield 88 %). 1H NMR (400 MHz, CDCl3): δ 7.85-7.83 
(m, 2H), 7.72-7.70 (m, 2H), 7.23 (s, 1H), 6.92 (d, J = 2.8 Hz, 1H), 6.71 (dd, J = 8.8, 2.8 Hz, 1H), 3.87-
3.84 (m, 2H), 3.11-3.08(m, 4H), 2.71-2.65 (m, 6H).  
2-(2-(4-(2,4-dichlorophenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10v). Pale white solid 
(509 mg, yield 29%) was obtained by column purification (1% MeOH/CH2Cl2). 1H NMR (400 MHz, 
CDCl3): δ 7.88-7.83 (m, 2H), 7.74-7.70 (m, 2H), 7.33 (d, J = 2.4 Hz, 1H),  7.15 (dd, J = 8.4, 2.4 Hz, 
1H), 6.91 (d, J = 8.4 Hz, 1H), 3.86 (t, J = 6.8 Hz, 2H), 3.06-2.95 (m, 4H), 2.78-2.68 (m, 6H).  
2-(2-(4-(2-Fluoro-4-methoxyphenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10w). Pale white 
solid (859 mg, yield 54%) was obtained by column chromatography (CH2Cl2-2% MeOH/CH2Cl2). 1H 
NMR (400 MHz, CDCl3): δ 7.87-7.83 (m, 2H), 7.74-7.70 (m, 2H), 6.87 (t, J = 9.2 Hz, 1H), 6.65-6.58 
(m, 2H), 3.86 (t, J = 6.8 Hz, 2H), 3.74 (s, 3H), 3.07-2.95 (m, 4H), 2.72-2.69 (m, 6H).
2-(2-(4-(2,4-Difluorophenyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (10x). White solid was 
obtained by silica gel with petrol ether/EtOAc, 20:1~5:1, (389 mg, yield 65 %). 1H NMR (400 MHz, 
CDCl3): δ 7.81-7.79 (m, 2H), 7.67-7.65 (m, 2H), 6.84-6.78 (m, 1H), 6.75-6.69 (m, 2H), 3.97 (m, 2H), 
2.93 (m, 4H), 2.66 (m, 6H).
General Procedure for Preparation of Compounds 11a-d, 11i-x. Hydrazine hydrate was added in excess (1 
~ 5 mL) to a solution of isoindoline-1,3-dione (3 mmol) in EtOH (25 mL) and the mixture was stirred at 
70 ˚C overnight. The solvent was removed in vacuo and EtOAc was added to the residue. The solids were 
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filtered, dried over Na2SO4 and evaporated in vacuo to give the crude product as a pale yellow oil or solid. 
The crude product is used in the next step without further purification.
General Procedure for Preparation of Compounds 12a-x. The mixture of the related amine (0.75 mmol), 
the sulfone / sulfoxide mixture (5) (0.50 mmol) and Et3N (1.0 mmol) was dissolved in CH3CN and 
refluxed overnight. After removing the solvent in vacuo, EtOAc was added and the organic phase was 
washed with H2O and brine (2 × 10 mL), dried over Na2SO4 and evaporated. The residue was purified by 
column chromatography using silica gel and EtOAc or EtOAc/MeOH to afford a white to off-white solid.
2-(Furan-2-yl)-N5-(2-(4-phenylpiperazin-1-yl)ethyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-
diamine (12a). Eluted with EtOAc/MeOH, 10:1 to afford the title compound as white powder (55 mg, 
yield: 14%). 1H NMR (400 MHz, MeOD): δ 7.68 (s, 1H), 7.22 (t, J = 8.4 Hz, 2H), 7.12 (d, J = 3.2 Hz, 
1H), 6.96 (d, J = 8.4 Hz, 2H), 6.84-6.81 (m, 1H), 6.60 (d, J = 1.6 Hz, 1H), 3.61-3.60 (m, 2H), 3.20 (t, 
J = 4.8 Hz, 4H), 2.72 (t, J = 4.8 Hz, 4H), 2.68-2.67 (m, 2H). 13C NMR (101 MHz, DMSO-d6): 161.6, 
159.7, 156.3, 151.5, 150.5, 146.7, 145.1, 129.4, 119.2, 115.8, 112.4, 112.1, 57.1, 53.2, 48.7, 38.5. 
HRMS (ESI) m/z [M+H]+ calcd for C20H24N9O+: 406.2026, found: 406.2092; HPLC: ret. time =11.96 
min., purity = 96.7%.
2-(Furan-2-yl)-N5-(3-(4-phenylpiperazin-1-yl)propyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-
diamine (12b). Eluted with EtOAc/MeOH, 10:1 to afford the title compound as white powder (87 mg, 
yield: 41%). 1H NMR (400 MHz, DMSO-d6): δ 8.42 and 8.13 (2 x s due to dimer formation, 2H, NH2), 
7.86 (s, 1H), 7.55 and 7.44 (2 x t due to dimer formation, J = 5.2 Hz, 1H, NH), 7.19 (t, J = 8.0 Hz, 
2H), 7.04-7.03 (m, 1H), 6.91 (d, J = 8.0 Hz, 2H), 6.75 (t, J = 6.8 Hz, 1H), 6.66 (s, 1H), 3.30-3.29 (m, 
4H), 3.12-3.10 (m, 6H), 2.40-2.36 (m, 2H), 1.74-1.71 (m, 2H). 13C NMR (101 MHz, DMSO-d6):  δ 
162.0, 161.6, 159.7, 156.3, 151.5, 151.1, 150.4, 146.7, 145.1, 129.4, 122.9, 119.1, 115.7, 112.4, 112.1, 
108.7, 56.1, 56.0, 53.3, 48.6, 26.5. HRMS (ESI) m/z [M+H]+ calcd for C21H26N9O+: 420.2182, found 
420.2253; HPLC: ret. time = 11.98 min., purity = 97.8 %. 
2-(Furan-2-yl)-N5-(2-(4-phenylpiperidin-1-yl)ethyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-
diamine (12c). Eluted with EtOAc/MeOH, 3:2 to afford the title compound as white powder (29 mg, 
yield: 14%). 1H NMR (400 MHz, DMSO-d6): 8.46 and 8.21 (2 x s due to dimer formation, 2H, NH2), 
7.88 (s, 1H), 7.35 and 7.33 (2 x t due to dimer formation, J = 7.2 Hz, 1H, NH), 7.31-7.22 (m, 4H), 
7.20-7.17 (m, 1H), 7.07 (d, J = 3.6 Hz, 1H), 6.69-6.68 (m, 1H), 3.45-3.42 (m, 2H), 3.05-3.02 (m, 2H), 
2.52-2.51 (m, 2H), 2.49-2.44 (m, 1H), 2.12-2.07(m, 2H), 1.76-1.63 (m, 4H). 13C NMR (101 MHz, 
DMSO-d6): 161.6, 159.7, 156.3, 150.5, 146.7, 146.6, 145.1, 128.8, 127.2, 126.4, 112.4, 112.1, 57.4, 
54.3, 42.3, 38.6, 33.5. HRMS (ESI) m/z [M+H]+ calcd for C21H25N8O+: 405.2073, found: 405.2142; 
HPLC: ret. time = 12.20 min., purity = 99.5%.
tert-Butyl-4-(2-(7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl)






piperazine-1-carboxylate (12d). Eluted with petrol ether/EtOAc from 1:1 to 1:9 to afford the title 
compound as white powder (20 mg, yield: 31%). 1H NMR (400 MHz, MeOD): δ 7.69 (d, J = 0.8 Hz, 
1H), 7.12 (d, J = 3.2 Hz, 1H), 6.61 (dd, J = 3.2 Hz, 0.8 Hz, 1H), 3.60-3.57 (m, 2H), 3.46-3.45 (m, 4H), 
2.63-2.62 (m, 2H), 2.52-2.50 (m, 4H), 1.46 (s, 9H). HRMS (ESI) m/z [M+H]+ calcd for C19H28N9O3+: 
430.2237, found: 430.2308; HPLC: ret. time = 11.86 min., purity = 96.3%. 
2-(Furan-2-yl)-N5-(2-(piperazin-1-yl)ethyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine di-
trifluoroacetate (12e). The Boc-protected compound (12d) (20 mg) was dissolved in a CH2Cl2/TFA 
mixture, 1:1 (5 mL). The mixture was stirred at room temperature for 24 hrs. A brown solid was obtained 
(13 mg, yield: 82%). 1H NMR (400 MHz, DMSO-d6): 8.41 and 8.16 (2 x s due to dimer formation, 2H, 
NH2), 7.86 (s, 1H), 7.30 (br s, 1H, NH), 7.04 (s, 1H), 6.67 (s, 1H), 3.50 (br s, 2H), 3.04 (br s, 4H), 2.60 
(br s, 4H), 2.50 (br s, 2H). 13C NMR (101 MHz, DMSO-d6): 161.7, 159.6, 150.6, 146.7, 145.4, 112.4, 
112.1, 108.6, 56.9, 50.3, 43.7, 38.2. HRMS (ESI) m/z [M+H]+ calcd for C18H22F6N9O5+: 557.1570, 
found: 330.1786 ([M+H+]-2TFA); HPLC: ret. time = 11.92 min., purity = 98.9 %.
2-(Furan-2-yl)-N5-(2-(4-methylpiperazin-1-yl)ethyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-
diamine (12f ). Eluted with EtOAc/MeOH, 3:2 to afford the title compound as white powder (61 mg, 
yield: 35%). 1H NMR (400 MHz, DMSO-d6): 8.16 (2 x s due to dimer formation, 2H, NH2), 7.81 (s, 
1H), 7.24 and 7.16 (2 x t due to dimer formation, J = 5.6 Hz, 1H, NH), 7.00-6.99 (m, 1H), 6.62-6.61 
(m, 1H), 3.33-3.32 (m, 2H), 2.46-2.45 (m, 2H), 2.42-2.36 (m, 4H), 2.27-2.24 (m, 4H), 2.07(s, 3H). 
13C NMR (101 MHz, DMSO-d6): 161.6, 159.7, 156.3, 150.5, 146.6, 145.1, 129.6, 112.4, 112.1, 57.1, 
55.2, 53.2, 46.2, 38.5. HRMS (ESI) m/z [M+H]+ calcd for C24H34N9O+: 344.1869, found: 344.1942; 
HPLC: ret. time = 11.70 min., purity = 99.2%.
N5-(2-(4-benzylpiperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-
diamine (12g). Eluted with EtOAc/MeOH, 3:2 to afford the title compound as white powder (34 mg, 
yield: 16%). 1H NMR (400 MHz, DMSO-d6): 8.39 and 8.13 (2 x s for due to dimer formation, 2H, 
NH2), 7.82 (s, 1H), 7.28-7.17 (m, 6H), 7.01-7.00 (m, 1H), 6.63-6.62 (m, 1H), 3.39 (s, 2H), 3.34-3.33 
(m,2H), 2.47-2.46 (m, 2H), 2.44-2.41 (m, 4H), 2.33-2.31 (m, 4H). 13C NMR (101 MHz, DMSO-d6): 
161.6, 159.7, 156.3, 150.5, 146.6, 145.1, 138.7, 129.3, 128.6, 127.3, 112.4, 112.1, 62.6, 57.6, 57.1, 
53.3, 53.1, 46.2, 38.5. HRMS (ESI) m/z [M+H]+ calcd for C21H25N8O+: 420.2181, found: 420.2254; 
HPLC: ret. time = 12.14 min., purity = 99.6%.
2-(Furan-2-yl)-N5-(2-(piperidin-1-yl)ethyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine 
(12h). Washed with CH3CN and CH2Cl2 to afford the title compound as white powder (63 mg, yield: 
43%). 1H NMR (400 MHz, MeOD): δ 7.69 (s, 1H), 7.12 (d, J = 8.4 Hz, 1H), 6.61-6.60 (m, 1H), 3.57 
(t, J = 6.8 Hz, 2H), 2.59-2.58 (m, 2H), 2.52-2.51 (m, 4H), 1.64-1.60 (m, 4H), 1.49-1.48 (m, 2H). 13C 
NMR (101 MHz, DMSO-d6): 161.6, 159.7, 156.3, 150.5, 146.7, 145.1, 112.4, 112.1, 57.8, 54.6, 38.6, 
26.1, 24.5. HRMS (ESI) m/z [M+H]+ calcd for C15H21N8O+: 329.1760, found: 329.1832; HPLC: ret. 
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time =11.31 min., purity = 96.3%.
2-(Furan-2-yl)-N5-(2-(4-(4-methylphenyl)piperazin-1-yl)ethyl)-[1,2,4]triazolo[1,5-a][1,3,5]
triazine-5,7-di-amine (12i). Eluted with EtOAc/MeOH, 5:1, to afford the title compound as white 
powder (65 mg, yield: 31%). 1H NMR (400 MHz, DMSO-d6): 8.42 and 8.19 (2 x s due to dimer 
formation, 2H, NH2), 7.86 (s, 1H), 7.35 and 7.28 (2 x s due to dimer formation, 1H, NH), 7.05 (s, 
1H), 7.01-7.00 (m, 2H), 6.84-6.82 (m,2H), 6.67 (s, 1H), 3.42 (br s, 2H), 3.06 (br s, 4H), 2.56 (br s, 
2H), 2.50 (br s, 4H), 2.18 (s, 3H). 13C NMR (101 MHz, DMSO-d6): 161.6, 160.0, 156.3, 150.5, 149.4, 
146.6, 145.1, 129.8, 128.0, 116.0, 112.4, 112.1, 57.1, 53.3, 49.1, 38.5, 20.5. HRMS (ESI) m/z [M+H]+ 
calcd for C21H26N9O+: 420.2182, found: 420.2253; HPLC: ret. time = 12.16 min., purity = 96.0%.
N5-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]
triazine-5,7-diamine (12j). Eluted with EtOAc/MeOH, 10:1, to afford the title compound as white 
powder (30 mg, yield: 14%). 1H NMR (400 MHz, DMSO-d6):  8.41 and 8.19 (2 x s due to dimer 
formation, 2H, NH2), 7.86 (s, 1H ), 7.35 and 7.28 (2 x s due to dimer formation, 1H, NH), 7.22-7.20 
(m, 2H), 7.05 (s, 1H), 6.93 (br s, 2H), 6.67 (s, 1H), 3.42 (br s. 2H), 3.12 (br s, 4H), 2.56 (br s, 2H), 
2.50 (br s, 4H). 13C NMR (101 MHz, DMSO-d6): 161.9, 159.8, 156.4, 150.3, 146.8, 145.1, 129.0, 
122.7, 117.2, 112.4, 112.1, 57.1, 53.0, 48.5, 38.5. HRMS (ESI) m/z [M+H]+ calcd for C20H23ClN9O+: 
440.1636, found: 440.1707; HPLC: ret. time = 12.41 min., purity = 95.0%.
N5-(2-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]
[1,3,5]triazine-5,7-diamine (12k). Eluted with EtOAc/MeOH, 5:1, to afford the title compound as 
white powder (50 mg, yield: 21%). 1H NMR (400 MHz, DMSO-d6): 8.43 and 8.19 (2 x s due to dimer 
formation, 2H, NH2), 7.86 (s, 1H ), 7.49 (d, J = 8.8 Hz, 2H) 7.37 and 7.30 (2 x s due to dimer formation, 
1H, NH), 7.06-7.05 (m, 1H), 7.05-7.04 (m, 2H), 6.67 (s, 1H), 3.43-3.42 (m, 2H), 3.27-3.25 (m, 4H), 
2.57-2.53 (m, 6H). 13C NMR (101 MHz, DMSO-d6): 161.6, 159.7, 156.3, 153.7, 150.5, 146.7, 145.1, 
126.6, 126.5, 118.4, 118.0, 114.6, 112.4, 112.1, 57.0, 53.0, 47.4, 38.5. HRMS (ESI) m/z [M+H]+ calcd 
for C21H23F3N9O+: 474.1899, found: 474.1969; HPLC: ret. time = 12.52 min., purity = 95.0%.
N5-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-
5,7-diamine (12l). Eluted with EtOAc/MeOH, 10:1, to afford the title compound as white powder (45 
mg, yield: 21%). 1H NMR (400 MHz, DMSO-d6): 8.19 and 8.12 (2 x s for due to dimer formation, 2H, 
NH2), 7.86 (s, 1H ), 7.35 and 7.28 (2 x s due to dimer formation, 1H, NH), 7.05-7.01 (m, 2H), 7.00 
(s, 1H), 6.94-6.91 (m, 2H), 6.67 (s,1H), 3.43-3.41 (m. 2H), 3.06 (br s, 4H), 2.57-2.53 (m, 6H). 13C 
NMR (101 MHz, DMSO-d6): 161.6, 161.1, 159.2, 156.7, 156.1, 155.8, 155.1, 150.7, 150.0, 147.9, 
146.2, 144.6, 117.0, 116.9, 115.3, 115.1, 111.9, 111.6, 57.0, 56.6, 52.7, 49.0, 38.4, 38.0. HRMS (ESI) 
m/z [M+H]+ calcd for C20H23FN9O+: 424.1931, found: 424.2002; HPLC: ret. time = 12.08 min., purity 
= 97.2%.







triazine-5,7-diamine (12m). Eluted with EtOAc/MeOH, 5:1, to afford the title compound as white 
powder (64 mg, yield: 29%). 1H NMR (400 MHz, DMSO-d6): 8.44 and 8.20 (2 x s for due to dimer 
formation, 2H, NH2), 7.86 (s, 1H ), 7.34 and 7.27 (2 x s due to dimer formation, 1H, NH), 7.05 (d, J 
= 2.4 Hz, 1H), 6.87 (d, J = 8.8 Hz, 2H), 6.79 (d, J = 8.8 Hz, 2H), 6.67 (s, 1H), 3.66 (s, 3H), 3.42-3.39 
(m, 2H), 3.00 (br s, 4H), 2.56-2.52 (m, 6H). 13C NMR (101 MHz, DMSO-d6): 161.6, 159.7, 156.3, 
153.3, 150.5, 146.6, 145.9, 145.1, 117.7, 114.7, 112.4, 112.1, 57.1, 55.6, 53.3, 50.0, 38.5. HRMS 
(ESI) m/z [M+H]+ calcd for C21H26N9O2+: 436.2131, found: 436.2202; HPLC: ret. time = 11.75 min., 
purity = 95.6%.
N5-(2-(4-([1,1’-biphenyl]-4-yl)piperazin-1-yl)ethyl)-2-(furan-2-yl)[1,2,4]triazolo[1,5-a][1,3,5]
trizaine-5,7-diamine (12n). Eluted with EtOAc/MeOH, 10:1, to afford the title compound as white 
powder (55 mg, yield: 23%). 1H NMR (400 MHz, DMSO-d6): 8.53 (s, 1H), 8.21 (br s, 2H, NH2), 
7.87 (s, 1H), 7.60-7.52 (m, 3H), 7.40-7.39 (m, 2H), 7.30-7.27 (m, 1H), 7.06-7.01 (m, 3H), 6.68 (s, 
1H), 4.31 (m, 2H), 3.49-3.43 (m, 2H), 3.20-3.19 (m, 4H), 2.60-2.58 (m, 4H). 13C NMR (101 MHz, 
DMSO-d6): 161.6, 159.7, 156.3, 150.8, 150.5, 146.6, 146.5, 145.1, 140.5, 130.7, 129.3, 127.6, 126.8, 
126.3, 115.9, 112.4, 112.1, 57.1, 53.2, 48.4, 38.5. HRMS (ESI) m/z [M+H]+ calcd for C26H28N9O+: 
482.2339, found: 482.2408; HPLC: ret. time = 11.98 min., purity = 97.8 %.
2-(furan-2-yl)-N5-(2-(4-(2-methyphenyl)piperazin-1-yl)ethyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-
5,7-diamine (12o). Eluted with EtOAc/MeOH, 3:2 to afford the title compound as white powder (116 
mg, yield: 55%). 1H NMR (400 MHz, DMSO-d6): 8.44 and 8.19 (2 x s due to dimer formation, 2H, 
NH2), 7.88 (s, 1H), 7.35 and 7.27 (2 x s due to dimer formation, 1H, NH), 7.16-7.11 (m, 2H), 7.06 (s, 
1H), 7.02 (d, J = 7.6 Hz, 1H), 6.95 (t, J = 7.2 Hz, 1H), 6.68 (s, 1H), 3.46-3.43 (m, 2H), 2.90-2.78 (m, 
4H), 2.61-2.55 (m, 6H), 2.24 (s, 3H). 13C NMR (101 MHz, DMSO-d6):  161.6, 161.2, 159.2, 155.9, 
151.3, 150.1, 146.2, 144.7, 131.7, 130.8, 126.5, 122.8, 118.7, 111.9, 111.7, 56.7, 53.3, 51.3, 38.0, 
17.6. HRMS (ESI) m/z [M+H]+ calcd for C21H26N9O+: 420.2182, found: 420.2252 ; HPLC: ret. time = 
12.37 min., purity = 99.6%.
2-(furan-2-yl)-N5-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-[1,2,4]triazolo[1,5-a][1,3,5]
triazine-5,7-diamine (12p). Eluted with EtOAc/MeOH, 3:2 to afford the title compound as white 
powder (130 mg, yield: 60%). 1H NMR (400 MHz, DMSO-d6): 8.44 and 8.20 (2 x s due to dimer 
formation, 2H, NH2), 7.86 (s, 1H), 7.40 and 7.27 (2 x s due to dimer formation, 1H, NH), 7.06 (s, 1H), 
6.91-6.90 (m, 2H), 6.85-6.84 (m, 2H), 6.67 (s, 1H), 3.79 (s, 3H), 3.43-3.42 (m, 2H), 2.95-2.94 (m, 
4H), 2.57-2.50 (m, 6H). 13C NMR (101 MHz, DMSO-d6): 161.2, 159.2, 155.9, 152.0, 150.0, 146.2, 
144.7, 141.3, 122.3, 120.8, 117.9, 111.9, 111.8, 111.6, 56.7, 55.3, 53.1, 50.1, 38.3. HRMS (ESI) m/z 
[M+H]+ calcd for C21H26N9O2+: 436.2131, found: 436.2007; HPLC: ret. time = 12.08 min., purity = 
99.9%.
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N5-(2-(4-(2-chlorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]
triazine-5,7-diamine (12q). Eluted with EtOAc/MeOH, 3:2 to afford the title compound as white 
powder (113 mg, yield: 51%). 1H NMR (400 MHz, DMSO-d6): 8.42 and 8.18 (2 x s due to dimer 
formation, 2H, NH2), 7.87 (s, 1H), 7.47-7.38 (dd, J = 7.6, 1.2 Hz, 1H), 7.35-7.25 (m, 2H), 7.15 (d, J = 
8.0 Hz, 1H), 7.05-7.01 (m, 2H), 6.68-6.67 (m, 1H), 3.45-3.40 (m, 2H), 2.98-2.97 (m, 4H), 2.61-2.49 
(m, 6H). 13C NMR (101 MHz, DMSO-d6): 161.2, 159.2, 155.9, 150.0, 149.1, 146.2, 144.7, 130.3, 
128.1, 127.6, 123.8, 120.8, 118.7, 111.9, 111.7, 56.6, 52.9, 50.9, 38.0. HRMS (ESI) m/z [M+H]+ calcd 
for C20H23ClN9O+: 440.1636, found: 440.1706 ; HPLC: ret. time = 12.27 min., purity = 99.5%.
N5-(2-(4-(2-fluorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-
5,7-diamine (12r). Eluted with EtOAc/MeOH, 10:1 to afford the title compound as white powder (66 
mg, yield: 31%). 1H NMR (400 MHz, DMSO-d6): 8.46 and 8.21 (2 x s due to dimer formation, 2H, 
NH2), 7.86 (s, 1H), 7.35 and 7.14 (2 x t due to dimer formation, J = 5.6 Hz, 1H, NH), 7.14-6.92 (m, 
5H), 6.68-6.67 (m, 1H), 3.44-3.43 (m, 2H), 3.02-3.01 (m, 4H), 2.60-2.59 (m, 4H), 2.57-2.53 (m, 2H). 
13C NMR (101 MHz, DMSO-d6): 161.6, 159.7, 156.6, 154.2, 150.5, 146.6, 145.1, 140.3, 125.3, 125.2, 
122.7, 122.6, 119.6, 116.5, 116.3, 112.4, 112.1, 57.0, 53.3, 50.6, 50.5, 38.4. HRMS (ESI) m/z [M+H]+ 
calcd for C20H23FN9O+: 424.1931, found: 424.2002; HPLC: ret. time = 12.00 min., purity = 95.6%.
N5-(2-(4-(3-fluorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-
5,7-diamine (12s). Eluted with EtOAc/MeOH, 3:2 to afford the title compound as white powder (96 
mg, yield: 45%). 1H NMR (400 MHz, DMSO-d6): 8.44 and 8.19 (2 x s due to dimer formation, 2H, 
NH2), 7.86 (s, 1H), 7.37 and 7.27 (2 x t due to dimer formation, J = 5.2 Hz, 1H, NH), 7.22-7.16 (m, 
1H), 7.05-7.04 (d, J = 3.2 Hz, 1H), 6.75-6.66 (m, 3H), 6.54-6.49 (m, 1H), 3.44-3.39 (m, 2H), 3.15 (br 
s, 4H), 2.55-2.52 (m, 6H). 13C NMR (101 MHz, DMSO-d6): 164.9, 162.5, 162.0, 161.6, 159.7, 156.6, 
156.3, 153.3, 153.2, 151.1, 150.5, 146.6, 145.1, 130.8, 130.7, 112.4, 112.1, 111.2, 105.1, 104.9, 102.2, 
102.0, 57.5, 57.0, 53.0, 48.1, 38.9, 38.4. HRMS (ESI) m/z [M+H]+ calcd for C20H23FN9O+: 424.1931, 
found 424.2002; HPLC: ret. time = 12.06 min., purity = 98.5%.
N5-(2-(4-(2,4-dimethylphenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]
triazine-5,7-diamine (12t). Eluted with EtOAc/MeOH, 5:1 to afford the title compound as white 
powder (128 mg, yield: 59%).  1H NMR (400 MHz, DMSO-d6): 8.40 and 8.17 (2 x s due to dimer 
formation, 2H, NH2), 7.88 (s, 1H), 7.33 and 7.26 (2 x t, J = 5.2 Hz, 1H, NH), 7.06-7.05 (m, 1H), 6.99-
6.90 (m, 4H), 6.68 (s, 1H), 3.43 (t, J = 6.0 Hz, 2H), 2.80 (br s, 4H), 2.59-2.51 (m, 6H), 2.20 (s, 6H). 
13C NMR (101 MHz, DMSO-d6): 161.2, 159.2, 155.9, 150.0, 148.9, 146.2, 144.6, 131.5, 131.4, 126.9, 
118.6, 111.9, 111.6, 56.7, 53.3, 51.5, 38.0, 20.3, 17.4. HRMS (ESI) m/z [M+H]+ calcd for C22H28N9O+: 
434.24113, found: 434.24088; HPLC: ret. time = 7.98 min., purity = 99.3%.
N5-(2-(4-(3,4-dichlorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]
[1,3,5]-triazine-5,7-diamine (12u). Eluted with EtOAc/MeOH, 10:1, to afford the title compound as 






white powder (128 mg, yield: 59%). 1H NMR (400 MHz, DMSO-d6): 8.44 and 8.20 (2 x s due to dimer 
formation, 2H, NH2), 7.87 (s, 1H ), 7.38 (d, J = 8.8 Hz, 1H), 7.29 (t, J = 5.2 Hz, 1H, NH), 7.12 (d, J 
= 2.8 Hz, 1H), 7.05 (d, J = 3.2 Hz, 1H), 6.94 (dd, J = 9.2, 2.8 Hz, 1H), 6.68 (dd, J = 3.2, 1.6 Hz, 1H), 
3.45-3.43 (m, 2H), 3.18 (br s, 4H), 2.55-2.51 (m, 6H). 13C NMR (101 MHz, DMSO-d6): 161.6, 159.7, 
156.3, 151.2, 150.5, 146.7, 145.1, 131.9, 130.9, 120.0, 116.6, 115.7, 112.4, 112.1, 57.0, 52.9, 48.0, 
38.4. HRMS (ESI) m/z [M+H]+ calcd for C20H22Cl2N9O+: 474.1246, found: 474.1317; HPLC: ret. time 
= 12.12 min., purity = 95.3%.
N5-(2-(4-(2,4-dichlorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]
triazine-5,7-diamine (12v). Eluted with EtOAc/MeOH, 5:1 to afford the title compound as white 
powder (94 mg, yield: 69%). 1H NMR (400 MHz, DMSO-d6): 8.40 and 8.16 (2 x s due to dimer 
formation, 2H, NH2), 7.86 (s, 1H), 7.52 (d, J = 2.0 Hz, 1H), 7.34 (dd, J = 8.4, 2.0 Hz, 1H), 7.25 (t, J 
= 5.2 Hz, 1H, NH), 7.15 (d, J = 8.4 Hz, 1H), 7.05 (s, 1H), 6.67 (s, 1H), 3.41 (t, J = 5.2 Hz, 2H), 3.10-
2.90 (m, 4H), 2.65-2.51 (m, 6H). 13C NMR (101 MHz, DMSO-d6): 161.2, 159.2, 155.8, 150.0, 148.1, 
146.2, 144.6, 129.6, 128.4, 128.0, 126.9, 122.1, 111.9, 111.6, 56.6, 52.8, 50.8, 38.0. HRMS (ESI) m/z 
[M+H]+ calcd for C20H22Cl2N9O+: 474.13189, found: 474.13182; HPLC: ret. time = 7.98 min., purity 
= 97.8%.
N5-(2-(4-(2-fluoro-4-methoxyphenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]
[1,3,5]triazine-5,7-diamine (12w). Eluted with EtOAc/MeOH, 5:1 to afford the title compound as 
white powder (113 mg, yield: 51%). 1H NMR (400 MHz, DMSO-d6): 8.43 and 8.19 (2 x s due to dimer 
formation, 2H, NH2), 7.87 (s, 1H), 7.34 and 7.25 (2 x t due to dimer formation, J = 5.2 Hz, 1H, NH), 
7.05-7.04 (m, 1H), 6.97 (t, J = 9.6 Hz, 1H), 6.80 (dd, J = 14.0, 7.6 Hz, 1H), 6.69-6.67 (m, 2H), 3.70 (s, 
3H), 3.44-3.41 (m, 2H), 2.91 (br s, 4H), 2.58-2.50 (m, 6H). 13C NMR (101 MHz, DMSO-d6): 161.6, 
161.2,159.2, 156.8, 156.2, 155.9, 155.1, 155.0, 154.4, 150.7, 150.1, 146.2, 144.7, 133.5, 133.4, 119.9, 
111.9, 111.7, 109.4, 103.0, 102.8, 57.1, 56.6, 55.5, 52.9, 50.8, 38.4, 38.0. HRMS (ESI) m/z [M+H]+ 
calcd for C21H25FN9O2+: 454.2037, found: 454.2105; HPLC: ret. time = 11.98 min., purity = 99.4%. 
N5-(2-(4-(3,4-difluorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]
triazine-5,7-diamine (12x). Eluted with EtOAc to afford the title compound as white powder (14 mg, 
yield: 25%). 1H NMR (400 MHz, MeOD): δ 7.69 (dd, J = 1.6, 0.8 Hz, 1H), 7.12 (d, J = 3.2 Hz, 1H), 
7.06-7.04 (m, 1H), 6.94-6.84 (m, 2H), 6.61 (dd, J = 3.2, 1.6 Hz, 1H), 3.62-3.60 (m, 2H), 3.08-3.07 (m, 
4H), 2.75-2.69 (m, 6H). HRMS (ESI) m/z [M+H]+ calcd for C20H22F2N9O+: 442.1837 found: 442.1907; 
HPLC: ret. time =12.18 min., purity = 95.9%.
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Pharmacological characterization
Materials: [3H]-ZM241385 (specific activity 50 Ci mmol-1) was purchased 
from ARC Inc. (St. Louis, USA). [3H]-1,3-dipropyl-8-cyclopentyl-xanthine 
([3H]-DPCPX, specific activity 116.7 Ci/mmol) was purchased from ARC 
Inc. (St. Louis, USA). Unlabeled ZM241385 was a gift from Dr. S. M. Poucher 
(Astra-Zeneca, Macclesfield, UK). CGS21680 was a gift from Dr. R. A. Lovell 
(Ciba-Geigy, Summit, NJ). NECA (5’-N-Ethylcarboxamidoadenosine) 
and DPCPX were purchased from Sigma-Aldrich (Steinheim, Germany). 
Adenosine deaminase (ADA) was purchased from Boehringer Mannheim 
(Mannheim, Germany). Bicinchoninic acid (BCA) and BCA protein 
assay reagent were obtained from Pierce Chemical Company (Rockford, 
IL, U.S.A.).  Human embryonic kidney 293 cells stably expressing the 
hA2AR (HEK293hA2AR) were kindly provided by Dr. J Wang (Biogen/
IDEC, Cambridge, MA). Chinese hamster ovary cells stably expressing the 
hA1R (CHOhA1R) were kindly provided by Prof. Steve Hill (University of 
Nottingham, UK). All other chemicals were of analytical grade and obtained 
from standard commercial sources. 
Cell culture and membrane preparation: Cell culture and membrane 
preparation were performed as reported previously.34,43
Radioligand displacement assay: The radioligand displacement from the 
hA1R and hA2AR was determined using the displacement assay as described 
previously.34,43
Radioligand competition association assay: The binding kinetics of 
unlabeled A2AR ligands were determined at 4 ˚C using the competition 
association assay as described previously.34,43
cAMP assay: HEK293hA2AR cells were cultured as a monolayer on 10 cm ø 
culture plates to 80 %-90 % confluency. Cells were harvested and centrifuged 
two times at 200 × g for 5 min. The amount of cAMP produced was 
determined with the LANCE® ultra cAMP 384 kit (Perkin-Elmer, Groningen, 
Netherlands). In general, 1000 cells/well were seeded on 384-well plates 
and incubated at ambient room temperature (22–25 ˚C). cAMP generation 
was performed in the stimulation buffer [N-2-hydroxyethylpiperazine-N’-






ethanesulphonic acid (HEPES), 5 mM; 0.1 % (w·v-1) BSA; cilostamide, 
50 µM; rolipram, 50 µM; adenosine deaminase (ADA), 0.8 IU/mL] 
Concentration-effect curves for 12x and 12c were obtained by adding 
HEK293hA2AR cells to the mixture of antagonist (12x or 12c) and 100 
nM NECA (prepared in the stimulation buffer) for a co-incubation of 30 
min. For assessment of either surmountable or insurmountable behavior, the 
antagonists (12x and 12c) were pre-incubated for 30 min or co-incubated 
with the agonist NECA at a concentration ranging from 100 µM to 0.1 nM 
for a duration of 30 min, where the antagonists’ concentrations were 0.3-, 
1-, 3- and 10-fold their respective Ki values. The incubation was stopped by 
adding detection mix and antibody solution, according to the instructions of 
the manufacturer. The generated fluorescence intensity was quantified on the 
EnVision® Multilabel Reader (PerkinElmer, Groningen, Netherlands). The 
data obtained were normalized according to the maximal response produced 
by 100 µM NECA. The shift in agonist EC50 was determined to perform 
Schild analyses. 
Data analysis. All experimental data was analyzed by using GraphPad Prism 
5.0 (GraphPad Software Inc., San Diego, CA). KD and Bmax values of [3H]-
ZM241385 at hA2AR membranes were obtained from Guo et al.34 IC50 values 
obtained from competition displacement binding data were converted into Ki 
values using the Cheng-Prusoff equation.44 Association and dissociation rates 
for unlabeled ligands were calculated by fitting the data in the competition 
association model using ‘kinetics of competitive binding’30, as described in 
Chapter 3.
Molecular property descriptors (MW, LogP, MSA, pKa) of the substituted 
C2-phenylpiperazine were calculated using MarinSketch 5.11 (ChemAxon, 
Huagary). (Multiple) Linear regression analysis was done by using Microsoft 
Excel 2003.
References:
1. Swinney DC. Biochemical mechanisms of drug action: what does it take for success? Nat Rev 
Drug Discov 2004;3(9):801-808.
2. Swinney DC. Can binding kinetics translate to a clinically differentiated drug? From theory to 
practice. Lett Drug Des Discov 2006;3(8):569-574.
3. Nunez S, Venhorst J, Kruse CG. Target-drug interactions: first principles and their application to 
140 |  Structure-kinetics relationships
drug discovery. Drug Discov Today 2012;17(1-2):10-22.
4. Zhang R, Monsma F. Binding kinetics and mechanism of action: toward the discovery and 
development of better and best in class drugs. Expert Opin Drug Discov 2010;5(11):1023-1029.
5. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead 
optimization. Nat Rev Drug Discov 2006;5(9):730-739.
6. Rosethorne EM, Turner RJ, Fairhurst RA, Charlton SJ. Efficacy is a contributing factor to 
the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. Naunyn 
Schmiedebergs Arch Pharmacol 2010;382(3):255-263.
7. Govern CC, Paczosa MK, Chakraborty AK, Huseby ES. Fast on-rates allow short dwell time 
ligands to activate T cells. Proc Natl Acad Sci U S A 2010;107(19):8724-8729.
8. Foote J, Eisen HN. Kinetic and affinity limits on antibodies produced during immune responses. 
Proc Natl Acad Sci U S A 1995;92(5):1254-1256.
9. Schreiber G. Kinetic studies of protein-protein interactions. Curr Opin Struct Biol 2002;12(1):41-
47.
10. Selzer T, Albeck S, Schreiber G. Rational design of faster associating and tighter binding protein 
complexes. Nat Struct Biol 2000;7(7):537-541.
11. Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Renard E, Trifilieff A, Charlton SJ. The 
Influence of Receptor Kinetics on the Onset and Duration of Action, and the Therapeutic Index 
of NVA237 and Tiotropium. J Pharmacol Exp Ther 2012;343(2):520-528.
12. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic 
and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an 
update. Pharmacol Rev 2011;63(1):1-34.
13. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 
2006;5(3):247-264.
14. Shook BC, Jackson PF. Adenosine A2A Receptor Antagonists and Parkinson’s Disease. ACS Chem 
Neurosci 2011;2(10):555-567.
15. Muller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential 
as novel drugs. Bba-Biomembranes 2011;1808(5):1290-1308.
16. Shah U, Hodgson R. Recent progress in the discovery of adenosine A2A receptor antagonists for 
the treatment of Parkinson’s disease. Curr Opin Drug Discov Devel 2010;13(4):466-480.
17. Poucher SM, Keddie JR, Singh P, Stoggall SM, Caulkett PW, Jones G, Coll MG. The in vitro 
pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist. 
Br J Pharmacol 1995;115(6):1096-1102.
18. Caulkett PWR, Jones G, Collis MG, Poucher SM; Imperial Chemical Indusry PLC, London, 
assignee. UK. 1991.
19. Vu CB, Pan D, Peng B, Kumaravel G, Smits G, Jin X, Phadke D, Engber T, Huang C, Reilly J, Tam 
S, Grant D, Hetu G, Petter RC. Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine 
as potent and selective adenosine A2a receptor antagonists. J Med Chem 2005;48(6):2009-2018.
20. Vu CB, Peng B, Kumaravel G, Smits G, Jin X, Phadke D, Engber T, Huang C, Reilly J, Tam S, 
Grant D, Hetu G, Chen L, Zhang J, Petter RC. Piperazine derivatives of [1,2,4]triazolo[1,5-a]
[1,3,5]triazine as potent and selective adenosine A2a receptor antagonists. J Med Chem 
2004;47(17):4291-4299.
21. Vu CB, Shields P, Peng B, Kumaravel G, Jin X, Phadke D, Wang J, Engber T, Ayyub E, Petter 
RC. Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor 
antagonists. Bioorg Med Chem Lett 2004;14(19):4835-4838.
22. Dolzhenko AV, Dolzhenko AV, Chui WK. Practical synthesis of regioisomeric 5(7)-amino-







23. Dolzhenko AV, Pastorin G, Dolzhenko AV, Chui WK. An aqueous medium synthesis and 
tautomerism study of 3(5)-amino-1,2,4-triazoles. Tetrahedron Lett 2009;50(18):2124-2128.
24. Jorg M, Agostino M, Yuriev E, Mak FS, Miller ND, White JM, Scammells PJ, Capuano B. 
Synthesis, molecular structure, NMR spectroscopic and computational analysis of a selective 
adenosine A(2A) antagonist, ZM 241385. Struct Chem 2013;24(4):1241-1251.
25. Jorg M, Shonberg J, Mak FS, Miller ND, Yuriev E, Scammells PJ, Capuano B. Novel adenosine 
A(2A) receptor ligands: A synthetic, functional and computational investigation of selected 
literature adenosine A(2A) receptor antagonists for extending into extracellular space. Bioorg 
Med Chem Lett 2013;23(11):3427-3433.
26. Caulkett PWR, Jones G, McPartlin M, Renshaw ND, Stewart SK, Wright B. Adenine isosteres 
with bridgehead nitrogen. Part 1. Two independent syntheses of the [1,2,4]triazolo[1,5-a][1,3,5]
triazine ring system leading to a range of substituents in the 2, 5 and 7 positions. J Chem Soc, 
Perkin Trans 1 1995(7):801-808.
27. Tenbrink RE. Pharmacia & Upjohn Company, MI, assignee. USA. 1999.
28. Martin GE, Elgin RJ, Jr., Mathiasen JR, Davis CB, Kesslick JM, Baldy WJ, Shank RP, DiStefano 
DL, Fedde CL, Scott MK. Activity of aromatic substituted phenylpiperazines lacking affinity for 
dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem 1989;32(5):1052-
1056.
29. Morita S, Kitano K, Matsubara J, Ohtani T, Kawano Y, Otsubo K, Uchida M. Practical application 
of the palladium-catalyzed amination in phenylpiperazine synthesis: An efficient synthesis of a 
metabolite of the antipsychotic agent aripiprazole. Tetrahedron 1998;54(19):4811-4818.
30. Motulsky HJ, Mahan LC. The kinetics of competitive radioligand binding predicted by the law of 
mass action. Mol Pharmacol 1984;25(1):1-9.
31. Vauquelin G, Van Liefde I, Vanderheyden P. Models and methods for studying insurmountable 
antagonism. Trends Pharmacol Sci 2002;23(11):514-518.
32. Kenakin T, Jenkinson S, Watson C. Determining the Potency and Molecular Mechanism of 
Action of Insurmountable Antagonists. J Pharmacol Exp Ther 2006;319(2):710-723.
33. Vauquelin G, Szczuka A. Kinetic versus allosteric mechanisms to explain insurmountable 
antagonism and delayed ligand dissociation. Neurochem Int 2007;51(5):254-260.
34. Guo D, Mulder-Krieger T, IJzerman AP, Heitman LH. Functional efficacy of adenosine A2A 
receptor agonists is positively correlated to their receptor residence time. Br J Pharmacol 
2012;166(6):1846-1859.
35. Sykes DA, Dowling MR, Charlton SJ. Exploring the mechanism of agonist efficacy: a relationship 
between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol 
2009;76(3):543-551.
36. Mantell SJ, Stephenson PT, Monaghan SM, Maw GN, Trevethick MA, Yeadon M, Keir RF, Walker 
DK, Jones RM, Selby MD, Batchelor DV, Rozze S, Chavaroche H, Hobson TJ, Dodd PG, Lemaitre 
A, Wright KN, Stuart EF. Inhaled adenosine A(2A) receptor agonists for the treatment of chronic 
obstructive pulmonary disease. Bioorg Med Chem Lett 2008;18(4):1284-1287.
37. Andersson K, Karlsson R, Lofas S, Franklin G, Hamalainen MD. Label-free kinetic binding data 
as a decisive element in drug discovery. Expert Opin Drug Dis 2006;1(5):439-446.
38. Gabrielsson J, Dolgos H, Gillberg PG, Bredberg U, Benthem B, Duker G. Early integration 
of pharmacokinetic and dynamic reasoning is essential for optimal development of lead 
compounds: strategic considerations. Drug Discov Today 2009;14(7-8):358-372.
39. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, Katritch V, Han GW, Roth CB, Heitman LH, 
142 |  Structure-kinetics relationships
IJzerman AP, Cherezov V, Stevens RC. Structural basis for allosteric regulation of GPCRs by 
sodium ions. Science 2012;337(6091):232-236.
40. Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, Cherezov V, Stevens RC. Structure of an 
agonist-bound human A2A adenosine receptor. Science 2011;332(6027):322-327.
41. Dror RO, Pan AC, Arlow DH, Borhani DW, Maragakis P, Shan Y, Xu H, Shaw DE. Pathway 
and mechanism of drug binding to G-protein-coupled receptors. Proc Natl Acad Sci U S A 
2011;108(32):13118-13123.
42. Kruse AC, Hu J, Pan AC, Arlow DH, Rosenbaum DM, Rosemond E, Green HF, Liu T, Chae PS, 
Dror RO, Shaw DE, Weis WI, Wess J, Kobilka BK. Structure and dynamics of the M3 muscarinic 
acetylcholine receptor. Nature 2012;482(7386):552-556.
43. Guo D, van Dorp EJ, Mulder-Krieger T, van Veldhoven JP, Brussee J, IJzerman AP, Heitman LH. 
Dual-point competition association assay: a fast and high-throughput kinetic screening method 
for assessing ligand-receptor binding kinetics. J Biomol Screen 2013;18(3):309-320.
44. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of 








Guo D, Mulder-Krieger T, IJzerman AP, Heitman LH.
Adapted from: 	À*>À>V2012; 166(6): 1846-1859.

This chapter assesses the binding kinetics of A2AR agonists and explores a 
possible relationship with their functional efficacy. A kinetic radioligand 
binding assay (a so-called competition association assay) has been set up, 
validated and optimized at the A2AR to examine the binding kinetics of 
unlabeled ligands. Functional efficacies of A2AR agonists were determined 
in two different assays: a novel label-free impedance-based assay and a more 
traditional cAMP determination. A correlation was observed between the 
receptor residence time of A2AR agonists and their intrinsic efficacies in both 
functional assays. The affinity of A2AR agonists was not correlated to their 
functional efficacy. This study indicates that the molecular basis of different 
agonist efficacies at the A2AR lies within their different residence times at this 
receptor.
About this chapter
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Introduction5.1 
Extracellular adenosine is a ubiquitous local hormone that has been reported 
to play an important physiological role in numerous tissues, for instance 
in the sleep/wake cycle and in inflammation. The nucleoside can bind and 
activate four subtypes of adenosine receptors.1 These are the adenosine A1, 
A2A, A2B and A3 receptors, which belong to the superfamily of G protein-
coupled receptors (GPCRs). The adenosine A1 and A3 receptors are mainly 
coupled to the enzyme adenylate cyclase in an inhibitory fashion via a Gi 
protein, whereas the A2A and A2B receptors stimulate this enzyme via a Gs 
protein.2 In this study we focused on agonists for the human adenosine 
A2A receptor (hA2AR), which have clinical relevance in various pathological 
conditions such as respiratory disorders and inflammatory conditions.3 
Traditionally, drug discovery campaigns of A2AR (and other GPCRs) 
agents usually include the identification of lead compounds in a dose-
dependent assessment of activities (i.e., EC50 or Ki values) under equilibrium 
conditions. The binding kinetics of the drug-target interaction are usually 
not taken into account. However, awareness of the importance of binding 
kinetics has started to increase, since accumulating evidence suggests that the 
in vivo effectiveness of ligands may be attributed to the time ligands reside 
at their receptor.4-7 The duration a drug stays in complex with the target is 
defined as ‘drug-target residence time’, which equals the reciprocal of the 
dissociation rate constant (1 / koff).8 
A recent study at the muscarinic M3 receptor showed a tight correlation 
between receptor residence time and agonist efficacy.9 This finding suggests 
that the molecular basis behind ligand efficacy may be inextricably linked to 
the ligand-receptor residence time. To verify this possible relationship, we 
determined the binding kinetics of ten A2AR agonists from different chemical 
classes (Figure 5.1) and extensively explored the putative relationship to 
their functional efficacies at the hA2AR. The agonist binding kinetics were 
quantified using a competition association method,10 which we adopted and 
further optimized into a fast, medium-throughput format. The A2AR agonist 
efficacies were measured, for the first time, in a novel label-free impedance-
based assay and in a ‘traditional’ cAMP assay.






Figure 5.1 | Chemical structures of ten A2AR agonists used in this chapter.
Methods5.2 
Chemicals and reagents
[3H]-ZM241385 (specific activity 28.4 Ci/mmol) was purchased from ARC 
Inc. (St. Louis, USA). Unlabeled ZM241385 was a gift from Dr. S. M. 
Poucher (Astra-Zeneca, Macclesfield, UK). CGS21680 was a gift from Dr. 
R. A. Lovell (Ciba-Geigy, Summit, NJ). NECA was purchased from Sigma-
Aldrich (Steinheim, Germany), UK432,097 was purchased from Axon 
(Groningen, Netherlands). LUF5448 and LUF5631 were synthesized in 
our laboratory as described previously by van Tilburg et al.11; LUF5549 and 
LUF5550 were described by van Tilburg et al.12; LUF5833, LUF5834 and 
LUF5835 were described by Beukers et al.13. Guanosine triphosphate (GTP) 
was purchased from Acros Organics (Geel, Belgium). Adenosine deaminase 
(ADA) was purchased from Boehringer Mannheim (Mannheim, Germany). 
Bicinchoninic acid (BCA) and BCA protein assay reagent were obtained from 
Pierce Chemical Company (Rockford, IL, U.S.A.). Human embryonic kidney 
293 cells stably expressing the hA2AR (HEK293hA2AR) were kindly provided 
by Dr. J Wang (Biogen/IDEC, Cambridge, MA). All other chemicals were of 
analytical grade and obtained from standard commercial sources.
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Cell culture
HEK293hA2AR cells were grown in culture medium consisting of Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% newborn calf 
serum (NCS), 50 µg/mL streptomycin, 50 IU/mL penicillin, and 500 µg/mL 
G418 at 37 ˚C and 7% CO2. Cells were subcultured twice a week at a ratio 
of 1:8 on 10 cm ø plates.
Cell membrane preparation
HEK293hA2AR cells were grown to 80%-90% confluency and detached 
from plates by scraping them into 5 mL PBS. Detached cells were collected 
and centrifuged at 700×g (3000 r.p.m.) for 5 min. Pellets derived from 30 
plates (15 cm ø) were pooled and resuspended in 20 mL of ice-cold 25 mM 
Tris-HCl buffer, pH 7.4. An UltraThurrax was used to homogenize the 
cell suspension. Membranes and the cytosolic fraction were separated by 
centrifugation at 100,000×g (31,000 r.p.m.) in a Beckman Optima LE-80K 
ultracentrifuge at 4 ˚C for 20 min. The pellet was resuspended in 10 mL of 
Tris buffer and the homogenization and centrifugation step was repeated. Tris 
buffer (10 mL) was used to resuspend the pellet and ADA was added (0.8 
IU/mL) to break down endogenous adenosine. Membranes were stored in 
250 µL aliquots at -80 ˚C. Membrane protein concentrations were measured 
using the BCA (bicinchoninic acid) method.14
Radioligand saturation and displacement assays
Membrane aliquots containing 20 µg of protein were incubated in a total 
volume of 100 µl of assay buffer (25 mM Tris-HCl, pH 7.4, supplemented with 
5 mM MgCl2 and 0.1% (w/v) 3-[(3-cholamidopropyl) dimethylammonio]-
1-propanesulfonate (CHAPS) at 5 ˚C for 2 hours to ensure the equilibrium 
was reached at all concentrations of radioligand. For saturation experiments, 






a range of concentrations (~0.2-10 nM) of [3H]-ZM241385 was used. 
Nonspecific binding was determined at three concentrations of radioligand in 
the presence of 100 µM CGS21680. Radioligand displacement experiments 
were performed using eleven concentrations of competing ligand in the 
presence of 5.5 nM [3H]-ZM241385. In such experiments ZM241385 
and NECA were tested in the absence or presence of 100 µM GTP. 
Nonspecific binding was determined in the presence of 100 µM CGS21680 
and represented less than 10% of the total binding. [3H]-ZM241385 did 
not bind specifically to membranes prepared from parental HEK293 cells. 
Incubations were terminated by rapid vacuum filtration to separate the 
bound and free radioligand through 96-well GF/B filter plates using a Perkin 
Elmer Filtermate-harvester (Perkin Elmer, Groningen, Netherlands) after 
the indicated incubation time. Filters were subsequently washed three times 
with ice-cold wash buffer (25 mM Tris HCl, pH 7.4, supplemented with 5 
mM MgCl2). The filter-bound radioactivity was determined by scintillation 
spectrometry using the P-E 1450 Microbeta Wallac Trilux scintillation 
counter (Perkin Elmer, Groningen, Netherlands).
Radioligand association and dissociation assays
Association experiments were performed by incubating membrane aliquots 
containing 20 µg of protein in a total volume of 100 µl of assay buffer (25 
mM Tris-HCl, pH 7.4, supplemented with 5 mM MgCl2 and 0.1% CHAPS) 
at 25 ˚C or 5 ˚C with 5.5 nM [3H]-ZM241385. The amount of radioligand 
bound to the receptor was measured at different time intervals during 
incubation for 30 min at 25 ˚C or 2 hours at 5 ˚C. Dissociation experiments 
were performed by pre-incubating membrane aliquots containing 20 µg of 
protein in a total volume of 100 µl of assay buffer (25 mM Tris-HCl, pH 7.4, 
supplemented with 5 mM MgCl2 and 0.1% CHAPS) either at 25 ˚C for 30 
minutes or at 5 ˚C for 2 hours with 5.5 nM [3H]-ZM241385. After the pre-
incubation, the dissociation was initiated by addition of 1 µM of unlabeled 
ZM241385 in 5 µL. The amount of radioligand still bound to the receptor 
was measured at various time intervals for a total duration of 30 min at 25 
˚C or 4 hours at 5 ˚C to ensure that [3H]-ZM241385 was fully dissociated 
from the hA2AR. Incubations were terminated and samples were obtained as 
described under Radioligand saturation and displacement assays.
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Radioligand competition association assay
The binding kinetics of unlabeled ligands were determined at 5 ˚C using the 
competition association assay as developed by Motulsky and Mahan.10 In 
the standard assay, three different concentrations of unlabeled ZM241385 or 
NECA were tested, namely at 1-, 3- and 10-fold its Ki value. For NECA its 
kinetics were also determined in the presence of 100 µM GTP. We also assessed 
binding kinetics in a simplified one-concentration competition association 
assay, at only 10-fold of the respective Ki value of the unlabeled ligands. The 
experiment was initiated by adding membrane aliquots containing 20 µg of 
protein at different time points. Incubations were terminated and samples 
were obtained as described under Radioligand saturation and displacement 
assays.
Label-free whole cell analysis (xCELLigence RTCA system)
Whole cell assays were performed on the xCELLigence RTCA system.15,16 
Briefly, a monolayer of cells adheres to an arrayed microelectrode embedded at 
the bottom of each well of an E-plate 96 (Roche Applied Science, Germany), 
which is compatible with the xCELLigence RTCA system. Upon activation 
of GPCR-mediated signaling, cell morphology changes and thereby affects 
the local ionic environment at the cell-electrode interface. This leads to an 
increased electronic readout of cell-sensor impedance (Z), which is displayed 
in real-time as the Cell Index (CI). Specifically, the CI value at each time point 
is defined as (Zi-Z0) Ω /15 Ω, where Zi is the impedance at each individual 
time point, and Z0 is the impedance derived from electrode/solution interface 
in the absence of cells prior to the start of the experiment. Thus, a loss of 
adhesion would generate a lower CI; an increase in cell adhesion, which is 
typical seen with GPCR-mediated activation, results in an overall increase in 
the CI.17-19
HEK293hA2AR cells were cultured as a monolayer on 10 cm ø culture 
plates to 80%-90% confluency and subsequently harvested and centrifuged 
two times at 1000 r.p.m for 5 min. Initially, 45 µL of culture media was 
added to wells in E-Plates 96 to obtain background readings (Z0) followed 
by the addition of 50 µL of cell suspension containing 20,000 cells / well. 






The E-plate containing the cells was left at room temperature for 15 min 
before being placed on the recording device station in the incubator at 37 ˚C 
in 5% CO2. Afterwards, cell attachment, spreading and proliferation were 
continuously monitored every 30 minutes. The cells were cultured until the 
end of log phase (~18-20 h) to obtain an optimal assay window. Prior to 
agonist application the interval between two measurements was adjusted to 
1 min. Subsequently 5 µL compound solution (final concentration of 0.5 
% DMSO) or vehicle control was added to each well, after which the CI 
was recorded for 30 minutes. For data analysis the individual CI traces were 
normalized by subtracting the baseline (vehicle control) to correct for any 
agonist-independent signals.
cAMP assay
HEK293hA2AR cells were cultured as a monolayer on 10 cm ø culture plates 
to 80%-90% confluency. Cells were harvested and centrifuged two times at 
1000 r.p.m for 5 min. The amount of cAMP produced was determined with 
the LANCE cAMP 384 kit (Perkin-Elmer, Groningen, Netherlands). In short, 
2500 cells/well were pre-incubated for 45 min at 37 ˚C and subsequently at 
room temperature for three hours with a range of agonist concentrations. 
cAMP generation was performed in the medium containing cilostamide 
(50 µM), rolipram (50 µM), and adenosine deaminase (0.8 IU/mL). The 
incubation was stopped by adding detection mix and antibody solution, 
according to the instructions of the manufacturer. The generated fluorescence 
intensity was quantified on the EnVision® Multilabel Reader (PerkinElmer, 
Groningen, Netherlands). cAMP production by agonists tested at 100-fold 
their Ki value on the parental HEK293 cell line represented less than 5% of 
maximal stimulation of cAMP production by 10 µM CGS21680 at the cells 
expressing the adenosine A2A receptor.
Data analysis
All experimental data was analyzed by using GraphPad Prism 5.0 (GraphPad 
Software Inc., San Diego, CA). KD and Bmax values of [3H]-ZM241385 at 
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hA2AR membranes were obtained by computational analysis of saturation 
curves. IC50 values obtained from competition displacement binding data 
were converted into Ki values using the Cheng-Prusoff equation.20 
Association data was fitted using one phase exponential association. Values 
for kon were obtained by converting kobs values using Equation 3 describe 
in Chapter 3. koff values were assessed from independent dissociation 
experiments. Dissociation data was fitted using one phase exponential decay. 
The association and dissociation rates were used to calculate the ‘kinetic KD’ 
using Equation 8 described in Chapter 3. 
Association and dissociation rates for unlabeled ligands were calculated 
by fitting the data in the competition association model using ‘kinetics of 
competitive binding’ describe in Chapter 3 (Equation 7).10
EC50 and Emax values in label-free whole cell assay were obtained by 
analyzing the normalized CI traces using RTCA Software 1.2 (Roche, 
Germany) to obtain peak responses within 30 min after compound addition. 
These peak values were exported to Prism 5.0, which yielded dose-response 
curves and were analyzed by nonlinear regression. 
The relative efficacies (τ) of agonists in label-free whole cell experiment 
and cAMP assay were also evaluated. Data were fitted to the operational 
model of Black and Leff,21 which correlates a biological effect E with agonist 
concentration [A] as a function of three parameters: Em, KA, and τ:
 
where Em, the operational maximum, represents the maximum possible effect 
in the tissue. KA is the dissociation constant of agonist and τ is the relative 
efficacy. The Em value was generated by fitting the dose-response curve for the 
full agonist (i.e., UK432,097). Its best-fit values were recorded to fit dose-
response curves of partial agonists and other full agonists by global fitting 
in the operational model in Prism 5.0 to generate their relative efficacies. 
All values obtained are means of at least three independent experiments 
performed in duplicate.
















Quantification of the KD and Bmax of [3H]-ZM241385 in 
saturation experiments
Saturation binding experiments were performed with [3H]-ZM241385 at 5 
˚C. The result of a representative saturation experiment is shown in Figure 5.2. 
[3H]-ZM241385 bound to a single class of binding sites at HEK293hA2AR 
membranes. The KD value was determined as 0.60 ± 0.07 nM and Bmax was 
1.9 ± 0.04 pmol/mg protein. The KD value for [3H]-ZM241385 obtained 
with these experiments was used to derive Ki values from IC50 values for ten 
A2AR agonists, as well as the unlabeled antagonist ZM241385 (see below). 





Quantification of the affinity (Ki) of A2AR ligands in 
displacement experiments
Displacement experiments with several A2AR ligands were performed 
to determine their affinities to the hA2AR. All compounds produced a 
concentration-dependent inhibition of specific [3H]-ZM241385 binding 
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(Figure 5.3) and their affinities are detailed in Table 5.1 and Table 5.3. 
Amongst all tested ligands, ZM241385 showed the highest affinity for the 
hA2AR with a Ki value of 0.4 ± 0.03 nM (Table 5.1) in the absence of 100 µM 
GTP; its Ki value determined in the presence of 100 µM GTP was the same 
(0.4 ± 0.02 nM, Figure 5.3A). Similarly, there was no significant difference 
between the kinetic or Ki values of NECA tested in the absence or presence 
of 100 µM GTP (Tables 5.2 and 5.3, Figure 5.3A). Affinities of other A2AR 
agonists were determined and showed a range of Ki values in the lower to 
higher nanomolar range (Table 5.3). The agonist with the lowest affinity was 
CGS21680 (Ki = 376 ± 12 nM), while the agonist with the highest affinity was 
LUF5835 (Ki =15 ± 4 nM). In general, the affinities of the ribose-containing 
agonists (e.g., LUF5448) were lower than those of the non-ribose agonists 
(e.g., LUF5833), as shown in Table 5.3.
Quantification of the association [kon (k1)] and dissociation 
rates [koff (k2)] of [3H]-ZM241385 at different temperatures
Figure 5.3 N*>iƂ\`Ã«>ViiÌvÃ«iVwVQ3H]-ZM241385 binding from the hA2AR by 
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To optimize the experimental conditions of the kinetic binding assays, [3H]-
ZM241385 association and dissociation experiments were carried out at 
both 25 ˚C and 5 ˚C. At both temperatures, the association and dissociation 
curve of [3H]-ZM241385 at the hA2AR were monophasic. At 25 ˚C (Figure 
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VƂÃÃV>Ì>`
`ÃÃV>Ì v Q3H]-ZM241385 at the hA2A, >Ì x Â
°







°f¼iÌVD’ = koff / kon.
Validation and optimization of the competition association 
assay at the hA2AR
With the pre-determined kon (k1) and koff (k2) values of [3H]-ZM241385 
from association and dissociation experiments, kon (k3) and koff (k4) values of 
unlabeled ligands could be determined by fitting the kinetic parameters into 
the model of ‘kinetics of competitive binding’ described in methods. Firstly, 
5.4A), [3H]-ZM241385 had a very fast association (kon = 2.4 ± 0.05 × 108 
M-1·min-1) and dissociation rate (koff = 0.48 ± 0.03 min-1). Decreasing the 
experimental temperature to 5 ˚C resulted in slower binding kinetics of [3H]-
ZM241385 with an association rate of 1.5 ± 0.06 × 107 M-1·min-1 and a 
dissociation rate of 0.011 ± 0.001 min-1 (Figure 5.4B, Table 5.1). We also 
conducted experiments at 15 ˚C; the kinetic rates determined were also fast 
(data not shown). Based on these initial tests, we chose 5 ˚C as the standard 
experimental condition for this study, since it enabled better accuracy and 
reproducibility of kinetic data.
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Figure 5.4 N *>iƂ\ Ìi>ÃÃV>Ì>``ÃÃV>Ìv Q3H]-ZM241385 at the hA2AR at 
Óx Â
Æ *>i 	\ Ìi >ÃÃV>Ì >``ÃÃV>Ìv Q3H]-ZM241385 at the hA2A, >Ì x Â
°
,i«ÀiÃiÌ>ÌÛi}À>«ÃvÀiiÝ«iÀiÌ«iÀvÀi``Õ«V>Ìi°
we validated the competition association assay at the hA2AR using unlabeled 
ZM241385. Its kon (k3) and koff (k4) values determined in this assay were 
2.0 ± 0.2 × 107 M-1·min-1 and 0.019 ± 0.003 min-1 respectively (Figure 5.5, 
Table 5.1), which corresponded rather well to the kinetic rates determined 
in ‘traditional’ association and dissociation experiments described in the 
previous paragraph (kon = 1.5 ± 0.06 × 107 M-1·min-1, koff = 0.011 ± 0.001 min-
1). Moreover, the ‘kinetic KD’ (0.95 ± 0.2 nM) derived from the competition 
association assay for unlabeled ZM241385 was similar to the affinity constant 
(Ki = 0.40 ± 0.03 nM) obtained from displacement experiments and the 
dissociation constant (KD) derived from saturation experiments (0.60 ± 0.07 
nM, Table 5.1). Taken together, this proved that the competition association 
assay can be applied to determine the binding kinetics of unlabeled ligands 
at the hA2AR.
Secondly, we modified the assay and improved its throughput by 
reducing the three-concentration dependent method to a one-concentration 
based method. Instead of testing at concentrations equivalent to 1-, 3- and 
10-fold the Ki value of unlabeled ZM241385, we only used 10-fold Ki. The 
latter yielded an assay window distinguishable from both the baseline and the 
control curve (Figure 5.5). Specifically, the data analyzed at 10-fold Ki alone 
of unlabeled ZM241385 showed a comparable result (kon = 2.8 ± 0.5 × 107 
M-1·min-1, koff = 0.025 ± 0.006 min-1) to that generated in a standard (three 
concentration) competition association experiment (Table 5.1). 
Next to that, we also determined the effect of GTP (100 µM) on the 






Figure 5.5 N 
«iÌÌ >ÃÃV>Ì iÝ«iÀiÌ ÜÌ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i >LÃiVi
v }>` ­Ã` Ã«iÀiÃ® À  Ìi«ÀiÃiViv iv`i Û>Õi ­i«ÌÞ Ã«iÀiÃ®] ÌÀii
fold Ki Û>Õi ­Ã`ÃµÕ>ÀiÃ®À Ìiv`iÛ>Õi ­i«ÌÞÃµÕ>ÀiÃ®vÕ>Lii`<Ó{£Înx°
,i«ÀiÃiÌ>ÌÛi }À>«Ã vÀ i iÝ«iÀiÌ «iÀvÀi`  `Õ«V>Ìi ­Ãii />Li x°£ vÀ
iÌVÛ>ÕiÃ®°
binding kinetics of an unlabeled agonist, NECA. Its kon and koff values 
determined in the standard three-concentration competition association assay 
in the absence of GTP were 8.1 ± 1.0 × 105 M-1∙min-1 and 0.038 ± 0.007 min-
1 (Table 5.2, Figure 5.6A), which were similar to these values determined in 
the presence GTP (kon = 9.8 ± 1.0 × 105 M-1∙min-1, koff = 0.036 ± 0.006 min-1, 
Table 5.2, Figure 5.6B). Furthermore, kon and koff values of unlabeled NECA 
assessed by using a concentration of 10-fold its Ki only, either in the absence 
or presence of 100 µM GTP, showed comparable results to that determined 
by the standard assay mentioned above (Table 5.2). It is also noteworthy that 
the calculated kinetic KD values from the one-concentration approach in the 
absence (KD = 58 nM) or presence (KD = 52 nM) of GTP are almost identical 
to the affinity determined in the displacement experiments (Ki = 64 ± 1 nM). 
Thus, the simplified one-concentration competition association assay in the 
absence of 100 µM GTP was used to determine the binding kinetics of other 
unlabeled agonists in the rest of this study.
Quantification of the binding kinetics of unlabeled ligands 
using the simplified competition association assay
By using the simplified competition association assay, the on- and off-rates of 
ten A2AR agonists were determined. Notably, a good correlation (Figure 5.7B, 
r2 = 0.99, p < 0.0001) was observed between the affinities (Ki) determined 
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-Ì>`>À`V«iÌÌ>ÃÃV>Ìa 8.1 ± 1.0 × 105 0.038 ± 0.007 9.8 ± 1.0 × 105 0.036 ± 0.006
-«wi`V«iÌÌ>ÃÃV>Ìb 5.0 ± 0.6×105 0.029 ± 0.005 9.1 ± 2.0 × 105 0.047 ± 0.01
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in equilibrium binding studies and KD values derived from the competition 
association assays (Table 5.3). This further proved that the simplified model is 
able to accurately quantify the association and dissociation rates of unlabeled 
ligands. Two distinct patterns of [3H]-ZM241385 binding were found 
in the presence of the agonists, which are depicted in Figure 5.7A: 1) the 
specific binding of [3H]-ZM241385 approached its equilibrium slowly and 
more gradually if [3H]-ZM241385 dissociated slower than the competitor 



















Cmpd kon (M-1ŪOKP-1) a koff (min-1) a 46
OKPb Kinetic KD (nM) c Ki (nM) d

-Ó£Ènä 5.0 ± 1.0 × 104 0.019 ± 0.004 53 ± 6 380 ± 66 376 ± 12
 
Ƃ 5.0 ± 0.6 × 105 0.029 ± 0.005 35 ± 4 58 ± 7 64 ± 1
UK432,097 5.0 ± 0.8 × 105 0.004 ± 0.003 250 ± 115 8.0 ± 3.7 22 ± 5
LUF5448 2.8 ± 0.1 × 105 0.063 ± 0.020 16 ± 3 225 ± 39 219 ± 15
LUF5549 2.4 ± 0.5 × 106 0.041 ± 0.010 24 ± 3 17 ± 2 24 ± 7
LUF5550 8.0 ± 2.0 × 105 0.087 ± 0.020 12 ± 1 110 ± 19 126 ± 10
LUF5631 8.0 ± 2.0 × 105 0.048 ± 0.020 21 ± 5 60 ± 17 44 ± 9
LUF5833 8.5 ± 3.0 × 106 0.16 ± 0.08 6.3 ± 1.8 19 ± 7 17 ± 4
LUF5834 1.1 ± 0.4 × 107 0.23 ± 0.10 4.2 ± 1.0 21 ± 7 16 ± 5
LUF5835 1.6 ± 0.8 × 107 0.29 ± 0.10 3.4 ± 0.6 18 ± 6 15 ± 4
>Ì>>ÀiÃÜ>Ãi>́ Ã°i°vÌÀiiÃi«>À>ÌiiÝ«iÀiÌÃi>V«iÀvÀi`̀ Õ«V>Ìi°
a kon and koff of unlabeled A2A,>}ÃÌÃÜiÀi`iÌiÀi`iVViÌÀ>ÌV«iÌÌ
>ÃÃV>Ì>ÃÃ>Þ°b,/­,iÃ`iVi/i®r£Éoff. 
ViÌVD = koff / kon. 
dÃ«>ViiÌv
Ã«iVwVQ3H]-ZM241385 binding from the hA2A,>ÌxÂ
°
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(k2 < k4, e.g., LUF5834); 2) the specific binding [3H]-ZM241385 became 
biphasic with a typical ‘overshoot’ followed by a continuous decline towards 
equilibrium if [3H]-ZM241385 dissociated faster than the competitor (k2 > 
k4, e.g., UK432,097). In accordance with these observations, UK432,097 
had a much slower off-rate (koff = 0.004 ± 0.003 min-1) than [3H]-ZM241385 
(koff = 0.011 ± 0.001 min-1). LUF5834 (koff = 0.23 ± 0.10 min-1) or LUF5550 
(koff = 0.087 ± 0.020 min-1) dissociated much faster from the receptor than 
[3H]-ZM241385. Furthermore, it follows from Table 5.3 that the values for 
binding kinetics of ribose-containing agonists were significantly different 
from those of non-ribose agonists. For instance, LUF5631 was 10-fold slower 
in association and 3.3-fold slower in dissociation compared to LUF5833.
Quantification of functional efficacies of A2AR agonists in a 
label-free whole cell assay
Changes in cell morphology by the addition of CGS21680 and other A2AR 
agonists to HEK293hA2AR cells were assessed in real-time with the impedance-
based assay system. Typically, upon agonist addition to HEK293hA2AR cells 
the impedance (displayed as cell index, CI) resulted in an immediate dose-
dependent increase to a peak level. After that, the CI trace decreased and 
gradually reached a plateau without returning to the baseline when monitored 
over a period of 30 min. A representative measurement of CGS21680-
induced impedance changes is plotted in Figure 5.8A. Concentration-effect 
curves were obtained from peak analysis of corresponding agonist-induced CI 
changes (Figure 5.8B). Agonist potencies, intrinsic efficacies and their relative 
efficacies (τ) analyzed in the operational model are detailed in Table 5.4. 
Specifically, amongst all tested agonists, UK432,097 had the highest efficacy, 
with a value of 114 ± 4% compared to the reference agonist CGS21680 
(set at 100%). Efficacies of other ribose-containing agonists LUF5448, 
LUF5549, LUF5550 and LUF5631 were 83 ± 5%, 92 ± 4%, 63 ± 6% and 
91 ± 8%, while the efficacies of the non-ribose agonists LUF5833, LUF5835 
and LUF5834 were 54 ± 9%, 47 ± 6% and 54 ± 8%, respectively. In Figure 
5.9A and 5.9B, correlations are shown between the agonist efficacy and either 
their affinities or receptor residence times, respectively. It follows from Figure 
5.9A that there was very little correlation between the affinity of the agonists 
and their efficacy, if at all (r2 = 0.13, p = 0.32). Interestingly, when the efficacy 
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of each agonist was compared to the logarithm of its residence time (Figure 
5.9B), a much better correlation was obtained (r2 = 0.90, p <0.0001), where 
the highest efficacy ligand UK432,097 had the longest residence time of 250 
± 115 min. In addition, no correlation was observed between functional 
potency and the logarithm of its residence time (r2 = 0.077, p = 0.44). The 
ranking of the relative efficacy, τ, is quite comparable to the intrinsic efficacy, 
where UK432,097 had the highest τ value of 51 ± 5; LUF5550 had the lowest 
value of 0.7 ± 0.07 (Table 5.4). Similarly, a positive link between receptor 
residence time and relative efficacy was observed (r2 = 0.60, p < 0.01).
Quantification of functional efficacies of A2AR agonists in a 
cAMP assay
The functional efficacy of all A2AR agonists was tested in a classic cAMP 
assay as well. The cAMP production was stimulated by adding increasing 
concentrations of different agonists. The effects were normalized and are 
6CDNG^#IQPKUVRQVGPE[CPFGHƂECE[FGTKXGFHTQODQVJE#/2CPFNCDGNHTGGYJQNG
EGNNCUUC[U
Agonist Label-free whole cell assay a E#/2CUUC[

50, nM Emax, % τ b 
50, nM Emax, % τ b

-Ó£Ènä 3.8 ± 0.4 100 ± 1 13 ± 5 19 ± 0.6 100 ±  2 4 ± 0.4
 
Ƃ 2.5 ± 0.1 90 ± 4 4 ± 0.8 27 ± 0.9 88 ± 3 3 ± 0.3
UK432,097 0.47 ± 0.01 114 ± 4 51 ± 5 1.7 ± 0.1 115 ± 2 14 ± 5
LUF5448 2.4 ± 1 83 ± 5  2 ± 0.4 172 ± 15 84 ± 3 2 ± 0.4
LUF5549 1.0 ± 0.4 92 ± 4 6 ± 0.8 10 ± 3 71 ± 6 1 ± 0.2
LUF5550 5.8 ± 1 63 ± 6 0.7 ± 0.07 195 ± 12 39 ± 1 0.5 ± 0.04
LUF5631 4.3 ± 1 91 ± 8 2 ± 0.3 36 ± 23 67 ± 5 1 ± 0.2
LUF5833 3.9 ± 0.6 54 ± 9 1 ± 0.3 44 ± 2 38 ± 2 0.5 ± 0.04
LUF5834 3.6 ± 0.7 47 ± 6 0.8 ± 0.2 21 ± 1 50 ± 1 0.7 ± 0.06
LUF5835 5.7 ± 2 54 ± 8 0.8 ± 0.08 17 ± 1 58 ± 2 0.9 ± 0.09
>Ì>>ÀiÃÜ>Ãi>́ Ã°i°vÌÀiiÃi«>À>ÌiiÝ«iÀiÌÃi>V«iÀvÀi`̀ Õ«V>Ìi°
a >}ÃÌ «ÌiVÞ ­
50® >` ivwV>VÞ ­max®ÜiÀi V>VÕ>Ìi` vÀ VViÌÀ>ÌÀiÃ«Ãi
VÕÀÛiÃ`iÀÛi`vÀ«i>>>ÞÃÃv
V>}iÃ°b/iÀi>ÌÛiivwV>VÞ­τ) was analyzed by 
Ìi«iÀ>Ì>`iv	>V>`ivvÕÃ}}L>wÌÌ}°21
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against Log RT (r2 = 0.74, pä°ää£®Æ*>i]VÀÀi>ÌvÌivÕVÌ>ivwV>VÞ`iÀÛi`
vÀ>LivÀiiÜiVi>ÃÃ>Þ>}>ÃÌÌivÕVÌ>ivwV>VÞ`iÀÛi`vÀVƂ*>ÃÃ>Þ­r2 
= 0.79, p < 0.001). Data used in these plots are detailed in Table 5.3 and Table 5.4. Data are 
expressed as mean ± s.e.m. from at least three independent experiments.
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shown as a percentage of maximal stimulation of cAMP production by 10 
µM CGS21680 (= 100%). Amongst all tested agonists (Figure 5.8C, Table 
5.4), UK432,097 had the highest efficacy of 115 ± 2% in this assay. Efficacies 
of ribose-containing agonists LUF5448, LUF5549, LUF5550 and LUF5631 
were 84 ± 3%, 71 ± 6%, 39 ± 1% and 67 ± 5%, while the efficacies of the 
non-ribose agonists LUF5833, LUF5834 and LUF5835 were 38 ± 2%, 50 ± 
1% and 58 ± 2%, respectively. Notably, the ranking of the agonists by their 
efficacy measured in the cAMP assay is quite comparable to the efficacy-
ranking obtained with the impedance-based assay (Figure 5.9D, r2 = 0.79, 
p < 0.001). Similarly, a positive link between the functional efficacy and the 
logarithm of a compound’s residence time was observed in this assay as well 
(Figure 5.9C, r2 = 0.74, p < 0.001), while no correlation was observed between 
functional efficacy and the logarithm of its Ki value (r2 = 0.10, p = 0.40). The 
ranking of the relative efficacy, τ, in this assay is also quite comparable to that 
obtained from the whole cell impedance-based assay, where UK432,097 had 
the highest (τ = 14 ± 5) and LUF5550 had the lowest relative efficacy (τ = 
0.5 ± 0.04; Table 5.4). These relative efficacies were again closely correlated to 
the receptor residence times of the agonists in the present chapter (r2 = 0.80, 
p < 0.001).
Discussion5.4 
In this study, the binding kinetics of unlabeled A2AR ligands were determined 
for the first time using the competition association assay method at the 
hA2AR. This approach has been shown to be highly accurate in determining 
the binding kinetics at the β-adrenergic receptor22,23 and more recently at 
the muscarinic M3 receptor.9,24 However, the standard model is laborious 
and time consuming when the kinetics of multiple compounds need to be 
determined, since it implies the use of three concentrations of each unlabeled 
ligand. In this study, the tested agonists were considered competitive with 
the radioligand as they fully displaced [3H]-ZM241385 from the receptor 
(Figure 5.3B). Therefore, we modified the three-concentration dependent 
assay into a one-concentration based method. From Table 5.1, it follows 
that this simplified method is sufficient in quantifying the binding kinetics, 
which eventually enables testing in a faster medium-throughput format, yet 
without loss of accuracy. Since we used an antagonistic radioligand, [3H]-
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ZM241385, we checked the GTP effect on the equilibrium affinity and the 
binding kinetics of one representative A2AR agonist, namely NECA. In our 
system hA2AR was insensitive to GTP (Table 5.2) and only one single binding 
site was observed (Figure 5.3A). Hence we did not continue to apply GTP 
in our assays. Subsequent quantification of the binding kinetics of ten A2AR 
agonists in the simplified model generated comparable ‘kinetic KD’ to their 
Ki values (Table 5.3). This excellent correlation (Figure 5.7B, r2 = 0.99, p < 
0.0001) proved the accuracy and efficiency of the one-concentration based 
competition association assay for the determination of a ligand’s association 
and dissociation rates at the hA2AR. 
To guarantee an accurate kinetic determination, experiments were 
carried out at 5˚C. Firstly, increasing the experimental temperature resulted 
in very fast kinetics of the radioligand, which is less practical to quantify 
the ligand-receptor binding kinetics. Secondly, it is reasonable to speculate 
that differences in receptor residence times will be more pronounced at 5˚C 
than at higher temperatures, which would allow an easier identification of 
compounds with longer residence times in future screening campaigns. It 
might be argued that such a low temperature cannot be representative for 
residence times observed in vivo. However, it was reported in a guinea pig 
bronchoconstriction model that UK432,097 (the agonist with the longest 
residence time in our studies) had a duration of action that lasted over eight 
hours, whereas the effect of the reference agonist CGS21680 quickly returned 
to baseline within 60 min.25,26 Admittedly, the long-lasting effect is likely to 
be influenced by a number of other factors such as dissolution rate, system 
pharmacokinetics or tissue residence/rebinding.27,28 Even so, it is noteworthy 
that a kinetic difference determined by this protocol (i.e., at 5 ˚C) is still 
inextricably linked to the in vivo efficacy of a drug candidate. 
In the present chapter, we observed a broad range of ligand-receptor 
residence times from 3.4 ± 0.6 min for LUF5835 to 250 ± 115 min for 
UK432,097. From Table 5.3, it follows that a non-ribose agonist (LUF5833, 
LUF5834 and LUF5835) associates to the receptor 10-100 fold faster, but 
remained at the receptor much shorter than a ribose-containing agonist 
(for structures see Figure 5.1). This observation supports the integral role 
of a ribose moiety in the binding kinetics upon agonist receptor activation. 
To activate the A2AR, common requirements include the destabilization of 
H-bond networks at W2466.48 and H2787.43 (superscripts refer to Ballesteros-
Weinstein numbering46) and, for example, the displacement of several 
structural water molecules.29,30 One can imagine that such ‘obstacles’ in 






the binding cavity will prevent the coordination of the ribose group and, 
as a result, slow down the agonist association process (Figure 5.10A). The 
lower on-rates of ribose-containing agonists that were observed compared 
to those of non-ribose agonists fit this hypothesis. It has been shown that 
upon receptor activation (Figure 5.10B), the ribose moiety inserts deeply 
into the binding cavity, as illustrated in the agonist-bound A2AR crystal 
structures,31,32 and is stabilized by key residues like S2777.42 and H2787.43. 
These residues, together with V843.32, L2496.51, are in close contact with the 
agonist ribose ring, and form essential H-bonds or non-polar interactions 
with the ribose moiety for agonist binding. Moreover, displacement of the 
structural water molecules from the hydrophobic pocket favors entropic 
energy,33 which further stabilizes the molecule in its interactions and allows it 
to stay longer. For the co-crystallized UK432,097 in particular it was shown 
that it has an extensive ligand-receptor interaction network, which includes 
eleven hydrogen bonds, one aromatic stacking and a number of van der Waals 
interactions, in the A2AR/UK432,097 complex.31 This further corroborates 
our finding that UK432,097 has the longest residence-time in the hA2AR. 
In the present chapter the A2AR-mediated activation was determined in 
two different functional assays, namely, in a novel label-free impedance-based 
assay (xCELLigence RTCA system), which was compared to a classic cAMP 
assay. Recently, label-free impedance-based technologies have been shown to 
have promising applications in assaying functional activity of GPCRs.34,35 
In particular, this assay does not require any labeling or recombinant 
expression of receptor or reporter proteins, since it is based on detection of 
cell morphological changes induced by an agonist. Using this impedance-
based technology, we were able to discriminate full from partial agonists at 
the hA2AR (Figure 5.8B and Table 5.4). Their efficacies were similar to those 
obtained in a traditional cAMP assay (Figure 5.8C and Table 5.4), which 
indicates that the novel label-free technology is a useful tool to study A2AR-
mediated activation. Notably, we observed a similar correlation between 
the residence time of an agonist and its functional efficacy in both assays: 
rather than the equilibrium affinity, the receptor residence time of an A2AR 
agonist has a much better correlation to its intrinsic efficacy (Figure 5.9). This 
correlation was found in other studies as well. For instance, in the case of the 
α2-adrenoceptor, the full agonist UK14,304 had a 12-fold longer residence 
time than the partial agonist clonidine.36 In another study, Sykes et al. tested 
seven agonists with a broad range of efficacies at the muscarinic M3 receptor.9 
Similarly, they found that a slowly dissociating M3 agonist appeared to cause 
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a higher efficacy in functional assays. Taken together with these observations, 
our results suggest that receptor residence time and functional efficacies are 
positively correlated, which may lead us to further understand the molecular 
basis of agonist functional efficacy at the hA2AR. 
In the label-free impedance based assay, we observed that the potencies 
(EC50) of the A2AR agonists were generally higher than the respective binding 
affinities (compare Table 5.4 to Table 5.3). A similar observation was reported 
in a study by Dionisotti et al. for the functional potency and binding affinity 
of NECA and CGS21680.37 Firstly, this discrepancy could be related to 
the effect of receptor reserve. Occupation of a fraction of the receptor is 
sufficient to obtain maximal activation in the signal transduction cascade,37 
which is supported by the relative low values of the relative efficacies (Table 
5.4). Secondly, we have used an antagonist radioligand ([3H]-ZM241385) to 
determine agonist affinity, which generally yields lower affinity values than 
when an agonist radioligand is used.38-40 It has been shown that the use of an 
agonistic radioligand, such as [3H]-NECA or [3H]-CGS21680 at the A2AR, 
results in agonist affinities close to their functional potencies.41,42 In the present 
chapter, we decided to use an antagonistic radioligand because it recognizes 
the whole receptor population (G protein-coupled and –uncoupled), which 
as a result provided a robust condition for kinetic measurements. Moreover, 
it should be mentioned that the results from the label-free impedance-based 
assay represent the integration of several signaling pathways, which might 
explain the difference in agonist potencies obtained in the impedance-based 
and the cAMP assay. To elaborate this phenomenon, several lines of research 
indeed indicate that the A2AR can interact with several ‘less traditional’ 
scaffold proteins, such as β-arrestin and α-actinin.43-45 This may further 
engage cell morphological changes next to effects induced via the classical Gs 
pathway, and as a result cause an increased, or at least different, potency in a 
whole cell impedance-based assay. We also explored the relative efficacy, τ, of 
agonists in the operational model of Black and Leff.21 Critically, we observed 
a correlation between the receptor residence time and the relative efficacy in 
the xCELLigence assay (r2 = 0.60, p < 0.01) but it was less significant than 
the correlation found in the cAMP assay (r2 = 0.80, p < 0.001). This might 
also be due to the fact that the label-free impedance-based assay combines 
cell morphological changes induced via several signaling pathways, as stated 
above.
In summary, we set up and validated a simplified competition association 
assay at the hA2AR, which allowed an accurate and fast measurement of a 






ligand’s binding kinetics. Agonist efficacy at the hA2AR was determined in 
a cAMP assay and, for the first time, in a novel label-free impedance-based 
system. In both functional assays, our data provide evidence that the receptor 
residence time is correlated to the functional efficacy at the hA2AR rather than 
the ‘traditional’ equilibrium affinity of a compound. This finding may lead 
to a further understanding of the fundamental basis of agonist efficacy at the 
hA2AR. 
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Chapter 6
Molecular basis of allosteric modulation 
Insight from a binding kinetics study at 
the human adenosine A1 receptor
Guo D, Venhorst SN, Massink A, Van Veldhoven JPD, Vauquelin G, 
IJzerman AP, Heitman LH.
Adapted from: Br J Pharmacol. submitted

Many G protein-coupled receptors (GPCRs) can be allosterically modulated 
by small molecule ligands. This modulation is best understood in terms of the 
kinetics of the ligand-receptor interaction. However, many current kinetic 
assays require at least the (radio-) labeling of the orthosteric ligand, which is 
impractical for studying a range of ligands. In this chapter we describe the 
application of a competition association assay at the adenosine A1 receptor 
(A1R) for this purpose. We used the competition association assay to examine 
the binding kinetics of several unlabeled A1R orthosteric agonists in the 
absence or presence of two allosteric modulators. We also tested two bitopic 
ligands, in which an orthosteric and an allosteric pharmacophore were 
covalently linked with different spacer lengths in between. The relevance of 
the competition association assay for the bitopic ligands’ binding kinetics 
was also explored by analyzing simulated data. The binding kinetics of an 
unlabeled ‘cold’ orthosteric ligand was influenced upon the addition of 
an allosteric modulator and such an effect was probe- and concentration-
dependent. Covalently linking the orthosteric and allosteric pharmacophores 
into one bitopic molecule had a substantial effect on the overall on- or off-rate. 
The competition association assay is a useful tool for exploring the allosteric 
modulation of the human adenosine A1 receptor. This assay may have general 
applicability to study allosteric modulation at other GPCRs as well.
About this chapter
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Introduction6.1 
Adenosine receptors are a subfamily within the class A of G protein-coupled 
receptors (GPCRs), which includes four subtypes, A1, A2A, A2B and A3.1 These 
receptors are ubiquitously expressed in many tissues and have been shown 
to play important roles in numerous physiological processes.2 Adenosine 
receptors can be activated by their endogenous ligand adenosine or by a range 
of synthetic small molecule agonists that share the same binding site as the 
natural ligand, which is referred to as the orthosteric site.3 Adenosine receptors 
also possess an allosteric site, which is a binding pocket topographically 
distinct from the orthosteric site.4 Currently, many GPCRs, including the 
adenosine receptor subfamily, have been reported to have one or several 
allosteric binding sites that interact with an allosteric modulator.5-10 Such a 
binding event is believed to result in receptor conformational changes, which 
in turn affect the binding of the orthosteric ligand, its potency and/or level 
of activation.11,12 Moreover, the extent of allosteric modulation also depends 
on the nature of the orthosteric ligand, so-called probe-dependency.8,13 These 
complexities add difficulties in understanding the concept and mechanism of 
allosteric modulation. 
Recently, an increasing amount of evidence suggests that ligand-receptor 
binding kinetics is an overlooked key factor in the broader concept of a 
drug’s mechanism of action (MOA).14,15 Insight in the ligand-receptor 
binding kinetics may further our knowledge of the molecular mechanism 
of GPCR allosterism and improve our understanding of this concept.16 
However, current kinetic studies of GPCR allosterism mostly rely on the 
‘probe’ dissociation experiment, i.e., determining the change in a radiolabeled 
orthosteric ligand’s dissociation rate.12,17,18 This radiolabeling process is both 
labor intensive and, importantly, only practical for high affinity ligands. As 
a consequence, the investigation of GPCR allosterism from a kinetic point 
of view has been limited. Therefore, it is highly desirable to measure the 
binding kinetics of label-free orthosteric ligands in the absence or presence of 
an allosteric modulator.
To determine the binding kinetics, we followed a recently validated 
competition association assay on the hA1R in our lab,19 based on the 
mathematical model described by Motulsky and Mahan.20 In the current 
study we examined the association and dissociation rates of several A1R 
agonists in the absence or presence of different allosteric modulators (Figure 






6.1). Amongst these compounds, CCPA (2-chloro-N6-cyclopentyladenosine) 
and NECA (N-5’-ethylcarboxamidoadenosine) are ribose-containing A1R 
receptor agonists,21,22 while LUF5834 (2-amino-4-(4-hydroxyphenyl)-6-(1H-
imidazol-2ylmethyl-sulfanyl)-pyridine-3,5-dicarbonitrile) is a A1R agonist 
without the ribose moiety.23 The allosteric modulators, PD81,723 (2-amino-
4,5-dimethyl-3-thienyl)-[3-(trifluoromethyl)-phenyl]methanone) and BC-1 
[i.e., compound 8j by Romagnoli et al.24, 2-amino-4-((4-(4-(trifluoromethyl)
phenyl)piperazin-1-yl)methyl)thiophen-3-yl)(4-chlorophenyl)methanone] 
are allosteric enhancers of the A1R24,25. The binding kinetics of two in-house 
synthesized ‘bitopic’ ligands, namely LUF6234 and LUF6258 (Figure 6.1),26 
were also investigated, as they are useful tools for the exploration of A1R 
allosteric modulation.27 These bitopic ligands share the same orthosteric 
and allosteric pharmacophores, mimicking LUF5519 [A1R agonist, N6-(4-
methoxyphenyl)adenosine] and PD81,723 respectively, which are covalently 
linked via a spacer with different lengths, i.e., five- and nine-carbon atoms, 
respectively. 
Figure 6.1 | Chemical structures of compounds used in this chapter. CCPA, NECA and 
LUF5519 are ribose-containing adenosine A
1
 receptor agonists, while LUF5834 is a non-
ribose agonist;21-23 PD81,723 and BC-1 are allosteric enhancers for adenosine A
1
 receptor 
agonists.24 LUF6234 and LUF6258 are in-house synthesized bitopic ligands for the adenosine 
A
1
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linker, respectively.
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Methods6.2 
Chemicals and reagents
[3H]-1,3-dipropyl-8-cyclopentylxanthine ([3H]-DPCPX, specific activity 
103 Ci/mmol) was purchased from ARC, Inc. (St. Louis, MO, USA). 
Unlabeled DPCPX and CCPA were from Sigma (St. Louis, MO, USA). 
NECA was purchased from Sigma-Aldrich (Steinheim, Germany). N6-
cyclopentyladenosine (CPA) was obtained from Research Biochemicals Inc. 
(Natick, MA, U.S.A.). LUF5834, PD81,723 and BC-1 were prepared in-house 
following synthesis routes as reported previously.23-25 LUF5519, LUF6234 
and LUF6258 were also synthesized in-house as described by Narlawar et 
al.26 The synthesis of LUF7160 [N6-(4-nonyloxyphenyl) adenosine] and 
LUF7161 [N6-(4-pentyloxyphenyl)adenosine] was performed following 
the same method in Narlawar et al.26. CHAPS [3-((3-cholamidopropyl)-
dimethylammonio)-1-propanesulfonate)] was obtained from Carl Roth 
GmbH (Karlsruhe, Germany). Chinese hamster ovary (CHO) cells stably 
expressing the human A1R (CHO-hA1R) were obtained from Prof. Steve Hill 
(University of Nottingham, UK). All other chemicals were of analytical grade 
and obtained from standard commercial sources.
Cell culture and membrane preparation
Cell culture and membrane preparation were performed as reported 
previously.19
Radioligand displacement assays
Membrane aliquots containing 5 µg of protein were incubated in a total 
volume of 100 µL assay buffer (50 mM Tris-HCl [pH 7.4], supplemented 
with 5 mM MgCl2 and 0.1% [w/v] CHAPS) at 25 ˚C for one hour. The 






displacement experiments were performed using eleven concentrations of 
competing ligands with 2.6 nM [3H]-DPCPX in the absence or presence 
of 10 µM of PD81,723 or BC-1. For the determination of the allosteric 
potency of PD81,723 and BC-1, 100 nM (IC80 value) CCPA was used in 
the presence of increasing concentrations of these two allosteric modulators 
to examine the potentiated [3H]-DPCPX displacement. Nonspecific binding 
was determined in the presence of 100 µM CPA and represented less than 
10% of the total binding. Incubations were terminated and samples were 
obtained as described previously.19
Radioligand association and dissociation assays
Association experiments were performed by incubating membrane aliquots 
containing 5 µg of protein in a total volume of 100 µL of assay buffer at 25 
˚C with 2.6 nM [3H]-DPCPX. The amount of radioligand bound to the 
receptor was measured at different time intervals during a total incubation of 
45 min in the absence or presence of 10 µM PD81,723. For the dissociation 
assay, membrane aliquots containing 5 µg of protein were allowed to reach 
equilibrium for one hour with the same amount of radioligand. After the pre-
incubation, radioligand dissociation was started by adding 10 µM of DPCPX 
at different time points in the absence or presence of 10 µM PD81,723. The 
amount of radioligand still bound to the receptor was measured at various 
time intervals for a total of one hour. Incubations were terminated and 
samples were obtained as described previously.19
Radioligand competition association assay
The binding kinetics of unlabeled ligands was quantified at 25 ˚C using 
the competition association assay based on the theoretical framework by 
Motulsky and Mahan.20 This method has been recently adopted and validated 
on the adenosine A1R in our lab,19 which enables accurate determination 
of unlabeled ligands’ binding kinetics. In the present chapter we followed 
the same method. In brief, we used a concentration of approximately 3- to 
10-fold Ki of the unlabeled ligand with or without the co-incubation of 1, 
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10 or 33 µM PD81,723 or BC-1. The experiment was initiated by adding 
membrane aliquots containing 5 µg of protein in a total volume of 100 µl 
assay buffer at different time points for a total incubation of one hour, except 
for LUF6234 and LUF6258, which were incubated for 2 hours given their 
slow kinetic profiles. Incubations were terminated and samples were obtained 
as described previously.19
Data analysis
All experimental data was analyzed by using GraphPad Prism 5.0 (GraphPad 
Software Inc., San Diego, CA). Radioligand displacement curves were fitted 
to one and two state/site binding models. kobs and koff values of [3H]-DPCPX 
in the absence or presence of PD81,723 were obtained from the association 
and dissociation curves. Values for kon were obtained by converting kobs values 
using the following equation:
k k kradioligand[ ]on
obs off=
−
Association and dissociation rates for unlabeled ligands were calculated 
by fitting the data in the competition association model using ‘kinetics of 
competitive binding’:20
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Where X is the time, Y is the specific [3H]-DPCPX binding (DPM), k1 and 
k2 are the kon (M-1·min-1) and koff (min-1) of [3H]-DPCPX pre-determined 
(1)
(2)






in radioligand association and dissociation assay respectively, L the 
concentration of [3H]-DPCPX used (nM), Bmax the total binding (DPM) 
and I the concentration unlabeled ligand (nM). Fixing these parameters 
allows the following parameters to be calculated: k3, which is the kon value 
(M-1·min-1) of the unlabeled ligand and k4, which is the koff value (min-1) of 
the unlabeled ligand. Ligand-receptor residence times (RT) were calculated 
using the following equation:28
RT k1 / off"
The derived association and dissociation rates of the unlabeled ligand were 






Differential equations (see below, Equations 5-11) were used to follow the 
time (t)-wise changes in target ‘AB’ occupancy by a bitopic ligand, ‘ab’, or a 
monovalent ligand, ‘c’, based on the thermodynamic model in Figure 6.2.29 
The abbreviation notions for different molecular complexes are in parentheses 
in Figure 6.2.
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Data simulations were performed to mimic the binding of a radioligand 
(represented by the target occupancy of ‘c’) by solving Equations 5-11 during 
a period of 5 min, either alone or in the presence of increasing concentrations 
of ‘ab’ with different combinations of microscopic kinetics defined as follows: 
1) k+a = 1 × 105 M-1∙min-1, k-a = 1 min-1, k+b = 1 × 105 M-1∙min-1, k-b = 1 min-1; 
2) k+a = 1 × 105 M-1∙min-1, k-a = 1 min-1, k+b = 1 × 106 M-1∙min-1, k-b = 1 min-1; 
3) k+a = 1 × 106 M-1∙min-1, k-a = 1 min-1, k+b = 1 × 105 M-1∙min-1, k-b = 1 min-1.
The binding kinetics of the monovalent ligand ‘c’ was defined as k+c = 1 × 107 
M-1∙min-1, k-c = 0.3 min-1 and [c] = 100 nM. The simulated data were collected 
at 0.5 min intervals for a total of 5 min and subsequently subjected to the 
competition association model using ‘kinetics of competitive binding’.20 The 
kinetics data obtained thereof were compared to the theoretically calculated 
values (by subjecting the defined microscopic rate constants mentioned 
above into Equation 12 and 13) to explore the relevance of using competition 
association assay for bitopic ligands’ binding kinetics.
Where k+a and k+b (M-1∙min-1) are the microscopic association rate constants 
of the bitopic ligand, ab, for a-A and b-B binding, k-a and k-b (min-1) are 
the dissociation rate constants of the bitopic ligand, ab, for a-A and b-B 
unbinding, L the total concentration of the bitopic ligand (M), c the 
concentration of the monovalent ligand (M), k+c and k-c are the association 
rate and dissociation rate for c-A binding/unbinding. αab and α’ab are the 
penalty factors to correct the kinetics of binding/unbinding of the second 
pharmacophore of a bitopic ligand. The macroscopic kon and koff value of a 
bitopic ligand can be theoretically calculated using the following equations:29
k k kon a b= ++ +
k k kL k k
k























Figure 6.2 | Schematic representation of the monovalent, ‘c’, and bitopic, ‘ab’, ligand-
target site interactions. The bitopic ligand bears two distinct pharmacophores: ‘a’ and 
‘b’. ‘AB’ is the target with distinct binding sites ‘A’ and ‘B’. ‘a’ and ‘c’ only bind to ‘A’ in a 
competitive manner and ‘b’ only binds to ‘B’. The abbreviated notation for the free target 
and target complexes is in parentheses. Formation of a trimeric species in which two bitopic 
ligands are bound to a single target (i.e. one via ‘a’ and the other via ‘b’) is not included 
in the model because, with the present microscopic rate constants, this species only 
marginally contributes to the total binding (data not shown). k+a, k+b and k+c (in M
-1Ċ-1) are 
the microscopic association rate constants and k-a, k-b and k-c (in min
-1) are the microscopic 
dissociation rate constants for a-A, b-B and c-A binding, respectively. The broken line 
divides the thermodynamic cycle model of bivalent ligand binding into two pathways/lanes 
that ‘ab’ can adopt to form the fully bound aABb state as outlined elsewhere.29
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Results6.3 
Quantification of the affinity (Ki) of A1R ligands in the 
absence or presence of PD81,723 or BC-1 in displacement 
experiments
To determine the affinities of several agonists at the A1R in the absence or 
presence of allosteric modulators, radioligand displacement experiments 
were performed. All compounds tested produced concentration-dependent 
inhibition of specific [3H]-DPCPX binding (Figure 6.3) and their affinities 
are detailed in Table 6.1. Among the agonists tested, the binding of CCPA 
and NECA were preferably fitted by a two-site/state competition model, 
whereas the non-ribose agonist LUF5834 was best described by a one-site/
state competition model. In the presence of 10 µM PD81,723, CCPA 
demonstrated a significant increase of both its high and low affinity (KH = 
2 ± 1 nM, KL = 77 ± 5 nM). This effect was even more pronounced upon 
the addition of BC-1. Notably, the two-site binding curve of CCPA was 
shifted to a one-site binding curve (Ki = 4.5 ± 0.3 nM) in the presence of 
this allosteric modulator. Similarly to CCPA, NECA had 3.7-fold and 21-
fold increased affinities (110 ± 50 nM and 20 ± 2 nM) in the presence of 
PD81,723 or BC-1, respectively. Both were mainly from a gain in affinity at 
the low-affinity binding site. In contrast to the ribose-containing agonists, 
i.e., CCPA and NECA, the binding affinity of LUF5834 to the A1R was not 
significantly altered by the presence of either allosteric modulator.
Quantification of the potency of two allosteric modulators
The potencies of PD81,723 and BC-1 were investigated by examining the 
enhanced [3H]-DPCPX displacement from the A1R by 100 nM CCPA 
(IC80) in the presence of increasing concentrations of these two allosteric 
modulators. It follows from Figure 6.3D that BC-1 had a 13-fold higher 
potency (EC50 = 1.5 ± 0.2 µM) than PD81,723 (EC50 = 19 ± 2 µM) for 
modulating CCPA binding to the A1R.

















increased concentrations of PD81,723 or BC-1 (Panel D). Representative graphs from one 
experiment performed in duplicate.
Quantification of the association (kon (k1)) and dissociation 
rates (koff (k2)) of [3H]-DPCPX in the absence or presence of 
PD81,723
Since knowledge of the association [kon (k1)] and dissociation rates [koff (k2)] of 
[3H]-DPCPX was necessary for subsequent competition association assays in 
the presence of an allosteric modulator, we performed a direct [3H]-DPCPX 
association and dissociation assay to determine DPCPX’s binding kinetics 
in the absence or presence of 10 µM PD81,723. As detailed in Table 6.2, 
[3H]-DPCPX displayed a fast association (1.7 ± 0.3 × 108 M-1·min-1) and 
dissociation rate (0.23 ± 0.02 min-1) in the absence of PD81,723, which 
values were not significantly affected by the presence of  PD81,723 (kon = 
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1.8 ± 0.1 × 108 M-1·min-1; koff =  0.22 ± 0.01 min-1). Similarly, BC-1, sharing 
the same chemical scaffold as PD81,723 (Figure 6.1), was reported to have 
a negligible effect on the binding of [3H]-DPCPX.24 Hence, it allowed us to 
further explore the binding kinetics of unlabeled agonists in the absence or 
presence of an allosteric modulator using the rate constants (k1 = 1.7 ± 0.3 
× 108 M-1·min-1 and k2 = 0.22 ± 0.01 min-1) of the antagonist [3H]-DPCPX.
Table 6.1 | [3H]-DPCPX displacement experiments by CCPA, NECA and LUF5834 on 
CHO-hA14OGODTCPGUKPVJGCDUGPEGQTRTGUGPEGQHφ/2&QT$%
Cmpd CCPA NECA LUF5834
KH (nM) KL (nM) RH­¯® Ki (nM) KH (nM) KL (nM) RH­¯® Ki (nM) Ki (nM)
Control 16±1 338±27 20±4 184±18 4±1 731±94 18±3 411±52 7.8±1.5
+ 10 µM PD81,723 2±1 77±5 27±7 43±8 6±4 200±78 26±9 110±50 9.6±2.6
+ 10 µM BC-1 n.a. n.a. n.a 4.5±0.3 8±2 128±27 10±3 20±2 6.7±1.5
Data are shown as mean ± s.e.m of three separate experiments each performed in duplicate. 
KH and KL, KiÛ>ÕiÃvÀÌi}>`Ü>vwÌÞÃÌ>Ìi]ÀiÃ«iVÌÛiÞ>`>ÀiÃÜvÀ`>Ì>
Ì>ÌVÕ`LiwÌÌi` Ì> ÌÜÃÌ>Ìi`iÆ>iÃÌ>Ìii analysis was also performed to 
ivviVÌÛiÞV«>Ài>>vwÌiÃ°,H]ÌivÀ>VÌvÀiVi«ÌÀÃÌi}>vwÌÞÃÌ>Ìi>`Ã
ÃÜ¯°°>°]Ì>Û>>Li°
Quantification of the binding kinetics of unlabeled agonists 
on the A1R in the absence or presence of an allosteric 
modulator by using the competition association assay
In our previous work at the adenosine A1R, we have validated the 
competition association assay to test a ligand’s binding kinetics.19 Here we 
adopted the method to examine the binding kinetics of three A1R agonists 
(CCPA, NECA, and LUF5834) in the absence or presence of two allosteric 
modulators (PD81,723 and BC-1). Several observations were made. Firstly, 
both allosteric modulators affected the orthosteric ligand’s affinity by 
influencing their binding kinetics (Table 6.3, Figure 6.4). Taking CCPA as an 
example, its dissociation rate decreased almost four-fold in the presence of 10 
µM PD81,723 (koff = 0.29 ± 0.02 min-1), while its association rate increased 
2.5-fold. As a result, the affinity (KD = 131 ± 21 nM) of CCPA was increased 






Table 6.2 | The association and dissociation rates of [3H]-DPCPX binding to CHO-hA1R 
OGODTCPGUKPVJGCDUGPEGQTRTGUGPEGQHφ/2&
Cmpd kon (M-1.min-1)a koff (min-1)b KD (nM)c
DPCPX 1.7 ± 0.3 x 108 0.23 ± 0.02 1.5 ± 0.3
+ PD81,723 1.8 ± 0.1 x 108 0.22 ± 0.01 1.2 ± 0.1






























over 10-fold in the presence of PD81,723 (11 ± 1 nM). In comparison, 10 
µM BC-1 lowered CCPA’s off-rate by ten-fold (koff = 0.11 ± 0.02 min-1) and 
raised its on-rate by three-fold (kon = 2.7 ± 0.4 × 107 M-1∙min-1). Overall, this 
resulted in an increased A1R affinity of 4.1 ± 0.6 nM. This finding correlated 
to our aforementioned statement that BC-1 is a more potent A1R allosteric 
modulator than PD81,723, yet with more detailed kinetic information. 
Secondly, the allosteric effect was concentration-dependent. It follows from 
Table 6.3 and Figure 6.4B that BC-1 slowed the dissociation rate of CCPA 
by eight- to ten-fold at low concentrations (i.e., 1 µM or 10 µM), while at 
a relatively high concentration (i.e., 33 µM), it further decreased CCPA’s 
off-rate by another three-fold. A similar trend was observed for PD81,723, 
though the effect was smaller in comparison to that of BC-1 (Figure 6.4A). 
Thirdly, A1R allosteric modulation was ‘probe-dependent’, i.e., the on- and 
off-rates of different orthosteric ligands were influenced to varying degrees in 
the presence of the same allosteric modulator. For instance, in the presence of 
10 µM PD81,723, the dissociation rates of ribose-containing agonists (CCPA 
and NECA) were decreased by approximately two- to five-fold, while the 
dissociation rate of the non-ribose agonist (LUF5834) was not significantly 
affected (0.92 ± 0.09 min-1 versus 0.78 ± 0.08 min-1, P = 0.31). Similarly, 
in the presence of the more potent allosteric modulator BC-1, all three 
orthosteric ligands underwent varying changes in their dissociation rates. A 
significant difference was observed for the residence times of LUF5834 and 
CCPA, i.e., three- or ten-fold increased to 3.1 ± 0.2 min-1 and 9.1 ± 0.9 min-
1, respectively. Furthermore, it is interesting to note that an opposite effect 
on the non-ribose agonist’s (LUF5834) association process was observed, 
compared to the ribose-containing ligands in the presence of 10 µM BC-
1. CCPA and NECA had an almost three-fold increase in their on-rates, 
while for LUF5834 a slightly decreased kon value was observed (1.1 ± 0.1 × 
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Figure 6.4N*>iƂ]Q3H]-DPCPX competition association assay in the absence or presence 
v Õ>Lii`

*ƂÜÌ À ÜÌÕÌ `vviÀiÌ VViÌÀ>ÌÃ v *n£]ÇÓÎ° *>i 	] Q3H]-
DPCPX competition association assay in the absence or presence of unlabeled CCPA with 
`vviÀiÌVViÌÀ>ÌÃv	
£°*>i









to Equation 2 described in the methods to calculate the kon and koff values of unlabeled 
ligands. Representative graphs from one experiment performed in duplicate. (See Table 6.3 
for kinetic values).
108 M-1∙min-1). Lastly, a good correlation (r2 = 0.90, p < 0.0001) between 
the pKi (Ki values from one-state Ki analysis) obtained from equilibrium 
displacement assays and the kinetically derived pKD values was found for all 
tested ligands. This proved the accuracy of the competition association assay 
for determination of an orthosteric agonist’s binding kinetics in the absence 
or presence of an allosteric modulator.






6CDNG  ^ $KPFKPI MKPGVKE nKPXGPVQT[o 
CUUQEKCVKQP TCVG FKUUQEKCVKQP TCVG TGUKFGPEG
VKOG CPF MKPGVKE -D) for CCPA, NECA and LUF5834 in the absence or presence of 
CP CNNQUVGTKEOQFWNCVQT 
2& QT $% CV %*1J#1R derived from competition 
association assays.
Cmpd kon (M-1.min-1)a koff (min-1)a RT (min)b KD (nM)c
CCPA 9.6 ± 1.8 x 106 1.17 ± 0.24 0.86 ± 0.17 131 ± 21
+1 µM PD81,723 1.9 ± 0.5 x 107 0.77 ± 0.03 1.3 ± 0.1 43 ± 7
+10 µM PD81,723 2.4 ± 0.5 x 107 0.29 ± 0.02 3.4 ± 0.2 11 ± 1
+33 µM PD81,723 3.4 ± 0.8 x 107 0.20 ± 0.02 5.0 ± 0.4 5.9 ± 1.9
+1 µM BC-1 3.5 ± 0.4 x 107 0.15 ± 0.01 6.6 ± 0.4 4.4 ± 0.3
+10 µM BC-1 2.7 ± 0.4 x 107 0.11 ± 0.02 9.1 ± 0.9 4.1 ± 0.6
+33 µM BC-1 3.2 ± 0.3 x 107 0.038 ± 0.004 26 ± 3 1.2 ± 0.1
NECA 0.9 ± 0.4 x 106 0.47 ± 0.19 2.1 ± 0.5 482 ± 167
+10 µM PD81,723 3.0 ± 0.3 x 106 0.21 ± 0.02 4.8 ± 0.3 70 ± 6
+10 µM BC-1 3.2 ± 0.5 x 106 0.09 ± 0.03 11 ± 2 28 ± 6
LUF5834 2.0 ± 0.2 x 108 0.92 ± 0.09 1.1 ± 0.1 4.6 ± 0.4
+10 µM PD81,723 2.6 ± 0.2 x 108 0.78 ± 0.08 1.3 ± 0.1 3.0 ± 0.2
+10 µM BC-1 1.1 ± 0.1 x 108 0.32 ± 0.02 3.1 ± 0.2 2.9 ± 0.2
Data are shown as mean ± s.e.m of three separate experiments each performed in duplicate. 
a kon (k3) and koff (k4) of unlabeled A1R agonists in the absence or presence of an allosteric 
`Õ>ÌÀ ­*n£]ÇÓÎ À 	
£® ÜiÀi `iÌiÀi`  Q3H]-DPCPX (2.6 nM) competition 
association assays. b RT (Residence Time) = 1 / koff. 
c Kinetic KD = koff / kon; kon (k3) and koff 
(k4®Û>ÕiÃvÕ>Lii`>Ì>}ÃÌÃÜiÀi}iiÀ>Ìi`vÀQ
3H]-DPCPX (2.6 nM) competition 
>ÃÃV>Ì>ÃÃ>Þ>ÃÃV>Ì>ÃÃ>ÞÃ>ÌÓxÂ
°
Quantification of the binding kinetics of bitopic ligands for 
the A1R in the absence or presence of an allosteric modulator 
by using the competition association assay
The binding kinetics of two in-house synthesized A1R bitopic ligands were 
investigated in the competition association assay. These two ligands, i.e., 
LUF6234 with five-carbon spacer length and LUF6258 with nine-carbon 
spacer length (Figure 6.1), were previously designed and synthesized as 
tools for understanding A1 receptor allosterism.26 Here we further examined 
192 |  Kinetics in GPCR allosteric modulation
the binding kinetics of both compounds and compared their values to 
the orthosteric ligand LUF5519 in combination with PD81,723 (each 
representing the orthosteric and allosteric pharmacophore of LUF6234 and 
LUF6258, respectively; see Figure 6.1 for chemical structures). In the absence 
of an allosteric modulator, LUF5519 displayed an on-rate of 2.0 ± 0.4 × 106 
M-1·min-1 and off-rate of 1.19 ± 0.19 min-1, which led to an affinity of 595 
± 92 nM (Figure 6.5, Table 6.4). Upon the addition of 10 µM PD81,723, 
the association rate of LUF5519 (kon = 2.4 ± 1.4 × 106 M-1∙min-1) did not 
significantly change while the dissociation rate decreased by approximately 
three-fold from 1.19 ± 0.19 min-1 to 0.38 ± 0.05 min-1 (Figure 6.5A and 
Table 6.4). However, after covalently linking the allosteric and orthosteric 
pharmacophores, both bitopic ligands demonstrated a significantly decreased 
association rate in comparison to LUF5519 (LUF6234, 5.3 ± 0.7 × 104 
M-1∙min-1 and LUF6258, 0.8 ± 0.3 × 104 M-1∙min-1), indicative of an extra 
hurdle for the receptor to accommodate large flexible molecules. With respect 
to their off-rates, both compounds displayed significantly longer receptor 
residence times (LUF6234, RT = 19 ± 3 min and LUF6258, RT = 48 ± 
6CDNG ^$KPFKPIRCTCOGVGTU HQTDKVQRKE NKICPFUCPFVJGKTEQPUVKVWGPVRCTVU KP VJG
CDUGPEGQTRTGUGPEGQH2&CV%*1J#1R derived from competition association 
assays.
Cmpd kon (M-1.min-1)a koff (min-1)a RT (min)b KD (nM)c
LUF5519 2.0 ± 0.4 x 106 1.19 ± 0.19 0.8 ± 0.1 595 ± 92
+ 10 µM PD81,723 2.4 ± 1.4 x 106 0.38 ± 0.05 2.6 ± 0.4 158 ± 41
LUF6234 (linker n=5) 5.3 ± 0.7 x 104 0.052 ± 0.007 19 ± 3 981 ± 65
+ 10 µM PD81,723 3.1 ± 0.1 x 106 0.40 ± 0.05 2.5 ± 0.3 129 ± 13
LUF6258 (linker n=9) 0.8 ± 0.3 x 104 0.021 ± 0.008 48 ± 11 2625 ± 810
+ 10 µM PD81,723 3.0 ± 1.4 x 104 0.021 ± 0.011 48 ± 15 700 ± 284
+ 33 µM PD81,723 5.8 ± 3.4 x 104 0.023 ± 0.014 43 ± 15 397 ± 194
LUF7161 2.7 ± 0.7 x 105 1.21 ± 0.32 0.8 ± 0.2 4481 ± 985
+ 10 µM PD81,723 3.8 ± 0.9 x 106 0.87 ± 0.21 1.1 ± 0.1 229 ± 45
Data are shown as mean ± s.e.m of three separate experiments each performed in duplicate. 
a kon (k3) and koff (k4) of unlabeled A1R agonists in the absence or presence of an allosteric 
`Õ>ÌÀ ­*n£]ÇÓÎ À 	
£® ÜiÀi `iÌiÀi`  Q3H]-DPCPX (2.6 nM) competition 
association assays. b RT (Residence Time) = 1 / koff. 
c Kinetic KD = koff / kon; kon (k3) and koff 
(k4®Û>ÕiÃvÕ>Lii`>Ì>}ÃÌÃÜiÀi}iiÀ>Ìi`vÀQ
3H]-DPCPX (2.6 nM) competition 
>ÃÃV>Ì>ÃÃ>Þ>ÃÃV>Ì>ÃÃ>ÞÃ>ÌÓxÂ
°










]Q3H]-DPCPX competition association assay in the absence or presence 
vÕ>Lii`1ÈÓxnÜÌÀÜÌÕÌ£äù*n£]ÇÓÎ°*>i]Q3H]-DPCPX competition 
>ÃÃV>Ì>ÃÃ>ÞÌi>LÃiViÀ«ÀiÃiVivÕ>Lii`1Ç£È£ÜÌÀÜÌÕÌ£äù
PD81,723. Concentrations of 3- to 10-fold Ki of the unlabeled orthosteric ligands were used 
ÌLÌ>ÌiL`}`>Ì>]ÜVÜiÀiwÌÌi`ÌÌiiµÕ>ÌÃ`iÃVÀLi`ÌiiÌ`Ã
to calculate the kon and koff values of unlabeled ligands. Representative graphs from one 
experiment performed in duplicate. (See Table 6.4 for kinetic values).
11 min) than LUF5519 (RT = 0.8 ± 0.1 min). Interestingly, the presence 
of ‘external’ PD81,723 significantly increased the association rates of both 
bitopic ligands (LUF6234, kon = 3.1 ± 0.1 × 106 M-1∙min-1; LUF6258, kon 
= 3.0 ± 1.4 × 104 M-1∙min-1), though LUF6258 was less affected than its 
five-carbon linker analogue. As for the dissociation rate, both bitopic ligands 
demonstrated different profiles upon the addition of PD81,723: LUF6234’s 
residence time was significantly reduced to 2.5 ± 0.3 min, while LUF6258’s 
residence time was not affected (48 ± 15 min), even after further raising the 
concentration of PD81,723 to 33 µM (Table 6.4). In addition, we examined 
the binding kinetics of a newly synthesized monovalent ligand LUF7161 
(Figure 6.1), which served as a control, since it contains the orthosteric part 
and the five-atom linker. It follows from Table 6.4 that LUF7161 had a similar 
dissociation rate (koff = 1.21 ± 0.32 min-1) as LUF5519, yet its association rate 
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to the A1R was approximately ten-fold lower (kon = 2.7 ± 0.7 × 105 M-1∙min-1) 
than LUF5519. Upon the addition of 10 µM PD81,723, the association rate 
of LUF7161 was 14-fold higher, while its dissociation rate was less affected 
in comparison to its kinetics in the absence of the allosteric modulator. The 
other monovalent ligand, i.e., with nine-atom linker (LUF7160), did not 
display significant radioligand displacement up to concentrations of 33 µM 
(data not shown), thus its binding kinetics were not determined.
Data simulations and assay validation for determining 
the bitopic ligands’ binding kinetics in the competition 
association assay
Simulated data were collected by consecutively solving the differential 
equations in Methods (Equations 5-11), which mimic the binding of 
a radioligand in the absence or presence of a bitopic ligand. Next, the 
Table 6.5 | Binding of the monovalent ligand ‘c’ (k+c = 1 × 107 M-1Ċ-1, k-c = 0.3 min-1 and 
QVRr£ää®Ü>ÃÃÕ>Ìi``ÕÀ}>Ìi>«ÃivxÌi>LÃiViÀ«ÀiÃiViv
different concentrations of three bitopic ligands ‘ab’ (their ‘microscopic’ association and 
`ÃÃV>ÌiÌVVÃÌ>ÌÃvLÌ«>À>V«ÀiÃÜiÀi`iwi`>ÃÝ>«iÃ£ÌÎ]
input parameters). The ‘macroscopic’ kinetic binding parameters of the bitopic ligands 
were calculated by using Equation 12 and 13 or by subjecting the simulated data into the 
competition association assay.20

















1 1 x 105 1 1 x 105 1 2.0 x 105 0.069 1.90 x 105 0.11
2 1 x 105 1 1 x 106 1 1.1 x 106 0.035 1.04 x 106 0.083
3 1 x 106 1 1 x 105 1 1.1 x 106 0.035 1.07 x 106 0.036
a k+a and k+b are the microscopic association rate constants and k-a and k-b are the microscopic 
dissociation rate constants of the bitopic ligand, ‘ab’, for a-A, and b-B binding to the target, 
‘AB’, respectively. b The ‘macroscopic’ kinetic binding parameters of the bitopic ligands 
were calculated by using Equation 12 and 13. c kon and koff values were determined by 
analyzing the simulated data in the  competition association model ‘kinetics of competitive 
binding’.20






binding kinetics of the bitopic ligand were analyzed using two methods: 1) 
by subjecting the defined microscopic kinetic constants (Table 6.5, ‘input 
parameters’) into Equation 12 and 13 to obtain the theoretical macroscopic 
binding parameters (Table 6.5, ‘calculated parameters’); 2) by subjecting the 
simulated data into the model of competition association assay to obtain the 
‘collected parameters’ in Table 6.5. In general, the binding kinetics analyzed 
by using both methods correlate well with each other. The association rates of 
the bitopic ligands from the competition association assay are similar to the 
theoretical values in all three examples. For instance, the collected kon value 
in Example 1 is 1.90 × 105 M-1.min-1, which correlates to its corresponding 
theoretical kon value of 2.0 × 105 M-1.min-1. Likewise, the dissociation rate can 
be reliably determined by using the competition association assay, although 
Example 2 demonstrates an approximately two-fold difference between the 
theoretically calculated koff (0.035 min-1) and the corresponding value from 
the competition association assay (0.085 min-1), which is robust enough for 
practical applications. Thus, the competition association assay enables the 
determination of a bitopic ligand’s binding kinetics.
Discussion6.4 
In the present chapter we examined the allosteric modulation of the adenosine 
A1 receptor from a kinetic perspective. We used a competition association 
assay to determine the binding kinetics of several unlabeled orthosteric 
agonists upon the addition of two allosteric modulators, i.e., PD81,723 
and BC-1. The competition association assay offers several, not yet ‘tapped’ 
advantages for the investigation of allosteric modulation. Firstly, it enables 
the measurement of the kinetic characteristics of a probe in an unlabeled 
form, expanding the availability of orthosteric ligands for probe-dependent 
investigations. Secondly, the method allows the determination of a complete 
‘inventory’ of binding kinetics. This includes a ligand’s association rate, 
dissociation rate, residence time and the ‘kinetic KD’. These abundant details 
are very useful to interpret the dynamic interactions between the ligand and 
receptor, especially given that many allosteric modulators have the propensity 
to alter the orthosteric ligand’s dissociation rates. For instance, upon the 
addition of PD81,723 or BC-1 the receptor-residence times of CCPA or 
NECA were prolonged. Such a change can be immediately captured in 
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the competition association assay from the typical ‘overshoot’ pattern as in 
Figure 6.4B or 6.4C, indicating a compound’s slower dissociation process 
than the radioligand.20 PD81,723 and other GPCR allosteric modulators are 
known to influence a probe’s affinity by changing its dissociation rate.25,30-33 
Their effect on the orthosteric ligand’s association rate, however, has been 
less investigated. Here, by using the competition association assay we found 
that an allosteric modulator could also change an orthosteric ligands’ affinity 
by influencing its association rate. For instance, CCPA’s association rate 
increased 2.5-fold upon the addition of 10 µM PD81,723, which, together 
with the four-fold decrease in the dissociation rate, resulted in the overall ten-
fold change in CCPA’s affinity. We also reaffirmed that the allosteric effect 
of both A1R modulators was concentration-dependent, evidenced by the 
concentration-dependent increase in CCPA’s RT (Table 6.3). Moreover, the 
kinetics of different orthosteric ligands were not equally altered, which reflects 
the specific feature of GPCR allosteric modulation, the so-called ‘probe-
dependency’.13 Such a phenomenon is not only limited to an orthosteric 
ligand’s affinity or potency, the parameters often investigated for GPCR 
allosterism, but is also reflected in the less examined orthosteric ligand’s 
dissociation and association rate. As evidence, CCPA and NECA’s association 
and dissociation rates were significantly changed upon the addition of 10 µM 
PD81,723, while not for LUF5834 (Table 6.3). Apparently, all these details 
of ligand-receptor interaction can be simultaneously obtained by using the 
competition association approach.
In the present chapter, we furthermore performed a competition 
association assay with bitopic ligands to study their kinetic behavior. A 
bitopic ligand is a useful tool to study the molecular mechanism of allosteric 
modulation.27 However, interpretation of its binding can be very complex. 
Different bitopic ligands may display three divergent binding modes: the 
ligand can be bound to the allosteric site only, to the orthosteric site only, or 
to both sites simultaneously if the length of the linker is optimal. Moreover, 
one receptor can be occupied by two bitopic ligands, i.e., one to the allosteric 
site and the other to the orthosteric site.26,27,34 A kinetics investigation of 
the bitopic ligand could add information to an affinity- or potency-based 
evaluation. Therefore, we selected two previously reported bitopic ligands,26 
namely LUF6234 and LUF6258, and examined their binding kinetics in 
the present chapter. We found that the theoretically calculated macroscopic 
kinetics correlated well with the values that were determined by analyzing 
the simulated data in the competition association assay (Table 6.5). Thus, 






Figure 6.6 | Proposed diagram of two distinct binding modes for the bitopic ligands 
in the absence or presence of further added allosteric modulator. Mode 1: the linker 
length of a bitopic is optimal to occupy both orthosteric and allosteric sites of the receptor. 
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in a non-optimal manner. Upon the addition of excess allosteric modulator, the monovalent 
ligand can occupy the allosteric site on the receptor and prevent the rebinding of the freshly 
dissociated allosteric pharmacophore in Mode 2 due to the bitopic ligand’s less optimal 
binding pose. In contrast, the binding of the bitopic ligand with optimal linker length (Mode 
1) is less affected in the presence of the monovalent ligand.
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the competition association assay enables sufficient quantification of the 
net changes of the bitopic ligands’ macroscopic binding kinetics. Next, 
we observed that due to covalently linking the orthosteric and allosteric 
pharmacophores the dissociation rates of both compounds were much slower 
than their orthosteric constituent, LUF5519, in the presence of PD81,723 
(Table 6.4). Such phenomenon can be explained by the fact that a freshly 
dissociated pharmacophore is obliged to remain in ‘forced proximity’ to its 
cognate binding site as long as the tethered, companion pharmacophore 
is still bound. This favors its rebinding to that site, thereby significantly 
slowing down the net dissociation process.29,35 To our knowledge, our 
present observation of the gained target-residence time of the bitopic ligand 
provides the first experimental evidence for such rebinding mechanism of low 
molecular weight ligands. 
To further understand the two bitopic ligands’ mode of binding to 
the A1R, we examined the effect of the addition of ‘external’ PD81,723 in 
studies with the bitopic ligand. In this way the monovalent modulator should 
be able to occupy the allosteric site on the receptor and thus prevent the 
rebinding of the freshly dissociated allosteric pharmacophore. Interestingly, 
both association and dissociation of LUF6234 became faster compared to 
its kinetics in the absence of PD81,723, indicative of competition between 
the allosteric part of LUF6234 and the ‘free’ allosteric modulator at the A1R 
allosteric binding site. In contrast, the dissociation rate of LUF6258 was 
unaffected upon the addition of 10 µM PD81,723, which was also the case 
when we raised the concentration of PD81,723 to 33 µM. Further increasing 
the concentration of the allosteric modulator may allow it to displace the 
allosteric pharmacophore of LUF6258 from the A1R allosteric site.35 
However, we did not attempt to do so, given that PD81,723 also significantly 
displaces the binding of an orthosteric ligand at concentrations of 100 µM 
and higher,36 while solubility is an issue too. Apparently, the monovalent 
ligand PD81,723 is less efficient in preventing the rebinding of the nine-
linker compound than its five-linker analogue at the same concentration. 
Such a discrepancy is most likely due to the flexibility of their linkers, where 
the nine-carbon linker has more freedom of rotation and thus increased the 
likelihood that both pharmacophores can tightly interact with the receptor 
(Figure 6.6, Mode 1). In contrast, the shorter five-carbon linker might be able 
to bridge both allosteric and orthosteric sites simultaneously, yet in a non-
optimal manner due to its short length and thus higher energy constraint 
(Figure 6.6, Mode 2).






Notably, our proposed binding modes of the two bitopic ligands expand 
on the conclusions previously drawn by Narlawar et al.26 where the authors 
suggested that the bitopic ligand with linker length of five (LUF6234) failed 
to completely occupy both allosteric site and orthosteric site while the one 
with linker length of nine (LUF6258) was able to occupy both sites. This 
conclusion was based on the hypothesis that if the linker is of sufficient 
length to allow simultaneous occupancy of the allosteric and orthosteric 
binding sites, the addition of further PD81,723 will have a minimal effect 
on the potency of the bitopic ligand, while for the bitopic ligand with 
insufficient linker length affinity will be significantly increased.26 Following 
this hypothesis, we would have reached the same conclusion if merely affinity 
was taken into consideration, since we also observed that LUF6234 displayed 
a strongly increased affinity upon the addition of PD81,723, while less so for 
LUF6258. However, it is also noteworthy from our study that both LUF6234 
and LUF6258 displayed significantly increased receptor residence times 
compared to that of the monovalent ligand in the presence of PD81,723 
(Table 6.4). Such a result strongly indicates that both allosteric and orthosteric 
sites on the A1R were simultaneously occupied for both compounds, which 
appeared to induce a synergistic effect—greater than simply combining two 
monovalent ligands—on the global receptor conformation. If LUF6234’s 
linker length had been insufficient to occupy both sites, it should have had a 
residence time comparable to the monovalent LUF7161, which in fact is not 
the case for this bitopic ligand. Apparently, investigation of binding kinetics 
adds significantly to understanding the molecular mechanism of the binding 
of a bitopic ligand.
In summary, we validated and showed the use of a competition association 
assay at the hA1R to determine the allosteric modulation of the binding 
kinetics of different A1R agonists. Our data suggests that the influence of 
an A1R allosteric enhancer (positive allosteric modulator) on the binding 
kinetics of the orthosteric agonist is dependent on the concentration of the 
allosteric modulator and the nature of the orthosteric ligand and that both the 
association and dissociation rates can be affected. Furthermore, we examined 
the binding kinetics of two bitopic ligands and investigated their binding 
mode. The relevance of the competition association assay for bitopic ligands’ 
binding kinetics was also explored by analyzing a series of simulations and 
comparing the result to the theoretically determined kinetics. Taken together, 
the competition association assay enables accurate determination of the 
binding kinetics of an orthosteric ligand, whether radiolabeled or no, in the 
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absence or presence of an allosteric modulator. We believe that this approach 
will have general applicability for the study of allosteric modulation at other 
GPCRs as well. 
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This thesis focuses on an emerging trend in medicinal chemistry, i.e. drug-
target residence time. In this concluding chapter, new insights gained from 
case studies at the adenosine A1 and A2A receptors are elaborated on, and 
suggestions for future investigations in this field are presented.
About this chapter
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Conclusions from this thesis7.1 
In the present thesis we have characterized the binding kinetics of several 
series of compounds on the adenosine A1 and A2A receptors. The spectrum of 
their residence times varies significantly, ranging from a few seconds to several 
minutes or hours. For instance, the residence times of 35 A1R antagonists 
lasted from 20 sec to 48 min at room temperature (Chapter 3). Likewise, 
the series of ZM241385 derivatives displayed divergent residence times at 
the A2AR, from 2 min to more than 5 h at 4 °C (chapter 4). Such values, in 
general, agree well with similar ranges of other ligand-GPCR residence times, 
which have been summarized in Chapter 2. One example is aprepitant, an 
NK1 receptor antagonist for chemotherapy-induced emesis. It has a target-
residence time of 222 min at 25 °C.1 Of note is that the ligands having 
receptor residence times longer than one or two hours are scarce for the 
adenosine receptors. So far we have not identified a residence time lasting as 
long as tiotropium (>24 h at the M3 receptor, 37 °C) or PF-4850890 (6.79 
h at the CRF1 receptor, 25 °C).2,3 It is worth mentioning that ZM241385 
displayed a target-residence time of 2.1 min at 25 °C, which was nearly 30-
fold shorter than its value (72 min) at 5 °C (Chapter 5). We speculate that 
the observed relatively short RT of adenosine receptor ligands may be derived 
from the nature of the ligands’ binding modes. Both tiotropium and PF-
4850890 bind deeply into their respective receptors4,5 and the binding cavities 
are covered by relatively large extracellular loops. In contrast, many adenosine 
receptor ligands, e.g., ZM241385 or UK432,097, are bound closer to the 
extracellular domain of the receptor, which, in addition, consists of relatively 
short and flexible extracellular loops.6,7 
The association rates of the adenosine receptor ligands also vary 
substantially. Their values are across several orders-of-magnitude. Such 
information greatly updates our current knowledge, which has taken the on-
rate to be diffusion-limited.8 We have found that this general assumption 
is not necessarily valid. For instance, the A2AR antagonists’ on-rates varied 
significantly from 0.10 nM-1∙min-1 to 0.0057 nM-1∙min-1 (Chapter 4)—
more than two orders-of-magnitude from the diffusion-limited value 
(approximately 1010 M-1∙min-1).9 The latter only describes the transport rate of 
one binding partner (e.g. a ligand) through the reaction solution toward the 
other (e.g. a receptor), which is quite different from the association rate (kon) 






of the binding process (formation of the ligand-receptor binary complex). 
The former depends on the viscosity of the medium, while the latter depends 
on the reaction mechanism.10 For the association rate of agonists, their values 
ranged from 5.0 × 104 M-1∙min-1 to 1.6 × 107 M-1∙min-1 at the adenosine A2A 
receptor (chapter 5), which are far from the diffusion-limited rate as well. 
Additionally, a ligand for a membrane-bound receptor could also partition 
into the membrane and then diffuse laterally to the binding site, a proposed 
mechanism for lipophilic compounds associating with the corticotropin-
releasing factor receptor 1.5 Apparently, an association rate can be far from 
the diffusion-limited rate. It is therefore necessary to examine both the on- 
and off-rate of a ligand for an optimized receptor interaction.
It is also of great interest to compare our results at the adenosine receptors 
with kinases or other enzymes. Of particular note is the induced, significant 
target isomerization upon ligand binding that is often encountered for 
enzyme-inhibitor interactions, a state also known as the transition-state. 
Such alternation of target conformations could yield a tightly bound binary 
complex, and thus “lock” the ligand for a long duration to exert its inhibitory 
effect. One example is GW572016 (Lapatinib), a tyrosine kinase inhibitor 
targeting epidermal growth factor receptor (EGFR) for cancer treatment.11 
It has a very slow off-rate from the purified intracellular domains of EGFR 
(0.0023 min-1, equivalent to a half-life of 5 h) compared with OSI-774 
and another EGFR selective inhibitor, ZD-1839 (Iressa). The latter two 
have a rapid off-rate, which translates to a half-life of less than 10 min. The 
difference in their binding kinetics was reflected in the distinct enzyme-
inhibitor crystal structures, where GW572016 was in an inactive-like 
conformation while OSI-774 and ZD-1839 were not. Ligands binding to 
the adenosine receptors may also select a certain conformation, which comes 
to mind when considering the fast exchange of receptor states between the G 
protein-coupled and uncoupled forms. However, it is important to point out 
that such state transformations of GPCRs are much faster than the ‘induced-
fit’ mechanism observed in the enzyme-inhibitor interactions. As evidence, 
a plot of kobs values of [3H]-NECA vs [3H]-NECA concentrations displayed 
a significant linear correlation (r2 = 0.96, p < 0.0001) at the adenosine A2A 
receptor, indicative of a one-step association and dissociation process, quite 
distinct from the ‘induced-fit’ mechanism (which would yield a hyperbolic 
relationship).8
Several binding kinetics assays have been used in the present thesis. One 
of the more traditional assays is the direct kinetic radioligand binding assay. It 
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is a straightforward method enabling robust and quantitative measurements 
of ligand-receptor binding kinetics. However, this assay’s low-throughput 
format and the technical difficulty of radiolabeling limit its application in 
kinetic profiling. The competition association assay based on the model of 
Motulsky and Mahan is a good alternative for the quantitative measurement 
of unlabeled ligands’ binding kinetics.12 It has been extensively applied in 
this thesis from Chapter 3 to Chapter 6 to examine the on- and off-rates of 
ligands of interest. We have also adopted the competition association assay 
and modified it into a fast, high-throughput screening assay, requiring only 
two assay points per compound (Chapter 3). This assay can be of general 
application for kinetics studies at other drug targets as well.
Kinetic profiling of a ligand-receptor interaction is an important addition 
to the classic equilibrium-based pharmacological evaluations. Combining 
both kinetics and equilibrium-based metrics can provide extra information 
for our understanding of complex pharmacological concepts, such as efficacy/
intrinsic activity and allosteric modulation. An attempt to explain different 
agonists’ functional efficacy was presented in Chapter 5, where we found 
that a sustained target-residence time was important for a higher level of 
cell signaling, at least for the adenosine A2A receptor. Likewise, we gained 
more molecular understanding of the phenomenon of allosteric modulation 
at the A1R. We learned that an allosteric modulator could alter an orthosteric 
ligand’s affinity not only via influencing its dissociation rate but also via 
changing its association rate. Additionally, linking an allosteric modulator 
with an orthosteric ligand into one molecule (a so-called bitopic ligand) 
displayed a synergistic effect on residence time, which was much longer 
than the combination of two monovalent ligands. Apparently, the analysis 
of ligand-receptor binding kinetics can add a wealth of knowledge to current 
pharmacological receptor concepts. 
Future perspectives7.2 
The studies outlined in this thesis aimed to explore ligand-receptor binding 
kinetics at G protein-coupled receptors, by a careful examination of the 
adenosine A1 and A2A receptors. In the (near) future, more knowledge can 
be obtained by further investigating the molecular basis of receptor kinetics, 
facilitated by the development of new technologies for rapid, online assessment 






of kinetic profiles of new compounds. Furthermore, translating the in vitro 
binding kinetics to in vivo effects of future drug candidates targeting the 
adenosine receptors (ARs) could potentially decrease drug attrition rates and 
eventually lead to the discovery of more efficacious and safer medicines.
Molecular understanding
a) Physiochemical and hydration properties of dynamic ligand-receptor 
interactions
For future investigations the combination of binding kinetics, structural 
biology and molecular dynamics may greatly advance our understanding 
of the dynamic process of ligand-receptor interactions. For instance, we 
could compute physicochemical properties and hydration properties of the 
protein target, especially to map the binding sites that trap water molecules 
in hydrophobic surroundings. Displacing such less stable, ‘unhappy’, water 
molecules could elicit a favorable binding state of the receptor, compared to 
its (unliganded) apo states, hence influencing a ligand’s residence time.13 It is 
thus of great interest to take the explicit water molecules into consideration 
for future molecular understanding of the dynamic process of ligand-receptor 
interactions. The important role of water molecules was also addressed in 
recent molecular dynamics simulations at the β2 receptor and the muscarinic 
M3 receptor.4,14,15 It was revealed that during the binding and unbinding 
process tremendous hydration and dehydration of both the ligand and the 
receptor was involved, which appears to be a critical process of great generality 
for a ligand’s association to and egress from its receptor. Structure-based 
drug discovery aimed for kinetically optimized compounds (e.g. compounds 
displacing ‘unhappy’ water molecules) can now be performed at the A2AR 
given the availability of a high-resolution crystal structure (PDB: 4EIY) 
and the more than 60 water molecules contained in the transmembrane 
domains.6 Moreover, the recent boom of adenosine A2A receptor crystal 
structures6,7,16,17 may greatly facilitate the molecular dynamic simulations of 
the ligand-receptor interactions. It was suggested that for the M3R and the 
β-adrenergic receptors their ligands traversed a dominant two-step pathway 
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as they bind to or unbind from the receptor, initially making contact with a 
vestibule on the receptors’ extracellular surface.4,14 Such observations could 
be common for other GPCRs as well. It will be of great interest to perform 
similar molecular dynamic simulations at the adenosine receptors for an 
atomic-level description of its kinetic process.
b) New pharmacological models to understand the nature of functional 
efficacy
In chapter 5, we have illustrated that the intrinsic efficacy of an A2A receptor 
agonist is inextricably linked to its receptor residence time. This gained 
knowledge aids us to further understand cell signaling upon ligand stimulation. 
Interestingly, one of the first attempts to define drug action from a kinetic 
perspective dates back to the early 1960s, when Paton proposed the ‘rate 
theory’ for a mechanistic explanation of efficacy.18 However, only few studies 
continued on the track of kinetics since then,19-21 which was later prevailed by 
other models that describes efficacy in terms of the ability to stabilize an active 
receptor conformation10,11 or a more recently proposed ‘stochastic switch’ of 
ligand binding between functionally distinct orientiations.22 Of note is that 
the kinetics of agonist binding and the subsequent conformational change of 
its receptor can influence each other. The binding of an agonist can induce 
receptor conformational changes and these changes potentially influence the 
ligand’s residence time, for instance, via the receptor isomerizing into a high-
affinity state and thus effectively locking the agonist.23,24 In our view both 
conformation-stabilization models and kinetic models are complementary to 
each other rather than contrasting. Thus, an integration of both elements 
may better explain the nature of functional efficacy. 
Furthermore, still little is known about the pharmacological consequences 
of cell/tissue/body exposure to agonists with a spectrum of receptor residence 
times. Will long receptor-residence time ligands cause higher levels of receptor 
desensitization or internalization? What is the connection between agonist-
receptor binding kinetics and the downstream signaling kinetics (i.e. link 
to biased signaling)? These are important questions for future mechanistic 
investigations. The results thereof will most likely affect the medicinal 
chemistry strategy aiming for long or short receptor residence time in the 
future.






c) Mathematical models for theoretical investigations of ligand-receptor 
binding kinetics
To further increase current molecular understanding of ligand-receptor 
binding kinetics, new theoretical models are also needed. A mathematical 
model and simulation have been presented in Chapter 6 for validation of 
the competition association assay. We used it to determine a bitopic ligand’s 
binding kinetics, for which it provided a powerful theoretical support. 
The strength of mathematical simulations is not restricted to validating 
experimental data. It also facilitates our understanding of complicated ligand-
receptor interactions especially for those experimental observations otherwise 
difficult to interpret. For instance, Vauquelin and colleagues reported several 
case studies where mathematical simulations were extensively used to examine 
the binding kinetics of a bitopic/bivalent ligand.25-27 Another example was 
reported by Charlton and colleagues in which they simulated the different 
onset of action of two M3R antagonists that bear distinct kinetic profiles.28 
More theoretical investigations of ligand-receptor binding kinetics should be 
performed in the future.
New technologies for assessing binding kinetics
An overview of current technologies for accessing ligand-receptor binding 
kinetics was described in Chapter 2. In general, most of kinetic profiling 
techniques rely heavily on radioligand binding or functional reversibility 
assays; the latter in a qualitative manner. New tools are welcome to satisfy the 
emerging requests in optimizing binding kinetics. Currently, there are several 
technologies that could be evaluated for future binding kinetics investigations. 
For instance, several groups recently reported the use of fluorescently labeled 
ligands in combination with confocal microscopy equipped with high flow 
perfusion to study ligand-receptor binding kinetics at the level of single 
living cells.29,30 Such tools enable the visualization and quantification of time-
dependent receptor occupancy at the cellular level. Other assay technologies 
can also be used for further development including fourier transform infrared 
spectroscopy (FTIR). This technology simultaneously collects spectral data in 
a wide spectral range, which can be translated into dynamic conformational 
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changes upon ligand-receptor or protein-protein interactions at an atomic 
level.31 One application of the FTIR technology in the field of GPCRs was 
reported by Elgeti et al. to study the conformational diversity of rhodopsin in 
a membrane environment—a study that extended the static picture provided 
by the available crystal structures.32 Cell-based label-free technologies, such 
as xCELLigence described in Chapter 5, enable real-time, online signal 
readout upon ligand addition—a feature that might be used in binding 
kinetics characterizations, as well. Additionally, surface plasmon resonance 
(SPR) is also a good tool to measure ligand-receptor binding kinetics, which 
has been well reviewed by Nunez et al.33 This assay is complementary to 
classical radioligand binding assays when a radioligand is not available. Of 
note is the current difficulty in the purification of target proteins from a 
membrane environment for the assay set-up—a technical bottleneck that 
needs to be overcome for its general application. It is also worth mentioning 
that applications of the above-mentioned new technologies might be limited 
to low throughput assay formats due to inherent technical difficulties. For a 
high-throughput format testing, one could consider scintillation proximity 
assay (SPA) or the recently developed Tag-lite® platform, avoiding a wash or 
filtration step as in traditional radioligand binding studies. Both assays allow 
continuous, multiple reads from one sample. The application of these two 
technologies has been exemplified at the GnRH receptor (SPA) and at the 
dopamine D2 receptor (Tag-lite® platform), respectively.34,35
Translation of in vitro binding kinetics to in vivo evaluation
Translating in vitro binding kinetics into an in vivo setting is essential for the 
prediction of drug efficacy and safety. Such a progress, needless to say, is quite 
difficult and complex. Two major issues need to be taken into account, which 
are addressed as follows.
1) There are mismatches in binding kinetics between human and 
laboratory animal species. An expected margin of safety in one species could 
possibly disappear in human if on- /off-rates at the target vary in different 
species. On the other hand, a compound discarded due to a poor margin of 
safety or selectivity in animal models could be adequately selective for the 
desired over the unwanted effects in human. Such variation in ligand-receptor 
binding kinetics would be particularly important when efficacy and safety 






studies are conducted in different species. Thus, we suggest including the 
investigation of ligand-receptor binding kinetics—at least for those candidate 
compounds progressing into (pre-) clinical phases—in those species that are 
anticipated in later proof-of-concept testing. 
2) The in vivo duration of drug action is not only dependent on 
macroscopic pharmacokinetic properties and long-lasting target binding 
but is also influenced by target rebinding. The local environment of many 
effect compartments may largely prevent the diffusion of free drug molecules 
moving away from their target. This could result in consecutive (re-)binding 
to the same target and/or targets nearby even when the drug’s concentration 
in the bulk phase has already dropped to near-zero levels.36,37 In light of this, 
one could consider examining ligand-receptor binding kinetics in more 
physiological relevant conditions, for instance, by using intact (primary) 
cells and assay conditions  reflecting those in vivo (e.g. buffer, temperature, 
pH).28,38 Data obtained under such circumstances could establish a bridge 
between the in vitro and in vivo setting and thus help their translation.
It is worth mentioning that there is not always a direct link between 
slow dissociation and long-lasting in vivo target engagement, as the rate of 
free drug elimination from the effect compartment is also a key influencing 
factor—a finding commented on by several groups.10,36,39,40 A collection of 
data sets from isolated cells, tissues, and animal models will provide more 
information. 
Final note7.3 
Ligand-receptor binding kinetics is increasingly recognized to play a pivotal 
role in the early phase of drug design and discovery. In this thesis, we 
extensively investigated the ligand-receptor binding kinetics, particularly 
residence time, at the adenosine A1 and A2A receptors. Our case studies at these 
two prototypical GPCRs demonstrate that binding kinetics as an emerging 
paradigm can provide additional information of drug-target interactions at 
the molecular level. 
We propose that a better molecular understanding of binding kinetics is 
needed to aid the development of drug candidates with optimized kinetics. 
We also anticipate the ensuing emergence of new technologies enabling 
rapid assessment of a compound’s binding kinetics in the future. Linking 
216 |  Conclusions and perspectives
these findings in in vitro settings to an existing data set of ex vivo / in vivo 
experiments may provide an evaluation scheme that is more predictive for 
drug efficacy and safety. Hopefully, this thesis will be an impetus for further 
binding kinetics-directed research in the (near) future.
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The present thesis starts with a general description of the current drug research 
pipeline and the high attrition rate therein (Chapter 1). Lack of clinical efficacy 
was reported as the main cause for drug failure. The concept drug-target 
residence time was then introduced, which is a paradigm suggested to be a 
better predictor for drug efficacy than the equilibrium–based metrics (i.e., Ki 
or IC50). The adenosine A1 and A2A receptors were chosen as two prototypical 
GPCRs for this thesis, since many ligands have been developed for these 
receptors after decades of medicinal chemistry efforts. Those compounds 
were good starting points for investigating ligand-receptor binding kinetics.
In Chapter 2, a series of prototypic GPCR ligands that have known 
kinetic information is reviewed. This is followed by an extensive discussion of 
the kinetic behaviour of GPCR ligands at four representatives GPCRs, which 
are the muscarinic M3, tachykinin NK1, dopamine D2 and corticotropin-
releasing CRF1 receptors. It was found that there is much less kinetic data for 
GPCR ligands than equilibrium-based data determined in the early phases 
of drug discovery; almost no detailed structure-kinetics relationship (SKR) 
studies have been reported previously, if any. 
Chapter 3 contains the set-up, validation and optimization of a novel 
kinetic screening method, the so-called dual-point competition association 
assay. This method enables fast and high-throughput screening, since it 
only requires a measurement of radioligand binding at two different time 
points. Such a dual-point measurement yields the kinetic rate index (KRI), a 
parameter coined for quickly assessing kinetic parameters. In this chapter, a 
screen with 35 high affinity A1R antagonists was described. Seven compounds 
were identified with a KRI-value above 1.2, indicating a relatively slow 
dissociation from the target. All other compounds had a KRI-value below 
or equal to 1.0, predicting a relatively fast dissociation rate. Several of these 
compounds were selected for follow-up kinetic quantification and were 
shown to have off-rates that corresponded to their KRI-values. Thus, the KRI 
and the dual-point assay can robustly predict a competitor’s dissociation rate. 
This assay can be applied to a wide range of drug targets as well. 
In Chapter 4, we performed an extensive SKR study on the A2AR in 
addition to a traditional SAR analysis—a combination strategy proposed in 
Chapter 2. The ensemble of 24 A2AR antagonists, all ZM241385 derivatives, 
displayed only minor or insignificant changes in affinity, while they varied 
substantially in their dissociation rates from the receptor. We believe such 
a combination of SKR and SAR analysis as on the A2AR will have general 
importance for other drug targets as well, since it can serve as a new strategy 
to tailor the interaction between a ligand and its receptor. 
An exploration of the molecular basis behind ligand (in vitro) efficacy 
is described in Chapter 5. In this chapter the binding kinetics of ten A2AR 
agonists from different chemical classes were determined and the putative 
relationship to their functional efficacies at the hA2AR was extensively 
examined in Chapter 5. Agonist binding kinetics were determined using the 
competition association method. The A2AR agonist funtional efficacies were 
measured in a label-free impedance-based assay and in a cAMP assay. It was 
found that the ligands’ efficacy at the adenosine A2A receptor is correlated 
with their divergent target-residences times. 
Likewise, the investigation of A1R allosterism from a binding kinetics 
perspective helped us in further understanding the molecular basis of 
receptor allosterism (Chapter 6). We showed that an allosteric modulator 
can alter the orthosteric ligand’s dissociation rate as well as the association 
rate; the latter less investigated before in literature. Such influence was probe- 
and concentration-dependent. This chapter also contains an examination of 
the binding kinetics of two bitopic ligands, LUF6234 and LUF6258, which 
consist of an allosteric and an orthosteric pharmacophore connected via a 
linker. Covalently linking both parts into one molecule had a substantial 
effect on the overall on- and off-rate. These (mathematical) analyses in terms 
of binding kinetics can add a wealth of knowledge to current pharmacological 
receptor concepts.  
Finally, general conclusions from the research described in this thesis 
are given and future perspectives in this field are presented (Chapter 7). In 
short, this thesis provides insights in drug-target binding kinetics. We hope 
this thesis will bring more awareness of the importance of ligand-receptor 
binding kinetics and thus result in more kinetics-based studies in future early 
phases of drug design and discovery, eventually leading to different or even 
better-in-class drug candidates for future clinical applications.
Samenvatting
Dit proefschrift begint met een beschrijving van het huidige proces 
van geneesmiddelontwikkeling en het hoge percentage van kandidaat 
geneesmiddelen dat voor lancering op de markt faalt (hoofdstuk 1). Gebrek 
aan klinische werkzaamheid is gerapporteerd als de belangrijkste oorzaak voor 
het falen van geneesmiddelontwikkeling. Al eerder is aangetoond, dat met 
behulp van de bindingskinetiek beter voorspeld kan worden welke kandidaat 
geneesmiddelen een goede werking zullen hebben dan met bestaande 
parameters, welke onder evenwichtscondities bepaald worden (Ki of IC50). 
De adenosine A1 en A2A receptoren werden gekozen als twee prototypische 
receptoren (G protein-coupled receptors of afgekort GPCRs) voor dit 
proefschrift, omdat door decennia van farmacochemische inspanningen 
al veel liganden voor deze receptoren ontwikkeld zijn. Deze chemische 
verbindingen waren goede aanknopingspunten voor het onderzoeken van de 
kinetiek van ligand-receptor binding.
In hoofdstuk 2 wordt een reeks prototypische GPCR liganden beschreven 
waarvan kinetische informatie beschikbaar is in de literatuur. Hierna volgt een 
uitvoerige beschrijving van het kinetische gedrag van GPCR liganden op vier 
representatieve GPCRs; de muscarine M3, de tachykinine NK1, de dopamine 
D2 en corticotropine releasing CRF1 receptoren. Het blijkt dat tijdens de 
vroege fasen van geneesmiddelontwikkeling veel minder kinetische gegevens 
beschikbaar zijn in vergelijking tot data bepaald onder evenwichtscondities. 
Daarom zijn er nog bijna geen gedetailleerde structuur-kinetiek relaties 
(SKR) gerapporteerd, terwijl al decennia lang structuur-affiniteit relaties 
(SAR) bepaald worden.
Hoofdstuk 3 omvat de opzet, validatie en optimalisatie van een nieuwe 
kinetische methode voor ligand screening, de zogenaamde twee-punts 
competitie associatie test. Deze methode zorgt voor een snelle en high-
throughput screening, omdat het slechts een meting van radioligand binding 
op twee verschillende tijdstippen vereist. Zo bepaalt een dual-point meting 
de kinetic rate index (KRI), een parameter die door ons werd ontwikkeld 
voor het snel beoordelen van ligand-receptor bindingskinetiek. 
In dit hoofdstuk wordt een selectie van 35 A1 receptor antagonisten met 
hoge affiniteit beschreven. Zeven verbindingen werden geïdentificeerd met een 
KRI-waarde boven de 1.2, wat wijst op een relatief langzame dissociatie van 
de receptor. Alle andere verbindingen hadden een KRI-waarde lager of gelijk 
aan 1.0, wat een relatief snelle dissociatiesnelheid voorspelt. Verscheidene 
van deze verbindingen werden geselecteerd voor vervolgstudies waarin 
dissociatiesnelheden met behulp van kinetische bindingsexperimenten werden 
bepaald. Het bleek dat deze dissociatiesnelheden overeenkomen met de eerder 
bepaalde KRI waarden. De KRI en de dual-point meting zijn dus in staat 
een robuuste voorspelling van de dissociatiesnelheid van het onderzochte 
ongelabelde ligand te geven. Deze test kan, naast adenosine receptoren, ook op 
andere GPCRs en aangrijpingspunten voor geneesmiddelen worden toegepast.
In hoofdstuk 4 wordt een uitgebreide SKR studie van de A2A receptor 
beschreven naast een traditionele SAR studie – een combinatiestrategie zoals 
beschreven in hoofdstuk 2. De groep van 24 A2A receptor antagonisten, alle 
ZM241385 derivaten, vertoont geen, of slechts kleine, verschillen in de affiniteit, 
terwijl aanzienlijke variatie in dissociatiesnelheden werd gevonden. Wij denken 
dat een dergelijke combinatie van SKR en SAR analyse op de A2A receptor ook 
van groot belang kan zijn voor andere GPCRs en aangrijpingspunten voor 
geneesmiddelen. Dan kan het dienen als een nieuwe strategie voor het op maat 
maken van de interactie tussen een ligand en zijn receptor.
Een verkenning van de moleculaire grondslag van de werkzaamheid 
van liganden (in vitro) wordt beschreven in hoofdstuk 5. In dit hoofdstuk 
werd de bindingskinetiek van tien A2A receptor agonisten uit verschillende 
chemische klassen bepaald en werd de relatie met hun functionele effectiviteit 
onderzocht. De bindingskinetiek van de agonisten werd bepaald met behulp 
van de competitie associatie test. De functionele werkzaamheid werd gemeten 
met een label-vrije - op electrische weerstand gebaseerde - methode en in een 
cAMP test. Er werd een correlatie gevonden tussen de effectiviteit van de 
liganden in de functionele experimenten en hun bindingskinetiek.
Door het concept van allostere modulatie van de A1 receptor te benaderen 
vanuit het perspectief van bindingskinetiek waren we in staat om de moleculaire 
basis van allostere modulatie beter te begrijpen (hoofdstuk 6). We toonden aan 
dat een allostere modulator zowel de associatie- als de dissociatiesnelheid van 
het orthostere ligand kan veranderen. Het effect op de associatiesnelheid is in 
de literatuur nog zeer weinig beschreven. Dit effect bleek zowel structuur- als 
de concentratieafhankelijk. 
Dit hoofdstuk bevat ook een onderzoek naar de bindingskinetiek van twee 
bitopische liganden, LUF6234 en LUF6258, welke bestaan uit een allostere en 
een orthostere farmacofoor verbonden via een linker. Het covalent koppelen 
van beide delen van een molecuul had een aanzienlijk effect op de totale 
associatie- en dissociatiesnelheden. Door een wiskundig model te gebruiken 
om de bindingskinetiek te analyseren waren we in staat een schat aan kennis 
toe te voegen aan de huidige farmacologische receptorconcepten.
Tot slot wordt een overzicht gegeven van de conclusies die zijn verkregen 
uit het in dit proefschrift beschreven onderzoek (hoofdstuk 7). Daarnaast 
worden toekomstperspectieven besproken. Kort samengevat geeft dit 
proefschrift inzichten in de bindingskinetiek van geneesmiddelen op hun 
aangrijpingspunt. We hopen dat dit proefschrift meer aandacht vestigt op 
het belang van het evalueren van bindingskinetiek voor de ontwikkeling van 
nieuwe geneesmiddelen. Dit zal hopelijk leiden tot andere en mogelijk betere 
kandidaat geneesmiddelen voor toekomstige klinische toepassingen.
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